"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,GB,A,GB 1122385 A,144-002-026-768-845,1968-08-07,1968,GB 4962864 A,1964-12-07,GB 4962864 A,1964-12-07,Improvements relating to magnetic storage arrangements,"1,122,385. Circuits employing bi-stable magnetic elements. PLESSEY UK Ltd. 3 Dec., 1965 [7 Dec.. 1964], No. 49628/64. Heading H3B. A magnetic storage element comprises a thin film F of isotropic material having a rectangular hysteresis characteristic, parallel first and second word conductors U, V and an orthogonal digit conductor D being positioned in operative proximity. All three conductors are energized to write a binary "" 1."" The film may be of nickel-iron alloy which is deposited on to a glass or copper cylindrical former by evaporation, chemical deposition or electroplating, the first and second word conductors being subsequently threaded through the cylindrical former. A matrix store is shown in Fig. 3 in which a binary word may be stored magnetically along any of the cylindrical films F1-F9. To write a word a first and a second word conductor U, V common to a selected cylindrical film are pulsed at the same time as digit conductors D1, D2 are selectively energized. Coincident energization of the word conductors U, V establishes a circumferential flux in the film which is angularly deflected by current in a digit conductor to store a binary "" 1 "" at that location. The direction of current in a digit conductor is opposite to store a binary "" 0 "" in which case the circumferential flux is angularly deflected in the opposite direction. Alternatively a binary "" 0 ""is characterized by circumferential flux, the digit conductor being unenergized. For reading out the first and second word conductors are both energized in the reverse direction, an output of characteristic polarity being induced in the digit conductor if a "" 1 "" is stored. An output of opposite polarity is obtained if a binary "" 0 "" was stored by the method involving flux deflection.",PLESSEY UK LTD,STAPLETON DAVID CHRISTOPHER,,https://lens.org/144-002-026-768-845,Granted Patent,no,0,0,4,4,0,G11C7/00;;G11C7/00;;G11C5/02;;G11C5/02;;G11C11/04;;G11C11/04,G11C5/02;;G11C7/00;;G11C11/04,H3B B201          AC;;H3B B201          CC;;H3B B202          AC;;H3B B202          CC;;H3B B203          AC;;H3B B203          CC;;H3B B204          AC;;H3B B204          CC;;H3B B208          AC;;H3B B208          CC;;H3B B210          AC;;H3B B210          CC;;H3B B211          AC;;H3B B211          CC;;H3B B231          AC;;H3B B231          CC;;H3B B235          AC;;H3B B235          CC;;H3B B277          AC;;H3B B277          CC;;H3B B303          AC;;H3B B303          CC;;H3B B350          AC;;H3B B350          CC;;H3B B404          AC;;H3B B404          CC;;H3B B420          AC;;H3B B420          CC;;H3B B425          AC;;H3B B425          CC;;H3B B426          AC;;H3B B426          CC;;H3B B427          AC;;H3B B427          CC;;H3X X5A           -,0,0,,,,EXPIRED
2,DE,A1,DE 1474442 A1,199-941-407-381-282,1970-07-30,1970,DE 1474442 A,1965-12-04,GB 4962864 A,1964-12-07,Magnetspeicheranordnung,,PLESSEY CO LTD,CHRISTOPHER STAPLETON DAVID,,https://lens.org/199-941-407-381-282,Patent Application,no,0,0,4,4,0,G11C7/00;;G11C7/00;;G11C5/02;;G11C5/02;;G11C11/04;;G11C11/04,G11C5/02;;G11C7/00;;G11C11/04,,0,0,,,,DISCONTINUED
3,GB,A,GB 1201610 A,066-086-379-840-228,1970-08-12,1970,GB 4923566 A,1966-11-02,GB 4923566 A,1966-11-02,IMPROVEMENTS RELATING TO MAGNETIC STORAGE ELEMENTS,"1,201,610. Magnetic structures; magnetic storage arrangements. PLESSEY CO. Ltd. 16 Oct., 1967 [2 Nov., 1966], No. 49235/66. Heading H1H. [Also in Division H3] Each magnetic storage element in a matrix store (see Division H3) comprises a non-magnetic word conductor 11, Fig. 2, having continuous superposed films 12, 14 of anisotropic magnetic material with high and low coercivities, respectively, and an orthogonal digit conductor 15, the preferred magnetization direction of the high coercivity film 12 being substantially parallel to the word conductor, while the preferred magnetization direction of the low coercivity film 14 is inclined slightly, e.g. by 5 degrees, to the axis of the digit conductor. Writing is effected by applying pulses simultaneously to the word and digit conductors so as to establish "" 0 "" or "" 1 "" characterizing closed loop magnetizations 16, 17, Fig. 3, through the high and low coercivity films of a storage element. Non-destructive read out is effected by applying a pulse to a digit conductor sufficient to permit the magnetization of the low coercivity film to move away temporarily from its hard direction in which it is normally held by the field of the high coercivity film. Alternatively non-destructive read out is obtained by pulsing the word conductor, in either case the pulse being insufficient to disturb the magnetization of the high coercivity film. A non-magnetic film 13, e.g. of copper, may be interposed between the films to prevent diffusion between the films during the formation by deposition.",PLESSEY CO LTD,STAPLETON DAVID CHRISTOPHER,,https://lens.org/066-086-379-840-228,Granted Patent,no,0,0,2,2,0,G11C15/02,G11C15/02,H3B B201          CD;;H3B B202          CD;;H3B B208          CD;;H3B B210          CD;;H3B B236          CD;;H3B B237          CD;;H3B B240          CD;;H3B B245          CD;;H3B B277          CD;;H3B B303          CD;;H3B B325          CD;;H3B B326          CD;;H3B B331          CD;;H3B B332          CD;;H3B B350          CD;;H3B B374          CD;;H3B B376          CD;;H3B B404          CD;;H3B B413          CD;;H3B B530          CD;;H3B B531          CD;;H3X X5A           -,0,0,,,,EXPIRED
4,US,A,US 5537483 A,170-119-371-574-795,1996-07-16,1996,US 16680193 A,1993-12-14,US 16680193 A;;US 96562592 A;;US 41637789 A,1989-10-03,Automated quality assurance image processing system,"An image processing system with a quality assurance feature is disclosed for determining the quality of the images being processed. The system includes a plurality of sections operating independently and concurrently to insure reliability. One section includes calculation of a quality assurance parameter dependent on the fill factor and the compression ratio determined before and after compression respectively. A second section includes histogram hardware for generating qualified histograms representative of foreground data, and background data transitions and a comparator for detecting overlap therebetween. A third section develops a histogram parameter based on the areas of the histograms and compares this parameter to the quality assurance parameter for concurrence. The system also includes autosizing means for detecting the borders of an image using fuzzy logic.",STAPLEVISION INC,STAPLETON JOHN J;;LORD CHRISTOPHER,,https://lens.org/170-119-371-574-795,Granted Patent,yes,13,96,1,1,0,H04N1/00002;;H04N1/00005;;H04N1/0001;;H04N1/00013;;H04N1/00029;;H04N1/00034;;H04N1/00039;;H04N1/00047;;H04N1/0005;;H04N1/00063;;H04N1/00068;;H04N1/00071;;H04N1/00082;;H04N1/32641;;H04N1/32678;;H04N1/40;;H04N1/00005;;H04N1/00068;;H04N1/00029;;H04N1/00034;;H04N1/32641;;H04N1/0001;;H04N1/00082;;H04N1/00002;;H04N1/00071;;H04N1/40;;H04N1/00013;;H04N1/00047;;H04N1/0005;;H04N1/32678;;H04N1/00039;;H04N1/00063,H04N1/00;;H04N1/40,382/309;;382/168;;382/192,4,0,,,"Russel Hsing, Techniques of Adaptive Threshold Setting for Document Scanning Applications , Optical Engineering, vol. 23, No. 3, May/Jun. 1984, pp. 288 293.;;Sampling Axioms for Image Quality Inspection by Man and Machine , StapleVision White Paper, no author given, Jul. 29, 1991, pp. 1 9.;;J. B. Stapleton et al., Automated Quality Assurance and AutoSizing Quicken Conversion from Film and Paper to Optical disc or FAX , StapleVision Inc., No date, pp. 573 578.;;Craig Landrum et al., Automatic Quality Assurance of Digitized Documents , PRC GIS/SEID, No date, pp. 1 5, also accompanying lecture notes pp. 1 6.",EXPIRED
5,US,A,US 5832140 A,110-169-516-378-795,1998-11-03,1998,US 45767695 A,1995-06-01,US 45767695 A;;US 16680193 A,1993-12-14,Automated quality assurance image processing system,"An image processing system with a quality assurance feature is disclosed for determining the quality of the images being processed. The system includes a plurality of sections operating independently and concurrently to insure reliability. One section includes calculation of a quality assurance parameter dependent on the fill factor and the compression ratio determined before and after compression respectively. A second section includes histogram hardware for generating qualified histograms representative of foreground data, and background data transitions and a comparator for detecting overlap therebetween. A third section develops a histogram parameter based on the areas of the histograms and compares this parameter to the quality assurance parameter for concurrence. The system also includes autosizing means for detecting the borders of an image using fuzzy logic.",STAPLEVISION INC,STAPLETON JOHN J;;LORD CHRISTOPHER,,https://lens.org/110-169-516-378-795,Granted Patent,yes,11,59,1,1,0,H04N1/393;;H04N1/40;;H04N1/393;;H04N1/40,H04N1/393;;H04N1/40,382/298;;382/199;;382/232;;382/287;;382/300,0,0,,,,EXPIRED
6,DE,A1,DE 1621148 A1,062-432-105-122-193,1971-04-15,1971,DE 1621148 A,1967-12-23,GB 5786766 A,1966-12-24,Verfahren und Vorrichtung zur Herstellung von logischen Elementen,,PLESSEY CO LTD,HUMPAGE JOHN;;CHRISTOPHER STAPLETON DAVID,,https://lens.org/062-432-105-122-193,Patent Application,no,0,0,5,5,0,C25D5/18;;C25D5/18;;C25D7/0607;;C25D7/0607;;H01F10/06;;H01F10/06,C25D5/18;;C25D7/06;;H01F10/06,,0,0,,,,DISCONTINUED
7,GB,A,GB 1213277 A,114-335-525-062-238,1970-11-25,1970,GB 5786766 A,1966-12-24,GB 5786766 A,1966-12-24,IMPROVEMENTS IN OR RELATING TO ELECTROPLATING METHODS AND APPARATUS,"1,213,277. Magnetic structures. PLESSEY CO. Ltd. 11 Dec., 1967 [24 Dec., 1966], No. 57867/66. Heading H1H. [Also in Division C7] In making a logical device, a Be/Cu wire 1 (or a hollow cylinder or strip) is electroplated with a thin film of Ni/Fe alloy (80% Ni, 20% Fe). In order to create a preferred direction of magnetization at right angles to the wire in the electroplated film, an alternating current may be superimposed on the electrodepositing current in the wire.",PLESSEY CO LTD,HUMPAGE JOHN;;STAPLETON DAVID CHRISTOPHER,,https://lens.org/114-335-525-062-238,Granted Patent,no,0,1,5,5,0,C25D5/18;;C25D5/18;;C25D7/0607;;C25D7/0607;;H01F10/06;;H01F10/06,C25D5/18;;C25D7/06;;H01F10/06,C7B BA1E          -;;C7B BA2D          -;;C7B BA2F          -;;C7B BA2G          -;;C7B BDC           DC;;C7B BDC           DR12;;C7B BDEG          DEG;;C7B BDLC          DLC;;C7B BDR           DR12;;C7B B1B           -;;C7B B120          DC;;C7B B120          DR12;;C7B B15X          -;;C7B B16X          -;;C7B B17           -;;C7B B235          DC;;C7B B267          DC;;C7B B268          DC;;C7B B306          DR12;;C7B B309          DR12;;C7B B343          DR12;;C7B B701          DR12;;C7B B724          DR12;;C7B B727          DR12;;C7B B806          DR12;;C7C CA175;;C7C CA18Y;;C7C CA255;;C7C CA256;;C7C CA264;;C7C CA308;;C7C CA569;;C7C CA581;;C7C CA587;;C7C CA588;;C7C CA60X;;C7C CA613;;C7C CA616;;C7C CA62X;;C7C CA62Y;;C7C CA625;;C7C CA628;;C7C CB168;;C7C CB205;;C7C CB209;;C7C CB223;;C7C CB224;;C7C CB238;;C7C CB24X;;C7C CB24Y;;C7C CB241;;C7C CB249;;C7C CB25X;;C7C CB25Y;;C7C CB252;;C7C CB257;;C7C CB30Y;;C7C CB323;;C7C CB349;;C7C CB35Y;;C7C CB366;;C7C CB369;;C7C CB378;;C7C CB404;;C7C CB406;;C7C CB448;;C7C CB458;;C7C CB46X;;C7C CB464;;C7C CB50X;;C7C CB50Y;;C7C CB513;;C7C CB555;;C7C CB556;;C7C CB561;;C7C CB573;;C7C CB58Y;;C7C CB581;;C7C CB584;;C7C CB587;;C7C CB592;;C7C CB598;;C7C CB60Y;;C7C CB604;;C7C CB615;;C7C CB620;;C7C CB634;;C7C CB647;;C7C CB649;;C7C CB652,0,0,,,,EXPIRED
8,GB,A,GB 1027042 A,053-060-390-227-371,1966-04-20,1966,GB 3268761 A,1961-09-12,GB 3268761 A,1961-09-12,Improvements in or relating to ferrimagnetic garnet materials,"1,027,042. Magnetic compositions. PLESSEY CO. Ltd. Sept. 5, 1962 [Sept. 12, 1961], No. 32687/61. Heading H1H. A ferrimagnetic garnet has the formula where X is a divalent metal Mg, Cu, Zn or Ni and Z is tetravalent Si or Ge and where 0À1 # p# 3 and 0 < q # 0À5 Basically the invention lies in substituting a mixture of bivalent and tetravalent ions for trivalent iron ions in a Y/Gd garnet to reduce coercivity. In preparation the oxides are mixed prefired for 12 hours at 1000‹ C. in O 2 , pressed into shape and sintered at 1400‹ C. for 6 hours in O 2 .",PLESSEY CO LTD,JACKSON ROGER CARR;;STAPLETON DAVID CHRISTOPHER,,https://lens.org/053-060-390-227-371,Granted Patent,no,0,2,2,2,0,C04B35/2608;;C04B35/2675,C04B35/26,C1J JFG           JFG;;C1J J37K          JFG;;C1J J37R          JFG;;C1J J37X          JFG;;C1J J38           J37,0,0,,,,EXPIRED
9,GB,B,GB 2338155 B,041-576-559-535-516,2003-02-12,2003,GB 9812081 A,1998-06-05,GB 9812081 A,1998-06-05,Hub system with ring arbitration,,3COM TECHNOLOGIES LTD,BREWER STEVEN;;STAPLETON NICHOLAS;;WALKER CHRISTOPHER ALAN,,https://lens.org/041-576-559-535-516,Granted Patent,no,2,0,4,4,0,H04L12/433;;H04L12/433,H04L12/433,H4P PPJD          PPJD,0,0,,,,EXPIRED
10,GB,A,GB 2338155 A,144-921-291-574-192,1999-12-08,1999,GB 9812081 A,1998-06-05,GB 9812081 A,1998-06-05,Data network hub with ring arbitration,"A data network hub comprises stacked hub units 1, 2 and 3 each of which can supply and receive data packets to and from network destinations via transmitters Tx and receivers Rx. The units are connected in a closed data transmission ring enabling packets received at any unit to be transmitted from any other unit. A unit acting as a master unit to supply packets to the ring modifies the packet headers to provide an arbitration header comprising a grant field, a request priority field, capable of indicating various different priority levels, and a grant priority field. When the hub unit acting as a master unit has no more packets to supply, it responds to an arbitration header which has a set request priority field by setting the grant field and the grant priority field. A hub unit which is not the master unit but has packets to supply to the ring responds to arbitration headers by setting the request priority field. A hub unit which is not the master unit but has packets to supply to the ring becomes the master in response to an arbitration header with the grant field set and a grant priority field indicating a priority level corresponding to the priority requested by this unit.",3COM TECHNOLOGIES LTD,BREWER STEVEN;;STAPLETON NICHOLAS;;WALKER CHRISTOPHER ALAN,,https://lens.org/144-921-291-574-192,Patent Application,no,2,11,4,4,0,H04L12/433;;H04L12/433,H04L12/433,H4P PPJD          PPJD,0,0,,,,EXPIRED
11,US,B1,US 6330245 B1,138-893-255-070-859,2001-12-11,2001,US 20765598 A,1998-12-09,GB 9812081 A,1998-06-05,Hub system with ring arbitration,"A data network hub unit is stackable with other such units to constitute a hub in which each of the units can supply data packets to network data destinations and receive data packets from network data sources, and to form a closed data transmission ring which enables packets received at any unit to be transmitted from any other unit. The hub unit includes arbitration control means responsive to packet headers circulating on said ring. The arbitration control means is operative: (i) when the hub unit acts a master unit to supply data packets, to modify data packets to provide them each with an arbitration header which includes a grant field, a request priority field, capable of indicating various different level of priority, and a grant priority field; (ii) when the hub unit is acting as the master unit and has no more data packets to supply to the ring, to respond to an arbitration header which has a set priority field by setting the grant field and setting the grant priority field; (iii) when the hub unit is not the master unit but has data packets to place on the ring, to respond to arbitration headers by setting a priority field; and (iv) when the hub unit is not the master unit but has data packets to send, to respond to an arbitration header which has the grant field set and a grant priority field indicating a priority level corresponding to the priority requested by this unit to become the master unit.",3COM TECHNOLOGIES LTD,BREWER STEVEN;;STAPLETON NICHOLAS M;;WALKER CHRISTOPHER A,HEWLETT-PACKARD COMPANY (2010-04-28);;3COM TECHNOLOGIES (1998-10-19),https://lens.org/138-893-255-070-859,Granted Patent,yes,4,42,4,4,0,H04L12/433;;H04L12/433,H04L12/433,370/424;;370/449;;370/452;;370/455;;709/251,0,0,,,,EXPIRED
12,AP,A0,AP 2015008695 A0,065-911-362-609-581,2015-08-31,2015,AP 2015008695 A,2014-03-07,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,Upgrading process streams,,XYLECO INC,COOPER CHRISTOPHER;;MUKHERJEE MAIA STAPLETON;;MASTERMAN THOMAS CRAIG,,https://lens.org/065-911-362-609-581,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,PENDING
13,DE,T2,DE 69703584 T2,151-261-035-557-249,2001-06-21,2001,DE 69703584 T,1997-07-23,GB 9615445 A;;GB 9701995 W,1996-07-23,Kaskadierung von Datenübertragungsvorrichtungen,,3COM TECHNOLOGIES GEORGETOWN,STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH R;;OVERS PATRICK,,https://lens.org/151-261-035-557-249,Granted Patent,no,0,0,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/14;;G06F13/40;;H04L29/02,,0,0,,,,EXPIRED
14,DE,D1,DE 69703584 D1,108-128-292-039-811,2000-12-28,2000,DE 69703584 T,1997-07-23,GB 9615445 A;;GB 9701995 W,1996-07-23,KASKADIERTER ANSCHLUSS VON KOMMUNIZIERENDEN GERÄTE,,3COM TECHNOLOGIES GEORGETOWN,STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH R;;OVERS PATRICK,,https://lens.org/108-128-292-039-811,Granted Patent,no,0,0,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/14;;G06F13/40;;H04L29/02,,0,0,,,,EXPIRED
15,GB,A,GB 1085524 A,199-668-551-674-536,1967-10-04,1967,GB 35764 A,1964-01-03,GB 35764 A,1964-01-03,Improvements in or relating to magnetic memory devices,"1,085,524. Magnetic structures. PLESSEYUK Ltd. Dec. 30, 1964 [Jan. 3, 1964], No. 357/64. Heading H1H. [Also in Division G4] A storage element comprises an apertured, rectangular element of square-loop material. The material may be thicker near the hole.",PLESSEY UK LTD,JONES ALAN;;STAPLETON DAVID CHRISTOPHER;;SIMPSON ANTHONY WILLIAM,,https://lens.org/199-668-551-674-536,Granted Patent,no,0,0,3,3,0,G11C17/02,G11C17/02,G4A A17B1         G;;G4A A8G           G;;G4C CRM           ARM;;G4C CRM           CRM;;G4C C17B1         CRM;;G4C C1702         C1702;;H3B B200          DE;;H3B B212          DE;;H3B B213          DE;;H3B B270          DE;;H3B B300          DE;;H3B B350          DE;;H3B B380          DE;;H3B B390          DE;;H3B B392          DE;;H3B B404          DE;;H3B B416          DE;;H3B B418          DE;;H3B B420          DE;;H3B B460          DE;;H3B B477          DE;;H3X X3A           X3,0,0,,,,EXPIRED
16,CN,A,CN 111094962 A,039-053-518-215-298,2020-05-01,2020,CN 201880043627 A,2018-04-27,US 201762491408 P;;US 2018/0029732 W,2017-04-28,GLASS ELECTROCHEMICAL SENSOR WITH WAFER LEVEL STACKING AND THROUGH GLASS VIA (TGV) INTERCONNECTS,"A method of forming a glass electrochemical sensor is described. In some embodiments, the method may include forming a plurality of electrical through glass vias (TGVs) in an electrode substrate; filling each of the plurality of electrical TGVs with an electrode material; forming a plurality of contact TGVs in the electrode substrate; filling each of the plurality of contact TGVs with a conductivematerial; patterning the conductive material to connect the electrical TGVs with the contact TGVs; forming a cavity in a first glass layer; and bonding a first side of the first glass layer to the electrode substrate.",CORNING INC,BELLMAN ROBERT ALAN;;KING JEFFREY STAPLETON;;POLLARD SCOTT CHRISTOPHER,,https://lens.org/039-053-518-215-298,Patent Application,no,5,2,5,5,0,G01N27/404;;G01N27/4062;;G01N27/404;;G01N27/4062;;C03C27/10;;C03C17/06;;C03C2217/254;;C03B33/0222;;C03C15/00;;C03C23/0025;;G01N27/413,G01N27/404;;G01N27/406;;H01L21/00,,0,0,,,,DISCONTINUED
17,EP,B1,EP 0912944 B1,073-910-551-473-068,2000-11-22,2000,EP 97932943 A,1997-07-23,GB 9701995 W;;GB 9615445 A,1996-07-23,CASCADE CONNECTION OF COMMUNICATING DEVICES,,3COM TECHNOLOGIES LTD,STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH DAVID R;;OVERS PATRICK,3COM TECHNOLOGIES (2000-05-17),https://lens.org/073-910-551-473-068,Granted Patent,yes,2,2,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/14;;G06F13/40;;H04L29/02,,0,0,,,,EXPIRED
18,US,B2,US 11630076 B2,102-926-284-581-65X,2023-04-18,2023,US 201816608500 A,2018-04-27,US 201816608500 A;;US 201762491408 P;;US 2018/0029732 W,2017-04-28,Glass electrochemical sensor with wafer level stacking and through glass via (TGV) interconnects,"A method of forming a glass electrochemical sensor is described. In some embodiments, the method may include forming a plurality of electrical through glass vias (TGVs) in an electrode substrate; filling each of the plurality of electrical TGVs with an electrode material; forming a plurality of contact TGVs in the electrode substrate; filling each of the plurality of contact TGVs with a conductive material; patterning the conductive material to connect the electrical TGVs with the contact TGVs; forming a cavity in a first glass layer; and bonding a first side of the first glass layer to the electrode substrate.",CORNING INC,BELLMAN ROBERT ALAN;;KING JEFFREY STAPLETON;;POLLARD SCOTT CHRISTOPHER,CORNING INCORPORATED (2018-04-26),https://lens.org/102-926-284-581-65X,Granted Patent,yes,19,0,5,5,0,G01N27/404;;G01N27/4062;;G01N27/404;;G01N27/4062;;C03C27/10;;C03C17/06;;C03C2217/254;;C03B33/0222;;C03C15/00;;C03C23/0025;;G01N27/413,C03B33/02;;C03C17/06;;C03C27/10;;G01N27/404;;G01N27/406,,4,3,083-474-843-312-447;;140-682-945-223-674;;027-301-467-360-712,10.1109/iembs.1997.758812;;10.1088/0960-1317/25/10/105013;;10.1088/0957-4484/18/13/135304;;21730378,"Choi et al; “A Microchip Electrochemical Immunosensor Fabricated Using Micromachining Techniques”; Proceedings of The 19th Annual Internaitonal Conference of The IEEE/EMBS. “Magnificent Milestones and Emerging Opportunities in Medical Engineering”; (Cat. No. 97CH36136); pp. 2264-2266; vol. 5, 1997.;;Gatty et al; “A Wafer-Level Liquid Cavity Integrated Amperometric Gas Sensor With PPB-Level Nitric Oxide Gas Sensitivity”; Journal of Micromachanics and Microengineering; vol. 25, No. 10, 105013;(2015); pp. 1-10.;;International Search Report and Written Opinion of The International Searching Authority; PCT/US2018/029732; dated Jul. 5, 2018; 15 Pages; European Patent Office.;;Wong et al; “Fabrication of Self-Sealed Circular Nano/Microfluidic Channels in Glass Substrates”; Nanotechnology, vol. 18, No. 13, (2007); pp. 1-6.",ACTIVE
19,EP,A2,EP 1008943 A2,181-556-530-149-417,2000-06-14,2000,EP 00102428 A,1997-07-23,EP 97932943 A;;GB 9615445 A,1996-07-23,Cascade connection of communicating devices,"A communications apparatus comprising a plurality of communication devices each having a plurality of ports and a data bus interconnecting the plurality of units, wherein each device is provided with means enabling the device to detect automatically its position on the data bus.",3COM IRELAND,STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH DAVID R;;OVERS PATRICK,3COM TECHNOLOGIES (2000-06-21),https://lens.org/181-556-530-149-417,Patent Application,yes,0,0,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/14;;G06F13/40;;H04L29/02,,0,0,,,,EXPIRED
20,DE,D1,DE 69720546 D1,178-231-817-053-486,2003-05-08,2003,DE 69720546 T,1997-07-23,GB 9615445 A,1996-07-23,Kaskadierter Anschluss von kommuniziernden Geräten,,3COM TECHNOLOGIES GEORGETOWN,STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH DAVID R;;OVERS PATRICK,,https://lens.org/178-231-817-053-486,Granted Patent,no,0,0,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/14;;G06F13/40;;H04L29/02,,0,0,,,,EXPIRED
21,EP,A1,EP 0912944 A1,194-220-351-685-276,1999-05-06,1999,EP 97932943 A,1997-07-23,GB 9701995 W;;GB 9615445 A,1996-07-23,CASCADE CONNECTION OF COMMUNICATING DEVICES,,3COM IRELAND,STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH DAVID R;;OVERS PATRICK,3COM TECHNOLOGIES (2000-05-17),https://lens.org/194-220-351-685-276,Patent Application,yes,0,2,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/14;;G06F13/40;;H04L29/02,,0,0,,,,EXPIRED
22,EP,B1,EP 1008943 B1,053-715-913-809-94X,2003-04-02,2003,EP 00102428 A,1997-07-23,EP 97932943 A;;GB 9615445 A,1996-07-23,Cascade connection of communicating devices,,3COM TECHNOLOGIES LTD,STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH DAVID R;;OVERS PATRICK,3COM TECHNOLOGIES (2000-06-21),https://lens.org/053-715-913-809-94X,Granted Patent,yes,2,0,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/14;;G06F13/40;;H04L29/02,,0,0,,,,EXPIRED
23,US,A1,US 2006/0137518 A1,195-217-301-912-847,2006-06-29,2006,US 1931104 A,2004-12-23,US 1931104 A,2004-12-23,Expandable hydraulic valve stack,"A hydraulic valve stack for a work machine is disclosed. The hydraulic valve stack has a base with a first mounting surface and a second mounting surface. The base is connectable to the work machine and has at least one fluid passageway extending through the base from the first mounting surface to the second mounting surface. The hydraulic valve stack also has a permanent valve assembly configured to control a permanent function of the work machine and an optional valve assembly configured to control an optional function of the work machine. The permanent valve assembly is connectable to the first mounting surface of the base, while the optional valve assembly is connectable to the second mounting surface of the base. Each of the permanent and the optional valve assemblies have at least one fluid passageway in communication with the at least one fluid passageway of the base.",CATERPILLAR INC,MORENCY CHRISTOPHER M;;STAPLETON EDWARD L;;PAYNE WESLEY T,CATERPILLAR INC (2005-03-10),https://lens.org/195-217-301-912-847,Patent Application,yes,9,5,3,3,0,E02F9/2267;;E02F9/2267;;F15B13/0839;;F15B13/0839;;F15B13/0828;;F15B13/0828;;F15B13/0896;;F15B13/0896;;Y10T137/87885;;Y10T137/87885,F15B13/04,91/418,0,0,,,,INACTIVE
24,US,B2,US 7293494 B2,033-918-193-554-137,2007-11-13,2007,US 1931104 A,2004-12-23,US 1931104 A,2004-12-23,Expandable hydraulic valve stack,"A hydraulic valve stack for a work machine is disclosed. The hydraulic valve stack has a base with a first mounting surface and a second mounting surface. The base is connectable to the work machine and has at least one fluid passageway extending through the base from the first mounting surface to the second mounting surface. The hydraulic valve stack also has a permanent valve assembly configured to control a permanent function of the work machine and an optional valve assembly configured to control an optional function of the work machine. The permanent valve assembly is connectable to the first mounting surface of the base, while the optional valve assembly is connectable to the second mounting surface of the base. Each of the permanent and the optional valve assemblies have at least one fluid passageway in communication with the at least one fluid passageway of the base.",CATERPILLAR INC,MORENCY CHRISTOPHER MICHAEL;;STAPLETON EDWARD LEE;;PAYNE WESLEY THOMAS,CATERPILLAR INC (2005-03-10),https://lens.org/033-918-193-554-137,Granted Patent,yes,9,5,3,3,0,E02F9/2267;;E02F9/2267;;F15B13/0839;;F15B13/0839;;F15B13/0828;;F15B13/0828;;F15B13/0896;;F15B13/0896;;Y10T137/87885;;Y10T137/87885,F01B29/04;;F15B13/00,91/54;;60/458;;137/884,0,0,,,,INACTIVE
25,DE,T2,DE 69720546 T2,141-846-397-557-108,2004-09-16,2004,DE 69720546 T,1997-07-23,GB 9615445 A,1996-07-23,Kaskadierter Anschluss von kommuniziernden Geräten,,3COM TECHNOLOGIES GEORGETOWN,STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH DAVID R;;OVERS PATRICK,,https://lens.org/141-846-397-557-108,Granted Patent,no,0,0,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/14;;G06F13/40;;H04L29/02,,0,0,,,,EXPIRED
26,WO,A1,WO 1998/003921 A1,036-187-299-352-27X,1998-01-29,1998,GB 9701995 W,1997-07-23,GB 9615445 A,1996-07-23,CASCADE CONNECTION OF COMMUNICATING DEVICES,"A communications apparatus comprising a plurality of communication devices each having a plurality of ports and a data bus interconnecting the plurality of units, wherein each device is provided with means enabling the device to detect automatically its position on the data bus.",3COM IRELAND;;STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH DAVID R;;OVERS PATRICK,STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH DAVID R;;OVERS PATRICK,,https://lens.org/036-187-299-352-27X,Patent Application,yes,2,7,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/40;;G06F13/14;;H04L29/02,,0,0,,,,PATENTED
27,US,A1,US 2020/0173956 A1,164-981-930-455-916,2020-06-04,2020,US 201816608500 A,2018-04-27,US 201816608500 A;;US 201762491408 P;;US 2018/0029732 W,2017-04-28,GLASS ELECTROCHEMICAL SENSOR WITH WAFER LEVEL STACKING AND THROUGH GLASS VIA (TGV) INTERCONNECTS,"A method of forming a glass electrochemical sensor is described. In some embodiments, the method may include forming a plurality of electrical through glass vias (TGVs) in an electrode substrate; filling each of the plurality of electrical TGVs with an electrode material; forming a plurality of contact TGVs in the electrode substrate; filling each of the plurality of contact TGVs with a conductive material; patterning the conductive material to connect the electrical TGVs with the contact TGVs; forming a cavity in a first glass layer; and bonding a first side of the first glass layer to the electrode substrate.",CORNING INC,BELLMAN ROBERT ALAN;;KING JEFFREY STAPLETON;;POLLARD SCOTT CHRISTOPHER,,https://lens.org/164-981-930-455-916,Patent Application,yes,1,3,5,5,0,G01N27/404;;G01N27/4062;;G01N27/404;;G01N27/4062;;C03C27/10;;C03C17/06;;C03C2217/254;;C03B33/0222;;C03C15/00;;C03C23/0025;;G01N27/413,G01N27/404,,0,0,,,,ACTIVE
28,EP,A3,EP 1008943 A3,186-932-464-049-415,2001-10-31,2001,EP 00102428 A,1997-07-23,EP 97932943 A;;GB 9615445 A,1996-07-23,Cascade connection of communicating devices,"A communications apparatus comprising a plurality of communication devices each having a plurality of ports and a data bus interconnecting the plurality of units, wherein each device is provided with means enabling the device to detect automatically its position on the data bus.",3COM TECHNOLOGIES LTD,STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH DAVID R;;OVERS PATRICK,3COM TECHNOLOGIES (2000-06-21),https://lens.org/186-932-464-049-415,Search Report,yes,2,0,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/14;;G06F13/40;;H04L29/02,,0,0,,,,EXPIRED
29,AU,A1,AU 2019/257501 A1,086-258-279-504-044,2019-11-21,2019,AU 2019/257501 A,2019-10-31,AU 2019/257501 A;;AU 2018/201758 A;;AU 2014/225446 A;;US 201361774735 P;;US 201361793336 P;;US 201361774773 P;;US 201361774740 P;;US 201361774731 P;;US 201361774780 P;;US 201361774761 P;;US 201361774744 P;;US 201361774746 P;;US 201361774684 P;;US 201361774723 P;;US 201361774754 P;;US 201361774775 P;;US 201361774750 P;;US 201361774752 P;;US 2014/0021815 W,2013-03-08,Upgrading Process Streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or 5 electrodialysis reversal. Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/086-258-279-504-044,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,DISCONTINUED
30,DE,A1,DE 102005052704 A1,022-276-598-396-877,2006-07-06,2006,DE 102005052704 A,2005-11-04,US 1931104 A,2004-12-23,Erweiterbarer Hydraulikventilstapel,"Ein Hydraulikventilstapel (44) für eine Arbeitsmaschine (10) wird offenbart. Der Hydraulikventilstapel hat eine Basis (50) mit einer ersten Montagefläche (54) und einer zweiten Montagefläche (56). Die Basis ist mit der Arbeitsmaschine zu verbinden und hat mindestens einen Strömungsmitteldurchlassweg (58), der sich durch die Basis von der ersten Montagefläche zur zweiten Montagefläche erstreckt. Der Hydraulikventilstapel hat auch eine permanente Ventilanordnung (94), die konfiguriert ist, um eine permanente Funktion der Arbeitsmaschine zu steuern, und eine optionale Ventilanordnung (100), die konfiguriert ist, um eine optionale Funktion der Arbeitsmaschine zu steuern. Die permanente Ventilanordnung ist mit der ersten Montagefläche der Basis zu verbinden, während die optionale Ventilanordnung mit der zweiten Montagefläche der Basis zu verbinden ist. Sowohl die permanenten als auch die optionalen Ventilanordnungen haben mindestens einen Strömungsmitteldurchlassweg (160, 140) in Verbindung mit dem mindestens einen Strömungsmitteldurchlassweg der Basis.",CATERPILLAR INC,MORENCY CHRISTOPHER M;;PAYNE WESLEY T;;STAPLETON EDWARD L,,https://lens.org/022-276-598-396-877,Patent Application,no,0,1,3,3,0,E02F9/2267;;E02F9/2267;;F15B13/0839;;F15B13/0839;;F15B13/0828;;F15B13/0828;;F15B13/0896;;F15B13/0896;;Y10T137/87885;;Y10T137/87885,F15B13/08;;B66F9/22;;E02F3/42;;E02F9/20;;F15B13/00;;F15B21/00,,0,0,,,,DISCONTINUED
31,US,A1,US 2023/0221278 A1,143-411-915-267-793,2023-07-13,2023,US 202318122192 A,2023-03-16,US 202318122192 A;;US 201916608500 A;;US 2018/0029732 W;;US 201762491408 P,2017-04-28,GLASS ELECTROCHEMICAL SENSOR WITH WAFER LEVEL STACKING AND THROUGH GLASS VIA (TGV) INTERCONNECTS,"A method of forming a glass electrochemical sensor is described. In some embodiments, the method may include forming a plurality of electrical through glass vias (TGVs) in an electrode substrate; filling each of the plurality of electrical TGVs with an electrode material; forming a plurality of contact TGVs in the electrode substrate; filling each of the plurality of contact TGVs with a conductive material; patterning the conductive material to connect the electrical TGVs with the contact TGVs; forming a cavity in a first glass layer; and bonding a first side of the first glass layer to the electrode substrate.",CORNING INC,BELLMAN ROBERT ALAN;;KING JEFFREY STAPLETON;;POLLARD SCOTT CHRISTOPHER,,https://lens.org/143-411-915-267-793,Patent Application,yes,2,0,5,5,0,G01N27/404;;G01N27/4062;;G01N27/404;;G01N27/4062;;C03C27/10;;C03C17/06;;C03C2217/254;;C03B33/0222;;C03C15/00;;C03C23/0025;;G01N27/413,C03C15/00;;G01N27/413;;C03C17/06;;C03C23/00;;C03C27/10,,2,0,,,"""Glass"" posted by the Materials Science & Engineering department of the University of New South Wales – Sydney, author unknown; https://www.unsw.edu.au/science/our-schools/materials/engage-with-us/high-school-students-and-teachers/online-tutorials/ceramics/glass#:~:text=Glasses%20are%20a%20unique% (Year: 2023);;Akartuna et al., slide deck entitled “Ceramic Materials – Chapter 5: Glass” for a Materials Science II lecture presented at the ETH-Zurich; chromextension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.nonmet.mat.ethz.ch/education/courses/Materialwissenschaft_1/Downloads_HS_2007/slides_chapter_5.pdf (Year: 2007)",PENDING
32,WO,A1,WO 2018/200920 A1,156-779-403-220-77X,2018-11-01,2018,US 2018/0029732 W,2018-04-27,US 201762491408 P,2017-04-28,GLASS ELECTROCHEMICAL SENSOR WITH WAFER LEVEL STACKING AND THROUGH GLASS VIA (TGV) INTERCONNECTS,"A method of forming a glass electrochemical sensor is described. In some embodiments, the method may include forming a plurality of electrical through glass vias (TGVs) in an electrode substrate; filling each of the plurality of electrical TGVs with an electrode material; forming a plurality of contact TGVs in the electrode substrate; filling each of the plurality of contact TGVs with a conductive material; patterning the conductive material to connect the electrical TGVs with the contact TGVs; forming a cavity in a first glass layer; and bonding a first side of the first glass layer to the electrode substrate.",CORNING INC;;BELLMAN ROBERT ALAN;;KING JEFFREY STAPLETON;;POLLARD SCOTT CHRISTOPHER,BELLMAN ROBERT ALAN;;KING JEFFREY STAPLETON;;POLLARD SCOTT CHRISTOPHER,,https://lens.org/156-779-403-220-77X,Patent Application,yes,7,0,5,5,0,G01N27/404;;G01N27/4062;;G01N27/404;;G01N27/4062;;C03C27/10;;C03C17/06;;C03C2217/254;;C03B33/0222;;C03C15/00;;C03C23/0025;;G01N27/413,G01N27/404;;G01N27/406;;H01L21/00,,0,0,,,,PENDING
33,WO,A1,WO 2014/138600 A1,016-864-761-407-972,2014-09-12,2014,US 2014/0021815 W,2014-03-07,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P,2013-03-08,UPGRADING PROCESS STREAMS,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials.. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. ] Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/016-864-761-407-972,Patent Application,yes,8,9,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,1,0,,,See also references of EP 2890798A4,PENDING
34,CA,A1,CA 2853622 A1,167-036-441-091-579,2013-05-23,2013,CA 2853622 A,2012-08-24,US 201161556270 P;;US 201213443947 A;;US 2012/0052185 W,2011-11-06,ASYMMETRIC RADIAL SPLINE SEAL FOR A GAS TURBINE ENGINE,"A shroud apparatus for a gas turbine engine includes: an annular shroud segment (26) having an arcuate bottom wall (52) defining an arcuate inner flowpath surface(62), spaced-apart forward and aft walls (54, 56) extending radially outward from the bottom wall (52), and spaced-apart side walls (58) extending radially outward from the bottom wall (52) and between the forward and aft walls (54, 56), each side wall (58) defining an end face (74) which includes: an axial slot (76) extending in a generally axial direction along the end face (74); a first radial slot (78) extending in a generally radial direction along the end face (74), and intersecting the axial slot (76); an axial spline seal (82) received in the axial slot (76); and a first radial spline seal (84) having an L-shape with radial and axial legs (88, 90), the radial leg (88)being substantially longer than the axial leg (90), wherein the radial leg (88) is received in the first radial slot (78), and the axial leg is received in the axial slot (76).",GEN ELECTRIC,STAPLETON DAVID SCOTT;;CEGLIO CHRISTOPHER MICHAEL;;CORREIA VICTOR HUGO SILVA,,https://lens.org/167-036-441-091-579,Patent Application,no,0,0,15,15,0,F01D11/005;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/11;;F05D2240/57;;F05D2240/57;;F05D2240/59;;F05D2240/59,F04D29/40,,0,0,,,,INACTIVE
35,NZ,A,NZ 751359 A,197-011-196-649-838,2019-09-27,2019,NZ 75135914 A,2014-03-07,US 201361774735 P;;US 201361774740 P;;US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P;;NZ 70611814 A,2013-03-08,Upgrading process streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER;;MEDOFF MARSHALL,,https://lens.org/197-011-196-649-838,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10;;B01D61/44;;B01J19/08,,0,0,,,,DISCONTINUED
36,US,B2,US 9637802 B2,014-364-209-825-982,2017-05-02,2017,US 201414299010 A,2014-06-09,US 201414299010 A;;US 2014/0021815 W;;US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P,2013-03-08,Upgrading process streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,XYLECO INC (2014-06-09),https://lens.org/014-364-209-825-982,Granted Patent,yes,51,7,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,B01D61/44;;B01D15/02;;B01D53/32;;B01J19/08;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C10L9/08;;C12M1/00;;C12P7/06;;C12P7/10;;C12P7/52;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/00;;E04B1/92;;G21F7/00;;H01J37/317,,14,1,169-141-851-602-500,pmc2635757;;19325822;;10.3390/ijms9091621,"Allison, “High Water Recovery with Electrodialysis Reversal,” GE Power and Water, Water and Process Technologies, Technical Paper, TP1071EN.doc, Mar. 2010 (5 pages).;;Bar, “Conversion of Sodium Acetate into Reusable Acetic Acid and Caustic Soda,” Membrane & Separation Technology News, Mar. 2006 (1 pages).;;Chu, “Overview of Light-Ion Beam Therapy,” Columbus-Ohio, ICRU-IAEA Meeting, Mar. 18-20, 2006 (20 pages).;;International Search Report issued by the United States Patent and Trademark Office as Searching Authority for International Patent Application No. PCT/US2014/021815 mailed May 23, 2014 (4 pages).;;Iwata et al., “Alternating-Phase-Focused IH-DTL for Heavy-Ion Medical Accelerators,” Proceedings of EPAC 2006, Edinburgh, Scotland, No Month Listed 2006 (pp. 2328-2330).;;Leitner et al., “Status of the Superconducting ECR Ion Source Venus,” Proceedings of EPAC 2000, Vienna, Austria, No Month Listed 2000 (pp. 1610-1612).;;No Author Listed, “Electrodialysis (ED) and Electrodialysis Reversal (EDR),” retrieved online at [URL:<<<http://webcache.googleusercontent.com/search?g=cache:vfsxcuDgFtUJ:www.usbr.gov/tsc/water/publications/reportpdfs/Primer%2520Files/07%2520-%2520Electrodialysis.pdf&cd=1&hl=en&ct=clnk&gl=us>>>] on Oct. 6, 2015 (5 pages).;;Philippidis, “Cellulose Bioconversion Technology,” Handbook on Bioethanol: Production and Utilization, Chapter 12, Wyman, C.E., ed., Taylor & Francis, Washington, DC, No Month Listed 1996 (35 pages).;;Prelec, “Ions and Ion Accelerators for Cancer Treatment,” FIZIKA B 6, vol. 4, No Month Listed 1997, (pp. 177-206).;;Written Opinion issued by the United States Patent and Trademark Office as Searching Authority for International Patent Application No. PCT/US2014/021815 mailed May 23, 2014 (4 pages).;;European Supplemental Search Report issued in EP14760021.7, mailed May 27, 2016 (7 pages).;;PC CELL GmbH, “Electrodialysis Cell Unit: PCCell ED 64 0 02—Technical Data”, Jan. 2006 (11 pages).;;Zheng et al., “Overview of biomass pretreatment for cellulosic ethanol production,” International Journal of Agricultural and Biological Engineering, Sep. 2009, vol. 2, No. 3, pp. 51-68.;;Taherzadeh et al., “Pretreatment of Lignocellulosic Wastes to Improve Ethanol and Biogas Production: A Review,” International Journal of Molecular Sciences, Sep. 1, 2008, vol. 9, No. 9, pp. 1621-1651.",ACTIVE
37,PH,A1,PH 12015500600 A1,075-571-277-503-664,2015-05-11,2015,PH 12015500600 A,2015-03-18,US 201361774740 P;;US 201361774775 P;;US 201361774746 P;;US 201361774684 P;;US 201361774752 P;;US 201361774735 P;;US 201361774754 P;;US 201361774773 P;;US 201361774723 P;;US 201361793336 P;;US 201361774780 P;;US 201361774750 P;;US 201361774744 P;;US 201361774731 P;;US 201361774761 P;;US 2014/0021815 W,2013-03-08,UPGRADING PROCESS STREAMS,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials.. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. ] Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MARSHALL MEDOFF;;CRAIG MASTERMAN THOMAS;;STAPLETON MUKHERJEE MAIA;;CHRISTOPHER COOPER,,https://lens.org/075-571-277-503-664,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,PENDING
38,WO,A2,WO 2013/074165 A2,011-193-525-898-347,2013-05-23,2013,US 2012/0052185 W,2012-08-24,US 201161556270 P;;US 201213443947 A,2011-11-06,ASYMMETRIC RADIAL SPLINE SEAL FOR A GAS TURBINE ENGINE,"A shroud apparatus for a gas turbine engine includes: an annular shroud segment having an arcuate bottom wall defining an arcuate inner flowpath surface, spaced-apart forward and aft walls extending radially outward from the bottom wall, and spaced-apart side walls extending radially outward from the bottom wall and between the forward and aft walls, each side wall defining an end face which includes: an axial slot extending in a generally axial direction along the end face; a first radial slot extending in a generally radial direction along the end face, and intersecting the axial slot; an axial spline seal received in the axial slot; and a first radial spline seal having an L-shape with radial and axial legs, the radial leg being substantially longer than the axial leg, wherein the radial leg is received in the first radial slot, and the axial leg is received in the axial slot.",GENEAL ELECTRIC COMPANY;;STAPLETON DAVID SCOTT;;CEGLIO CHRISTOPHER MICHAEL;;CORREIA VICTOR HUGO SILVA,STAPLETON DAVID SCOTT;;CEGLIO CHRISTOPHER MICHAEL;;CORREIA VICTOR HUGO SILVA,,https://lens.org/011-193-525-898-347,Patent Application,yes,0,2,15,15,0,F05D2240/59;;F05D2240/57;;F05D2240/11;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/59;;F05D2240/57;;F01D11/005,F04D29/40,,0,0,,,,PENDING
39,WO,A8,WO 2013/074165 A8,047-561-467-725-60X,2013-06-27,2013,US 2012/0052185 W,2012-08-24,US 201161556270 P;;US 201213443947 A,2011-11-06,ASYMMETRIC RADIAL SPLINE SEAL FOR A GAS TURBINE ENGINE,"A shroud apparatus for a gas turbine engine includes: an annular shroud segment having an arcuate bottom wall defining an arcuate inner flowpath surface, spaced-apart forward and aft walls extending radially outward from the bottom wall, and spaced-apart side walls extending radially outward from the bottom wall and between the forward and aft walls, each side wall defining an end face which includes: an axial slot extending in a generally axial direction along the end face; a first radial slot extending in a generally radial direction along the end face, and intersecting the axial slot; an axial spline seal received in the axial slot; and a first radial spline seal having an L-shape with radial and axial legs, the radial leg being substantially longer than the axial leg, wherein the radial leg is received in the first radial slot, and the axial leg is received in the axial slot.",GEN ELECTRIC;;STAPLETON DAVID SCOTT;;CEGLIO CHRISTOPHER MICHAEL;;CORREIA VICTOR HUGO SILVA,STAPLETON DAVID SCOTT;;CEGLIO CHRISTOPHER MICHAEL;;CORREIA VICTOR HUGO SILVA,,https://lens.org/047-561-467-725-60X,Amended Application,no,0,0,15,15,0,F01D11/005;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/11;;F05D2240/57;;F05D2240/57;;F05D2240/59;;F05D2240/59,F04D29/40,,0,0,,,,PENDING
40,GB,A,GB 2492783 A,105-065-435-070-927,2013-01-16,2013,GB 201111893 A,2011-07-12,GB 201111893 A,2011-07-12,Vehicle seat frame with detent mechanism,"An automobile seat has a back part 1 and a cushion part. The back part 1 is movable relative to the cushion part to a dumped state to allow access to rear seats of the automobile. A detent mechanism is provided to retain the back part in the dumped state unless as least a predetermined minimum force is applied to move the back part out of the dumped state. The detent mechanism may be formed by a cam follower 9 which moves relative to a cam profile 8 as the seat back is moved relative to the seat cushion. The cam follower may be urged into contact with the cam profile by a resilient member , such as a torsion bar, and the cam profile may be shaped so that the resilient member is compressed as the back part is moved out of the dumped state.",BENTLEY MOTORS LTD,STAPLETON NICHOLAS JAMES;;HUDSWELL MICHAEL ROY;;CHRISTOPHER HUGH;;SOUTHERINGTON PAUL,,https://lens.org/105-065-435-070-927,Patent Application,no,7,0,3,3,0,B60N2/20;;B60N2/20;;B60N2/10;;B60N2/14;;B60N2/225;;B60N2/2252;;B60N2002/952,B60N2/20;;B60N2/10;;B60N2/14,,0,0,,,,ACTIVE
41,BR,A8,BR 112014010747 A8,152-289-684-850-243,2017-06-20,2017,BR 112014010747 A,2012-08-24,US 2012/0052185 W;;US 201161556270 P;;US 201213443947 A,2011-11-06,aparelho de cobertura para um motor de turbina a gás,,GEN ELECTRIC,CHRISTOPHER MICHAEL CEGLIO;;DAVID SCOTT STAPLETON;;VICTOR HUGO SILVA CORREIA,,https://lens.org/152-289-684-850-243,Patent Application,no,0,0,15,15,0,F01D11/005;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/11;;F05D2240/57;;F05D2240/57;;F05D2240/59;;F05D2240/59,F01D11/00,,0,0,,,,DISCONTINUED
42,JP,A,JP 2019201642 A,155-036-951-162-837,2019-11-28,2019,JP 2019104386 A,2019-06-04,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P,2013-03-08,FLOW OF UPGRADING PROCESS,"To provide a method and equipment which are used to create a useful product from a biomass material.SOLUTION: A method includes: a process of saccharifying a cellulose-based material or a lignocellulose-based material to obtain saccharified biomass liquid containing glucose and xylose; a process of selectively fermenting the glucose to create fermentation broth containing unconverted xylose and fermentation product derived from fermentation of the glucose; and a process of removing salt, partially ionized acid or completely ionized acid from the fermentation broth by using a first electrodialysis system; and a process of neutralizing the removed salt by using a second electrodialysis system in which the second electrodialysis system is equipped with an electrodialysis system of a bipolar membrane.SELECTED DRAWING: Figure 1A",XYLECO INC,MARSHALL MEDOFF;;THOMAS CRAIG MASTERMAN;;MAIA STAPLETON MUKHERJEE;;CHRISTOPHER COOPER,,https://lens.org/155-036-951-162-837,Patent Application,no,8,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/56;;B01D61/44;;B01D61/58;;B09B3/00;;B09B5/00;;C12P7/10,,0,0,,,,PENDING
43,US,A1,US 2020/0156039 A1,087-435-120-777-703,2020-05-21,2020,US 201916704850 A,2019-12-05,US 201916704850 A;;US 201815913740 A;;US 201715487565 A;;US 201414299010 A;;US 2014/0021815 W;;US 201361793336 P;;US 201361774780 P;;US 201361774775 P;;US 201361774684 P;;US 201361774761 P;;US 201361774731 P;;US 201361774773 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774723 P,2013-03-08,UPGRADING PROCESS STREAMS,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/087-435-120-777-703,Patent Application,yes,0,1,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,B01J19/08;;B01D15/02;;B01D53/32;;B01D61/44;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/02;;C10L9/08;;C12M1/00;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/00;;D21C9/00;;E04B1/92;;G21F7/00;;H01J37/317,,0,0,,,,DISCONTINUED
44,US,B1,US 6523070 B1,102-641-286-916-397,2003-02-18,2003,US 23039100 A,2000-02-23,GB 9615445 A;;GB 9701995 W,1996-07-23,Communication device with circuitry to promote cascade series connection including identification of device position in the series and sensing the end device in the series,"
    A communications apparatus comprising a plurality of communication devices each having a plurality of ports and a data bus interconnecting the plurality of units, wherein each device is provided with means enabling the device to detect automatically its position on the data bus. 
",3COM CORP,STAPLETON NICHOLAS;;WALKER CHRISTOPHER;;SMITH DAVID R;;OVERS PATRICK M,HEWLETT-PACKARD COMPANY (2010-04-28);;3COM TECHNOLOGIES (1999-02-15),https://lens.org/102-641-286-916-397,Granted Patent,yes,8,50,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/40;;G06F13/14;;H04L29/02,709/250;;709/253;;710/126;;710/129,0,0,,,,EXPIRED
45,SG,A,SG 11201502397T A,132-160-196-207-328,2015-04-29,2015,SG 11201502397T A,2014-03-07,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,UPGRADING PROCESS STREAMS,,XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/132-160-196-207-328,Unknown,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,PENDING
46,US,A1,US 2014/0318969 A1,155-744-835-515-401,2014-10-30,2014,US 201414299010 A,2014-06-09,US 201414299010 A;;US 2014/0021815 W;;US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P,2013-03-08,UPGRADING PROCESS STREAMS,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,XYLECO INC (2014-06-09),https://lens.org/155-744-835-515-401,Patent Application,yes,3,7,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,B01D61/44,204/540,0,0,,,,ACTIVE
47,SG,A,SG 10201704485U A,167-153-326-631-130,2017-06-29,2017,SG 10201704485U A,2014-03-07,US 201361774684 P;;US 201361774723 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774761 P;;US 201361774773 P;;US 201361774775 P;;US 201361774780 P;;US 201361793336 P,2013-03-08,UPGRADING PROCESS STREAMS,,XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/167-153-326-631-130,Unknown,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,,,0,0,,,,PENDING
48,EA,B1,EA 030216 B1,191-704-647-966-554,2018-07-31,2018,EA 201591323 A,2014-03-07,US 201361774684 P;;US 201361774723 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774761 P;;US 201361774773 P;;US 201361774775 P;;US 201361774780 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,METHOD FOR UPGRADING SACCHARIFIED BIOMASS LIQUID,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/191-704-647-966-554,Granted Patent,no,4,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,ACTIVE
49,AU,B2,AU 2018/201758 B2,067-375-165-025-452,2019-11-21,2019,AU 2018/201758 A,2018-03-12,AU 2018/201758 A;;AU 2014/225446 A;;US 201361774735 P;;US 201361793336 P;;US 201361774773 P;;US 201361774740 P;;US 201361774731 P;;US 201361774780 P;;US 201361774761 P;;US 201361774744 P;;US 201361774746 P;;US 201361774684 P;;US 201361774723 P;;US 201361774754 P;;US 201361774775 P;;US 201361774750 P;;US 201361774752 P;;US 2014/0021815 W,2013-03-08,Upgrading Process Streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or 5 electrodialysis reversal. Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/067-375-165-025-452,Granted Patent,no,5,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,INACTIVE
50,NZ,A,NZ 706118 A,083-416-503-399-536,2019-09-27,2019,NZ 70611814 A,2014-03-07,US 2014/0021815 W;;US 201361774731 P;;US 201361774735 P;;US 201361774684 P;;US 201361774773 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P,2013-03-08,Upgrading process streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials.. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. ] Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER;;MEDOFF MARSHALL,,https://lens.org/083-416-503-399-536,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10;;B01D61/44;;B01J19/08,,0,0,,,,DISCONTINUED
51,BR,A2,BR 112015019380 A2,157-582-748-604-493,2017-12-12,2017,BR 112015019380 A,2014-03-07,US 2014/0021815 W;;US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P,2013-03-08,aprimoramento de fluxos de processos,,XYLECO INC,CHRISTOPHER COOPER;;MAIA STAPLETON MUKHERJEE;;MARSHALL MEDOFF;;THOMAS CRAIG MASTERMAN,,https://lens.org/157-582-748-604-493,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,INACTIVE
52,IN,A,IN 3298CHN2014 A,013-874-064-622-554,2015-10-09,2015,IN 3298CHN2014 A,2014-05-01,US 201161556270 P;;US 201213443947 A;;US 2012/0052185 W,2011-11-06,ASYMMETRIC RADIAL SPLINE SEAL FOR A GAS TURBINE ENGINE,A shroud apparatus for a gas turbine engine includes: an annular shroud segment (26) having an arcuate bottom wall (52) defining an arcuate inner flowpath surface(62) spaced apart forward and aft walls (54 56) extending radially outward from the bottom wall (52) and spaced apart side walls (58) extending radially outward from the bottom wall (52) and between the forward and aft walls (54 56) each side wall (58) defining an end face (74) which includes: an axial slot (76) extending in a generally axial direction along the end face (74); a first radial slot (78) extending in a generally radial direction along the end face (74) and intersecting the axial slot (76); an axial spline seal (82) received in the axial slot (76); and a first radial spline seal (84) having an L shape with radial and axial legs (88 90) the radial leg (88)being substantially longer than the axial leg (90) wherein the radial leg (88) is received in the first radial slot (78) and the axial leg is received in the axial slot (76).,GEN ELECTRIC,STAPLETON DAVID SCOTT;;CEGLIO CHRISTOPHER MICHAEL;;CORREIA VICTOR HUGO SILVA,,https://lens.org/013-874-064-622-554,Patent Application,no,0,0,15,15,0,F01D11/005;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/11;;F05D2240/57;;F05D2240/57;;F05D2240/59;;F05D2240/59,F01D11/00,,0,0,,,,PENDING
53,EP,A4,EP 2890798 A4,060-458-685-873-251,2016-06-29,2016,EP 14760021 A,2014-03-07,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,UPGRADING PROCESS STREAMS,,XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,"XYLECO, INC. (2018-02-28)",https://lens.org/060-458-685-873-251,Search Report,no,4,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,G01T7/08;;C10L9/08,,1,0,,,See also references of WO 2014138600A1,ACTIVE
54,MX,A,MX 2015011318 A,059-049-808-173-608,2016-03-03,2016,MX 2015011318 A,2014-03-07,US 201361774684 P;;US 201361774723 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774761 P;;US 201361774773 P;;US 201361774775 P;;US 201361774780 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,UPGRADING PROCESS STREAMS.,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials.. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. ] Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MEDOFF MARSHALL;;COOPER CHRISTOPHER;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON,,https://lens.org/059-049-808-173-608,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,ACTIVE
55,AU,A1,AU 2014/225446 A1,073-591-020-478-008,2015-04-02,2015,AU 2014/225446 A,2014-03-07,US 201361774735 P;;US 201361793336 P;;US 201361774773 P;;US 201361774740 P;;US 201361774731 P;;US 201361774780 P;;US 201361774761 P;;US 201361774744 P;;US 201361774746 P;;US 201361774684 P;;US 201361774723 P;;US 201361774754 P;;US 201361774775 P;;US 201361774750 P;;US 201361774752 P;;US 2014/0021815 W,2013-03-08,Upgrading process streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials.. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. ] Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/073-591-020-478-008,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,INACTIVE
56,CA,A1,CA 2886776 A1,166-948-584-310-447,2014-09-12,2014,CA 2886776 A,2014-03-07,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,UPGRADING PROCESS STREAMS,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials.. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. ] Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/166-948-584-310-447,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,DISCONTINUED
57,MX,B,MX 368602 B,160-588-259-762-437,2019-10-09,2019,MX 2015011318 A,2014-03-07,US 201361774684 P;;US 201361774723 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774761 P;;US 201361774773 P;;US 201361774775 P;;US 201361774780 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,UPGRADING PROCESS STREAMS.,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials.. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. ] Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MEDOFF MARSHALL;;COOPER CHRISTOPHER;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON,,https://lens.org/160-588-259-762-437,Granted Patent,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10;;B01D15/02;;B01D53/02;;B01D53/32;;C07C29/149;;C10G1/00;;C10L9/08;;C12P7/52;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/00,,0,0,,,,ACTIVE
58,EP,A1,EP 2890798 A1,102-747-165-074-002,2015-07-08,2015,EP 14760021 A,2014-03-07,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,METHOD FOR OBTAINING SACCHARIFIED BIOMASS WITH RADIATION AND ELECTRODIALYSIS,,XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,"XYLECO, INC. (2018-02-28)",https://lens.org/102-747-165-074-002,Patent Application,yes,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,G01T7/08;;C10L9/08,,0,0,,,,ACTIVE
59,GB,B,GB 2492783 B,117-693-466-746-160,2018-06-06,2018,GB 201111893 A,2011-07-12,GB 201111893 A,2011-07-12,Frame for vehicle seat with a detent mechanism,,BENTLEY MOTORS LTD,NICHOLAS JAMES STAPLETON;;MICHAEL ROY HUDSWELL;;HUGH CHRISTOPHER;;PAUL SOUTHERINGTON,,https://lens.org/117-693-466-746-160,Granted Patent,no,7,0,3,3,0,B60N2/20;;B60N2/20;;B60N2/10;;B60N2/14;;B60N2/225;;B60N2/2252;;B60N2002/952,B60N2/20;;B60N2/10;;B60N2/14,,0,0,,,,ACTIVE
60,GB,A,GB 2331435 A,118-946-476-662-146,1999-05-19,1999,GB 9900809 A,1997-07-23,GB 9701995 W;;GB 9615445 A,1996-07-23,Casdade connection of communicating devices,"A communications apparatus comprising a plurality of communication devices each having a plurality of ports and a data bus interconnecting the plurality of units, wherein each device is provided with means enabling the device to detect automatically its position on the data bus.",3COM IRELAND,STAPLETON NICHOLAS;;WALKER CHRISTOPHER ALAN;;SMITH DAVID R;;OVERS PATRICK,,https://lens.org/118-946-476-662-146,Patent Application,no,2,0,14,14,0,G06F13/4068;;G06F13/4072;;G06F13/4068;;G06F13/4072,G06F13/14;;G06F13/40;;H04L29/02,H4P PPF           PPF,0,0,,,,DISCONTINUED
61,EP,A2,EP 2776681 A2,173-845-438-977-237,2014-09-17,2014,EP 12832724 A,2012-08-24,US 201161556270 P;;US 201213443947 A;;US 2012/0052185 W,2011-11-06,ASYMMETRIC RADIAL SPLINE SEAL FOR A GAS TURBINE ENGINE,,GEN ELECTRIC,STAPLETON DAVID SCOTT;;CEGLIO CHRISTOPHER MICHAEL;;CORREIA VICTOR HUGO SILVA,,https://lens.org/173-845-438-977-237,Patent Application,yes,0,0,15,15,0,F01D11/005;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/11;;F05D2240/57;;F05D2240/57;;F05D2240/59;;F05D2240/59,F01D11/00,,1,0,,,See references of WO 2013074165A2,DISCONTINUED
62,BR,A2,BR 112014010747 A2,004-929-061-372-51X,2017-06-13,2017,BR 112014010747 A,2012-08-24,US 2012/0052185 W;;US 201161556270 P;;US 201213443947 A,2011-11-06,aparelho de cobertura para um motor de turbina a gás,,GEN ELECTRIC,CHRISTOPHER MICHAEL CEGLIO;;DAVID SCOTT STAPLETON;;VICTOR HUGO SILVA CORREIA,,https://lens.org/004-929-061-372-51X,Patent Application,no,0,0,15,15,0,F01D11/005;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/11;;F05D2240/57;;F05D2240/57;;F05D2240/59;;F05D2240/59,F01D11/00,,0,0,,,,DISCONTINUED
63,CU,A7,CU 20150101 A7,054-020-372-256-937,2016-03-31,2016,CU 20150101 A,2014-03-07,US 201361774684 P;;US 201361774723 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774761 P;;US 201361774773 P;;US 201361774775 P;;US 201361774780 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,MÉTODO PARA OBTENER AZÚCARES DERIVADOS DE LÍQUIDOS DE BIOMASA SACARIFICADOS,"La invención describe un método para obtener azúcares derivados de líquidos de biomasa sacarificados. Este método consiste en pretratar un material celulósico o lignocelulósico para radiación por inonización. Posteriormente, el método consiste en sacarificar el material celulósico o lignocelulósico radiado para obtener líquidos de biomasa sacarificados. Finalmente, el método consiste en eliminar las sales, ácidos parcialmente ionizados o ácidos completamente ionizados, de los líquidos de biomasa sacarificada con un sistema de electrodiálisis. De esta forma la biomasa (por ejemplo, biomasa vegetal, biomasa animal y biomasa de desechos urbanos) es procesada para producir intermedios y productos útiles, tales como energía, combustibles, alimentos o materiales.",XYLECO,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MARIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/054-020-372-256-937,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,PENDING
64,US,B2,US 9810086 B2,067-517-593-814-213,2017-11-07,2017,US 201213443947 A,2012-04-11,US 201213443947 A;;US 201161556270 P,2011-11-06,Asymmetric radial spline seal for a gas turbine engine,"A shroud apparatus for a gas turbine engine includes: an annular shroud segment having an arcuate bottom wall defining an arcuate inner flowpath surface, spaced-apart forward and aft walls extending radially outward from the bottom wall, and spaced-apart side walls extending radially outward from the bottom wall and between the forward and aft walls, each side wall defining an end face which includes: an axial slot extending in a generally axial direction along the end face; a first radial slot extending in a generally radial direction along the end face, and intersecting the axial slot; an axial spline seal received in the axial slot; and a first radial spline seal having an L-shape with radial and axial legs, the radial leg being substantially longer than the axial leg, wherein the radial leg is received in the first radial slot, and the axial leg is received in the axial slot.",CORREIA VICTOR HUGO SILVA;;CEGLIO CHRISTOPHER MICHAEL;;STAPLETON DAVID SCOTT;;GEN ELECTRIC,CORREIA VICTOR HUGO SILVA;;CEGLIO CHRISTOPHER MICHAEL;;STAPLETON DAVID SCOTT,GENERAL ELECTRIC COMPANY (2012-04-06),https://lens.org/067-517-593-814-213,Granted Patent,yes,25,5,15,15,0,F01D11/005;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/11;;F05D2240/57;;F05D2240/57;;F05D2240/59;;F05D2240/59,F01D9/04;;F01D11/00,,2,0,,,"Search Report and Written Opinion from corresponding PCT Application No. PCT/US2012/052185, dated May 31, 2013.;;Unofficial English Translation of Japanese Office Action issued in connection with corresponding JP Application No. 2014539946 dated Mar. 8, 2016.",ACTIVE
65,EP,A1,EP 3564713 A1,032-537-526-862-66X,2019-11-06,2019,EP 19164550 A,2014-03-07,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;EP 14760021 A;;US 201361774723 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,UPGRADING PROCESS STREAMS USING ELECTRODIALYSIS,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.
",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/032-537-526-862-66X,Patent Application,yes,4,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,G01T7/08;;B01D61/42;;B01D61/44;;C10L9/08,,1,1,069-080-192-654-937,10.1016/j.cis.2005.09.005;;16325751,"NAGARALE R K ET AL: ""Recent developments on ion-exchange membranes and electro-membrane processes"", ADVANCES IN COLLOID AND INTERFACE SCIENCE, ELSEVIER, NL, vol. 119, no. 2-3, 28 February 2006 (2006-02-28), pages 97 - 130, XP027908769, ISSN: 0001-8686, [retrieved on 20060228]",DISCONTINUED
66,CN,A,CN 105452474 A,057-511-556-700-663,2016-03-30,2016,CN 201480011095 A,2014-03-07,US 2014/0021815 W;;US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P,2013-03-08,Upgrading process streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal.] Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/057-511-556-700-663,Patent Application,no,13,2,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,2,0,,,"华东建筑设计研究院有限公司: ""《给水排水设计手册 第4册 工业给水处理 第二版》"", 30 April 2002, 中国建筑工业出版社;;张晖 等主编: ""《环境工程原理》"", 31 July 2011",INACTIVE
67,IL,A,IL 260267 A,150-871-511-836-68X,2018-07-31,2018,IL 26026718 A,2018-06-25,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,Upgrading process streams,,XYLECO INC;;CHRISTOPHER COOPER;;MARSHALL MEDOFF;;THOMAS CRAIG MASTERMAN;;MAIA STAPLETON MUKHERJEE,CHRISTOPHER COOPER;;MARSHALL MEDOFF;;THOMAS CRAIG MASTERMAN;;MAIA STAPLETON MUKHERJEE,,https://lens.org/150-871-511-836-68X,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,,,0,0,,,,PENDING
68,AU,A1,AU 2018/201758 A1,198-157-028-423-715,2018-04-05,2018,AU 2018/201758 A,2018-03-12,AU 2018/201758 A;;AU 2014/225446 A;;US 201361774735 P;;US 201361793336 P;;US 201361774773 P;;US 201361774740 P;;US 201361774731 P;;US 201361774780 P;;US 201361774761 P;;US 201361774744 P;;US 201361774746 P;;US 201361774684 P;;US 201361774723 P;;US 201361774754 P;;US 201361774775 P;;US 201361774750 P;;US 201361774752 P;;US 2014/0021815 W,2013-03-08,Upgrading Process Streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or 5 electrodialysis reversal. Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/198-157-028-423-715,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,INACTIVE
69,BR,B1,BR 112015019380 B1,011-604-248-497-943,2020-04-07,2020,BR 112015019380 A,2014-03-07,US 2014/0021815 W;;US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P,2013-03-08,aprimoramento de fluxos de processos,"aprimoramento de fluxos de processos a biomassa (por exemplo, biomassa vegetal, biomassa animal e biomassa de resíduos municipais) é processada para produzir intermediários e produtos úteis, como energia, combustíveis, alimentos ou materiais. sistemas, métodos e equipamentos são descritos para aprimoramento de fluxos de processos usando eletrodiálise ou eletrodiálise reversa. muitas matérias-primas lignocelulósicas potenciais estão disponíveis hoje, incluindo resíduos agrícolas, biomassa lenhosa, resíduos municipais, óleos ou massas de sementes e macroalgas, para citar algumas.",XYLECO INC,CHRISTOPHER COOPER;;MAIA STAPLETON MUKHERJEE;;MARSHALL MEDOFF;;THOMAS CRAIG MASTERMAN,,https://lens.org/011-604-248-497-943,Granted Patent,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,INACTIVE
70,US,B2,US 9925496 B2,135-258-233-522-250,2018-03-27,2018,US 201715487565 A,2017-04-14,US 201715487565 A;;US 201414299010 A;;US 2014/0021815 W;;US 201361793336 P;;US 201361774773 P;;US 201361774731 P;;US 201361774723 P;;US 201361774780 P;;US 201361774775 P;;US 201361774684 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774761 P,2013-03-08,Upgrading process streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,XYLECO INC (2014-06-09),https://lens.org/135-258-233-522-250,Granted Patent,yes,52,1,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,B01D61/44;;C12P7/10;;C12P7/56;;C13K13/00,,13,1,169-141-851-602-500,pmc2635757;;19325822;;10.3390/ijms9091621,"Allison, “High Water Recovery with Electrodialysis Reversal,” GE Power and Water, Water and Process Technologies, Technical paper, TP1071EN.doc, Mar. 2010 (5 pages).;;Chu, “Overview of Light-Ion Beam Therapy,” Columbus-Ohio, ICRU-IAEA Meeting, Mar. 18-20, 2006 (20 pages).;;Bar, “Conversation of Sodium Acetate into Reusable Acetic Acid and Caustic Soda,” Membrane & Separation Technology News, Industry Insight, vol. 24,, No. 6, 1 page (Mar. 2006).;;Supplementary European Search Report dated May 27, 2016 for European Patent Application 14760021.7.;;International Search Report and Written Opinion dated May 23, 2014 for International Patent Application No. PCT/US2014/021815 (5 pages).;;Iwata et al., “Alternating-Phase-Focused IH-DTL for Heavy-Ion Medical Accelerators,” Proceedings of EPAC 2006, Edinburgh, Scotland, pp. 2328-2330 (2006).;;Leitner et al., “Status of the Superconducting ECR Ion Source Venus,” Proceedings of EPAC 2000, Vienna, Austria, pp. 1610-1612 (2000).;;TSC's Water Treatment Engineering Team, “Electrodialysis (ED) and Electrodialysis Reversal (EDR),” retrieved online Oct. 6, 2015 <http://webcache.googleusercontent.com/search?q=cache:vfsxcuDgFtUJ:www.usbr.gov/tsc/water/publications/reportpdfs/Primer%2520Files/07%2520-%2520Electrodialysis.pdf+&cd=l&h1=en&ct=clnk&gl=us> (5 pages).;;PCCELL GmbH, “Electrodialysis Cell Unit: PCCell Ed 64 0 02—Technical Data,” Version: Jan. 2006, 11 pages (Jan. 2006).;;Philippidis, “Cellulose Bioconversion Technology,” Handbook on Bioethanol: Production and Utilization, Chapter 12, Wyman, ed., Taylor & Francis, Washington, DC, 35 pages (1996).;;Prelec, “Ions and Ion Accelerators for Cancer Treatment,” FIZIKA B 6, vol. 4, pp. 177-206 (1997).;;Taherzadeh and Karimi, “Pretreatment of Lignocellulosic Wastes to Improve Ethanol and Biogas Production: A Review,” International Journal of Molecular Sciences, vol. 9, pp. 1621-1651 (2008).;;Zheng et al., “Overview of biomass pretreatment for cellulosic ethanol production,” International Journal of Agricultural and Biological Engineering, vol. 2, No. 3, pp. 51-68 (Sep. 2009).",ACTIVE
71,PL,T3,PL 2890798 T3,158-596-763-326-106,2020-03-31,2020,PL 14760021 T,2014-03-07,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P;;EP 14760021 A;;US 2014/0021815 W,2013-03-08,METHOD FOR OBTAINING SACCHARIFIED BIOMASS WITH RADIATION AND ELECTRODIALYSIS,,XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/158-596-763-326-106,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,G01T7/08;;C10L9/08,,0,0,,,,PENDING
72,US,B2,US 10543460 B2,189-639-627-319-595,2020-01-28,2020,US 201815913740 A,2018-03-06,US 201815913740 A;;US 201715487565 A;;US 201414299010 A;;US 2014/0021815 W;;US 201361793336 P;;US 201361774773 P;;US 201361774731 P;;US 201361774723 P;;US 201361774780 P;;US 201361774775 P;;US 201361774684 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774761 P,2013-03-08,Upgrading process streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,XYLECO INC (2014-06-09),https://lens.org/189-639-627-319-595,Granted Patent,yes,404,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,B01D61/44;;B01D15/02;;B01D53/32;;B01J19/08;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/02;;C10L9/08;;C12M1/00;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/00;;D21C9/00;;E04B1/92;;G21F7/00;;H01J37/317,,165,65,169-141-851-602-500;;089-601-196-553-822;;001-783-472-853-088;;065-593-622-106-235;;142-794-948-665-223;;119-498-661-194-102;;042-445-781-025-775;;156-390-678-884-182;;064-260-820-243-589;;086-423-100-753-064;;036-918-536-415-884;;172-181-093-863-668;;070-388-179-998-870;;022-881-092-775-947;;105-105-196-010-153;;104-864-860-428-568;;197-070-131-561-982;;077-578-135-179-330;;013-408-354-006-487;;044-035-359-362-662;;102-030-515-960-322;;019-920-602-265-252;;099-030-120-177-951;;118-711-156-754-483;;061-927-197-780-596;;033-539-563-569-572;;015-713-951-758-779;;037-376-376-974-187;;003-263-175-895-592;;044-494-746-154-823;;105-353-928-898-059;;074-922-777-193-522;;005-485-253-328-996;;051-435-684-016-014;;019-052-428-109-643;;010-333-968-076-559;;034-265-827-998-268;;084-834-191-870-955;;106-768-613-231-576;;004-409-251-635-22X;;007-761-902-932-802;;047-357-076-345-37X;;030-359-994-281-207;;018-677-214-975-97X;;080-708-616-057-319;;039-941-953-318-633;;034-862-860-004-523;;151-040-430-104-70X;;000-183-195-092-675;;008-011-839-883-107;;031-382-290-277-391;;018-434-146-384-724;;064-166-688-808-763;;085-224-250-706-783;;058-012-914-815-39X;;011-815-858-168-944;;020-577-919-065-531;;029-108-223-001-236;;023-243-562-807-959;;001-491-651-097-885;;052-589-609-987-783;;046-868-606-528-05X;;073-760-432-230-070;;000-787-188-672-361;;069-080-192-654-937,pmc2635757;;19325822;;10.3390/ijms9091621;;10.1016/j.ymben.2012.05.003;;22677452;;10.1023/a:1008881731894;;10.1007/978-1-4612-0057-4_50;;10.1385/abab:107:1-3:603;;12721439;;10.1016/s0960-8524(99)00161-3;;10.2141/jpsa.41.229;;10.1007/s10295-007-0296-3;;18205019;;10.1063/1.59300;;10.5772/16848;;10.5897/ajmr2012.2465;;10.1021/jf1008023;;pmc2923870;;20669951;;10.1139/v10-153;;10.1007/s10295-010-0727-4;;20454831;;10.1016/j.biortech.2010.05.031;;20627714;;10841281;;10.1163/156856200743715;;10.1016/0032-9592(92)80024-w;;10.2172/926125;;10.1109/ppc.1995.596677;;10.1021/ie9800896;;12549371;;10.5772/23927;;10.3775/jie.79.540;;10.1142/s0256767908003096;;10.1016/s0065-2164(08)70598-7;;20883732;;10.1016/j.jbiotec.2010.09.938;;10.17221/3411-cjfs;;10.1155/2013/329379;;10.1021/jf00115a009;;10.1002/bit.260251111;;18548598;;10.3993/jfbi03201308;;10.1201/9780203508206.ch16;;10.2172/921839;;10.1016/0141-4607(80)90002-5;;17225102;;10.1007/s00253-006-0779-6;;10.1002/bit.260240421;;18546388;;10.1007/s12010-009-8893-4;;20099047;;14592744;;10.1016/s0960-8524(03)00172-x;;10.1002/bit.260280921;;18561236;;10.1016/1359-0197(87)90044-0;;10.1021/ie801542g;;10.1016/0146-5724(83)90017-1;;12103362;;10.1016/s1389-0344(02)00007-2;;10.1128/jb.00713-12;;pmc3457242;;22865845;;10.1106/lvy7-vbvf-v8lr-l5at;;10.1007/s00253-006-0379-5;;16528511;;10.1016/s0142-9612(00)00101-0;;11055281;;10.1002/(sici)1099-0518(20000501)38:9<1673::aid-pola33>3.0.co;2-t;;10.1016/s0926-6690(97)00037-x;;10.1016/j.biortech.2004.06.025;;15588770;;pmc3067259;;21193678;;10.1128/aem.02076-10;;21729724;;10.1016/j.jbiotec.2011.06.017;;10.1007/s00253-002-1092-7;;12382043;;10.1016/0969-806x(95)00374-7;;18930388;;10.1016/j.biortech.2008.09.010;;10.1080/10409230391036757;;10.1080/10409230390242443;;14551235;;10.1002/bit.23153;;21455937;;10.1038/nbt1316;;17572667;;10.1007/s00253-002-1016-6;;12111142;;10.1016/j.biortech.2007.12.008;;18248982;;10.1016/s0378-5173(01)00655-x;;11397568;;10.1007/s10562-007-9052-6;;10.1016/j.biortech.2007.09.032;;17967532;;10.1021/ac034241b;;14632079;;10.1007/s12010-008-8305-1;;18651247;;10.1016/j.cis.2005.09.005;;16325751,"Allison, “High Water Recovery with Electrodialysis Reversal,” GE Power and Water, Water and Process Technologies, Technical Paper, TP1071EN.doc, Mar. 2010 (5 pages).;;Bar, “Conversion of Sodium Acetate into Reusable Acetic Acid and Caustic Soda,” Membrane & Separation Technology News, Industry Insight, vol. 24, No. 6, 1 page (Mar. 2006).;;Chu, “Overview of Light-Ion Beam Therapy,” Columbus-Ohio, ICRU-IAEA Meeting, Mar. 18-20, 2006 (20 pages).;;International Search Report and Written Opinion dated May 23, 2014 for International Patent Application No. PCT/US2014/021815 (4 pages).;;Iwata et al., “Alternating-Phase-Focused IH-DTL for Heavy-Ion Medical Accelerators,” Proceedings of EPAC 2006, Edinburgh, Scotland, pp. 2328-2330 (2006) (3 pages).;;Leitner et al., “Status of the Superconducting ECR Ion Source Venus,” Proceedings of EPAC 2000, Vienna, Austria, pp. 1610-1612 (2000) (3 pages).;;PCCELL GmbH, “Electrodialysis Cell Unit: PCCell ED 64 0 02—Technical Data,” Version: Jan. 2006, 11 pages (Jan. 2006).;;Philippidis, “Cellulose Bioconversion Technology,” Handbook on Bioethanol: Production and Utilization, Chapter 12, Wyman, ed., Taylor & Francis, Washington, DC, 35 pages (1996).;;Prelec, “Ions and Ion Accelerators for Cancer Treatment,” FIZIKA B 6, vol. 4, pp. 177-206 (1997) (31 pages).;;Taherzadeh and Karimi, “Pretreatment of Lignocellulosic Wastes to Improve Ethanol and Biogas Production: A Review,” International Journal of Molecular Sciences, vol. 9, pp. 1621-1651 (2008) (31 pages).;;TSC's Water Treatment Engineering Team, “Electrodialysis (ED) and Electrodialysis Reversal (EDR),” (5 pages), retrieved online Oct. 6, 2015, <http://webcache.googleusercontent.com/search?q=cache:vfsxcuDgFtUJ:www.usbr.gov/tsc/water/publications/reportpdfs/Primer%2520Files/07%2520-%2520Electrodialysis.pdf+&cd=1&hl=en&ct=clnk&gl=us>.;;Zheng et al., “Overview of biomass pretreatment for cellulosic ethanol production,” International Journal of Agricultural and Biological Engineering, vol. 2, No. 3, pp. 51-68 (Sep. 2009) (18 pages).;;Xiao et al., “Metabolic engineering of D-Xylose pathway in Clostridium beijerinckii to optimize solvent production from xylose mother liquid,” Metabolic Engineering, 14, pp. 569-578 (2012).;;El Kanouni et al., “The improvement of glucose/xylose fermentation by Clostridium acetobutylicum using calcium carbonate,” World Journal of Microbiology and Biotechnology, 14, pp. 431-435 (1998).;;Oh, H. et al., “Lactic Acid Production Through Cell-Recycle Repeated-Batch Bioreactor,” Appl. Biochem. Biotechnol., vol. 105-108: 603-613 (2003).;;Osmundsen, C.M., “Catalysis & Biomass: Strategies for Biomass Conversion to Fuels and Chemicals,” for Halder Topsoe/DTU (Mar. 2011, 39 pages).;;Palmqvist and Hahn-Hagerdal, “Fermentation of lignocellulosic hydrolysates. II: inhibitors and mechanisms of inhibition,” Bioresource Technology, vol. 74, pp. 25-33 (2000).;;Razak, S. et al., “Biodegradable Polymers and their Bone Applications: A Review,” Intl. J. Basic & Applied Sciences, vol. 12(1): 31-49 (2012).;;Rotary Drum Vacuum Filter, by Komline-Sanderson, 1996 (8 pages).;;Saleh et al., “Carbohydrases are Digested by Proteases Present in Enzyme Preparations During in vitro Digestion,” J. Poultry Sci., vol. 41, pp. 229-235 (2004).;;Sarath et al., “Opportunities and roadblocks in utilizing forages and small grains for liquid fuels,” J. Ind. Microbial. Biotechnol., vol. 35, pp. 343-354 (2008).;;Scharf and Wieszczycka, “Electron Accelerators for Industrial Processing—a Review,” 15th International Conference on the Applications of Accelerators in Research and Industry, Denton, TX, USA, pp. 949-952 (1999).;;Search Report for corresponding Singapore Patent Application No. 11201502385R, search completed May 13, 2016 (5 pages).;;Seiboth et al., “Trichoderma reesei: A Fungal Enzyme Producer for Cellulosic Biofuels,” Biofuel Production—Recent Developments and Prospects, Chapter 13, pp. 309-340 (2011).;;Sharmin et al., “A Review of Pentose Utilizing Bacteria From Bagasse Hemicellulose,” Afr. J. Microbial. Res. vol. 7, No. 22 pp. 2694-2700 (2013).;;Shepherd, A. “Activated Carbon Adsorption for Treatment of VOC Emissions,” Presented at the 13th Annual EnviroExpo, Boston, Massachusetts (May 2001, 4 pages).;;Sluiter et al., “Compositional Analysis of Lignocellulosic Feedstocks. 1. Review and Description of Methods,” Journal of Agricultural and Food Chemistry, vol. 58, pp. 9043-9053 (2010).;;Smith et al., “Irradiation Enhancement of Biomass Conversion,” Radiation Physics and Chemistry, vol. 25, Nos. 1-3 , pp. 27-33 (Jan. 1, 1985).;;Sriwongsa, K. et al., “Radiation-Induced Crosslinking of Polylactic Acid: Effects of Air and Vacuum,” for TIChE International Conference at Hatyai, Songkhla Thailand (Nov. 10-11, 2011, 5 pages).;;Stevens, “On the Stowage of Ships and Their Cargoes,” Section 190, Fermentation, Nabu Press, 3 pages (Jan. 7, 2010).;;Strempek, J.R. et al., A Technical Paper, “Innovative Solutions for a Challenging Biomass Fuel and Boiler Upgrade Project,” TAPPI Engineering Pulping, Environmental Conference Aug. 28-31, 2005 (11 pages).;;Supplementary European Search Report issued in Corresponding European Patent Application No. EP 14 76 0226, dated Jun. 1, 2016 (8 pages).;;Swanson, “Radiological Safety Aspects of the Operation of Electron Linear Accelerators,” International Atomic Energy Agency, Technical Reports Series No. 188, Chapter 2.1, 343 pages (1979).;;Swanson, W.P., “Toxic Gas Production At Electron Linear Accelerators,” Stanford Linear Accelerator Center, Stanford University, Stanford, California 94305 (Feb. 1980, 11 pages).;;Swanson. K. “Broadbeam—Getting Started with EB,” PCT Engineered Systems LLC. (2012, 9 pages).;;Tao et al., “Efficient process for the conversion of xylose to furfural with acidic ionic liquid,” Can. J. Chem., vol. 89, pp. 83-87 (2011).;;Technical Bulletin by Osprey Corporation, Spring 2004 (2 pages).;;Technical Study Report on “Biomass Fired—Fluidized Bed Combustion Boiler Technology for Cogeneration” by UNEP www.uneptie.fr/energy (Sep. 2007, 68 pages).;;Technology Focus Report: Blends of PLA with Other Thermoplastics, for NatureWorks LLC. www.natureworksllc.com (2007, 6 pages).;;Tewari et al., “Role of Pretreatments on Enzymatic Hydrolysis of Agricultural Residues for Reducing Sugar Production,” J. Chem. Tech. Biotechnol., vol. 38, No. 38, pp. 153-165 (1987).;;The Conair Group, Inc., “Access Loader with Easy Loading Control (ELC), Models AL2 and AL5—User Guide”, www.conairnet.com 109 pages (2008).;;The Conair Group, Inc., “CAML-EVG Compressed Air Material Evacuator—User Guide,” www.conairnet.com 47 pages (2001).;;Vidya et al., “Pretreatment of lignocellulose by gamma rays and electron beam for enhanced degradation by Phanerochaete chrysosporium,” Asian Journal of Microbiology, Biotechnology & Environmental Sciences, vol. 8, No. 2, pp. 253-258 (2006).;;Walton, S. et al., “Production of lactic acid from hemicellulose extracts by Bacillus coagulans MXL-9,” J. Ind. Microbiol. Biotechnol., vol. 37: 823-830 (2010).;;Wang et al., “Efficient Cellulase Production from Corn Straw by Trichoderma Reesei LW1 Through Solid State Fermentation Process,” Ethnobotanical Leaflets, vol. 2005, No. 1, Article 7, 8 pages (2005).;;Wang, L. et al., “Efficient production of L-lactic acid from corncob molasses, a waste by-product in xylitol production, by a newly isolated xylose utilizing Bacillus sp. strain,” Bioresour. Technol. (2010, 8 pages).;;Wang, N. et al., “Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers: I. Synthesis and characterization,” J. Biomater. Sci. Polymer Edn., vol. 11(3): 301-318 (2000).;;Wayman et al., “Bioconversion of Waste Paper to Ethanol, ” Process Biochemistry, vol. 27, No. 4, pp. 239-245 (Jul. 1992).;;Wee, Y-J, et al., “Biotechnological Production of Lactic Acid and Its Recent Applications,” Food Technol. Biotechnol., vol. 44(2): 163-172 (2006).;;Werpy, T. et al., “Top Value-Added Chemicals from Biomass, vol. I—Results of Screening for Potential Candidates from Sugars and Synthesis Gas,” by Pacific Northwest National Laboratory, for U.S. Department of Energy (Aug. 2004, 77 pages).;;Whitham et al., “12 MW, 100 KW, 7000 Hour/Year Modulator for Titan Scan,” Tenth IEEE International Pulsed Power Conference, Digest of Technical Papers, vol. 1, pp. 534-538 (Jul. 3-6, 1995).;;Wilson, “Filler and Coating Pigments for Papermakers,” Industrial Minerals and Rocks: Commodities, Markets and Uses, Part III, No. 96, pp. 1287-1300 (2006).;;Wooley et al., “A Nine-Zone Simulating Moving Bed for the Recovery of Glucose and Xylose from Biomass Hlydrolyzate,” Ind. Eng. Chem. Res., vol. 37, pp. 3699-3709 (1998).;;Written Opinion for Corresponding Singaporean Application No. 11201502410W dated Nov. 2, 2017 (7 pages).;;Written Opinion for International Application No. PCT/US2014/021796 dated May 21, 2014 (5 pages).;;Written Opinion for International Application No. PCT/US2014/021813 dated Jun. 2, 2014 (7 pages).;;Written Opinion for International Patent Application No. PCT/US2014/021638, dated Jun. 12, 2014 (5 pages).;;Xia et al., “Saccharification of Corn Stover by Immobilized Trichoderma reesei cells,” English Language Abstract, Acta Microbiologica Sinica, vol. 38, No. 2 , pp. 114-119 (1998).;;Xiao, L. et al., “Poly(Lactic Acid)-Based Biomaterials: Synthesis, Modification and Applications,” Biomedical Science, Engineering and Technology http://www.intechopen.com/books/biomedical-science-engineering-and-technology/poly-lactic-acid-based-biomaterials-synthesis-modification-and-applications (Accessed Jun. 12, 2014 38 pages).;;Xiao, Y., A Thesis entitled: “Functional Polymers by Enzymatic Catalysis,” Supported by Marie Curie Action RTN program Biocatalytic Approach to Material Design, Contract No. MRTN-CT-2004-505147 (2009, 148 pages).;;Yamada et al., “Decomposition Behavior of Waste Paper with Hot Compressed Water,” English Language Synopsis, Journal of the Japan Institute of Energy, vol. 79, No. 6 , pp. 540-547 (Jun. 2000).;;Zhang, W-x and Wang, Y-z, “Synthesis and Properties of High Molecular Weight Poly(Lactic Acid) and Its Resultant Fibers,” Chinese J. Polymer Sci., vol. 26(4): 425-432 (2008).;;Ghosh and Singh , “Physicochemical and Biological Treatments for Enzymatic/Microbial Conversion of Lignocellulosic Biomass,” Advances in Applied Microbiology, vol. 39, pp. 295-333 (1993).;;Graham-Rowe, “Electron Beams Could be Used to Irradiate Post,” Daily News , 2 pages (Oct. 24, 2001).;;Grimmler et al., “Transcriptional analysis of catabolite repression in Clostridium acetobutylicum growing on mixtures of D-glucose and D-xylose” Journal of Biotechnology, 150, pp. 315-323, (2010).;;Gundel, L.A. et al., “A Pilot Study of Energy Efficient Air Cleaning for Ozone,” Indoor Environment Department, Environmental Energy Technologies Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720 (Nov. 28, 2002, 14 pages).;;Habova, V. et al., “Modem Method of Lactic Acid Recovery from Fermentation Broth,” Czech J. Food Sci., vol. 22(3): 87-94 (2004).;;Halasz, K. And Csoka, L., “Plasticized Biodegradable Poly(lactic acid) Based Composites Containing Cellulose in Micro-and Nanosize,” J. Engineer., vol. 2013, Article ID 329379 (2012, 9 pages).;;Han et al., “Chemical and Physical Properties of Sugarcane Bagasse Irradiated with g Rays,” J. Agric. Food Chem., vol. 31, pp. 34-38 (1983).;;Han et al., “Effect of Gamma-Ray Irradiation on Alcohol Production From Corn,” Biotechnol. Bioeng., vol. 25, No. 11, pp. 2631-2640 (1983).;;Hanis et al., “Effect of Gamma Irradiation on Survival of Natural Microflora and Some Nutrients in Cereal Meals,” Cereal Chemistry, vol. 65, No. 5, pp. 381-383 (1988).;;Hassan, E., et al., “Dynamic Mechanical Properties and Thermal Stability of Poly(lactid acid) and Poly(butylene succinate) Blends Composites,” J. Fiber Bioengineer. Inform., vol. 6(1): 85-94 (2013).;;Haug, G., “Aspects of Rotary Vacuum Filter Design & Performance,” Reprint from Fluid/Particle Separation Journal, vol. 13(1): Apr. 2000 (19 pages).;;Henton, D.E. et al., “Polylactic Acid Technology,” Ch. 16, in Natural Fibers, Biopolymers, and Biocomposites http://www.jimluntllc.com/pdfs/polylactic_acid_technology.pdf (Accessed Jun. 12, 2014, pp. 527-577).;;Holladay, J.E. et al., “Top Value-Added Chemicals from Biomass, vol. II—Results of Screening for Potential 26 Candidates from Biorefinery Lignin,” by Pacific Northwest National Laboratory, for U.S. Department of Energy under Contract DE-AC05-76RL01830 (Oct. 2007, 87 pages).;;Ibrahim and Pearce, “Effects of Gamma Irradiation on the Composition and In Vitro Digestibility of Crop By-Products,” Agricultural Wastes, vol. 2, pp. 253-259 (1980).;;INGEO Resin Product Guide, for NatureWorks LLC. www.natureworksllc.com (2011, 4 pages).;;International Search Report and Written Opinion for International Application No. PCT/US14/21584 dated Jun. 13, 2014 (7 pages).;;International Search Report and Written Opinion issued in PCT/US2014/021609, dated May 22, 2014 (9 pages).;;International Search Report for International Application No. PCT/US2014/021796 dated May 21, 2014 (2 pages).;;International Search Report for International Application No. PCT/US2014/021813 dated Jun. 2, 2014 (3 pages).;;International Search Report for International Patent Application No. PCT/US2014/021638, dated Jun. 12, 2014 (3 pages).;;John et al., “Fermentative Production of Lactic Acid From Biomass: An Overview on Process Developments and Future Perspectives,” Appl. Microbial. Biotechnol. vol. 74, No. 3 pp. 524-534 (2007).;;Jonglertjunya, W. et al., “Utilization of Sugarcane Bagasses for Lactic Acid Production by Acid Hydrolysis and Fermentation Using Lactobacillus sp.,” World Academy of Science, Engineering and Technology, vol. 66: 173-178 (2012).;;Kamakura and Kaetsu, “Radiation Degradation and the Subsequent Enzymatic Hydrolysis of Waste Papers,” Biotechnol. Bioeng., vol. 24, pp. 991-997 (1982).;;Kamp, P. “Inbicon Biomass Refinery Cellulosic Ethanol Technology Platforms; Growth and Sustainability through Biomass Refining, CHP—Technology Review,” Inbicon Leifmark, North America Business Development (2010, 40 pages).;;Kang et al., “Bioconversion of kraft paper mill sludges to ethanol by SSF and SSCF,” Appl. Biochem. Biotechnol., vol. 161, pp. 53-66 (2010).;;Kang et al., “Production of cellulases and hemicellulases by Aspergillus niger KK2 from lignocellulosic biomass,” Bioresource Technology, vol. 91, pp. 153-156 (2004).;;Khan et al., “Effect of Electron-Beam Irradiation Pretreatment on the Enzymatic Hydrolysis of Softwood, ” Biotechnol. Bioeng., vol. 28, pp. 1449-1453 (1986).;;Khan et al., “Electron beam irradiation pretreatment and enzymatic saccharification of used newsprint and paper mill wastes, ”International Journal of Radiation Applications and Instrumentation. Part C. Radiation Physics and Chemistry, vol. 29, No. 2, pp. 117-120 (1987).;;Korolev et al., “Characteristics of Sealed-Off Electron Gun with Wide Beam,” Proceedings of EPAC 2004, Lucerne, Switzerland, pp. 2727-2729 (2004).;;Krane, “Introductory Nuclear Physics,” John Wiley & Sons, Inc., 858 pages (1988).;;Krumeich, F., “Properties of Electrons, their Interactions with Matter and Applications in Electron Microscopy,” Laboratory of Inorganic Chemistry, ETH Zurich, HCI-H1111, CH-8093 Zurich http://www.microscopy.ethz.ch/downloads/Interactions.pdf (Accessed Jun. 12, 2014 24 pages).;;Kumar et al., “Methods for Pretreatment of Lignocellulosic Biomass for Efficient Hydrolysis and Biofuel Production,” Ind. Eng. Chem. Res., vol. 48, No. 8, 17 pgs. (Jan. 1, 2009).;;Leonhardt et al., “Gamma and Electron Radiation Effects on Straw,” Radial Phys. Chem., vol. 21, No. 4, pp. 397-400 (1983).;;Levy et al., “Modification of polysaccharides and plant cell wall by endo-1, 4, b-glucanase and cellulose-binding domains, ”Biomolecular Engineering, vol. 19, No. 1, pp. 17-30 (2002).;;Liu, L. et al., “Phosphoketolase Pathway for Xylose Catabolism in Clostridium acetocuylicum Revealed by C Metabolic Flux Analysis,” J. Bacteriol., vol. 194(19): 5413-5422 (Oct. 2012).;;Lunt, J. and Shafer, A.L., “Polylactic Acid Polymers from Corn—Applications in the Textiles Industry,” for Cargill Dow Polymers LLC., Minnetonka, MN 55345 http://jimluntllc.com/pdfs/PolylacticAcidPolymersFromCorn.pdf (Accessed Jun. 12, 2014, 8 pages).;;Maas, R.H.W. et al., “Lactic Acid Production From Xylose by the Fungus Rhizopus Oryzae,” Appl. Microbiol. Biotechnol., vol. 72: 861-868 (2006).;;Malinowski, R. et al., “Effects of Electron Radiation on Properties of PLA,” Archives of Materials Science and Engineering, vol. 49(1 ): 25-32 (May 2011).;;McMillan, Jr. “Analysis of Vibratory Equipment Using the Finite Element Method,” A Research Paper Submitted in Partial Fulfillment of the Requirements for the Master of Science Degree in Manufacturing Engineering; The Graduate School University of Wisconsin-Stout, 59 pages (May 2011).;;Middleton, J.C. and Tipton, A.J., “Synthetic Biodegradable Polymers as Orthopedic Devices,” Biomaterials, vol. 21: 2335-2346 (2000).;;Miller, D.J. and Doidge, B.R., “Biochemicals From Corn: Update 2008,” for Ontario BioAuto Council, Ontario Agri-Food Technologies, Ontario Ministry of Agriculture, Food and Rural Affairs (46 pages).;;Moniz-Xavier, A.M.M., Master Thesis entitled “Study of Lactic Acid Polycondensation and Lactide Production,” Developed for the Dissertation Project realized in Eidgenossische Technische Hochschule Zurich, for Universidade do Porto (Jul. 2010, 71 pages).;;Moon, S-L, et al., “Melt Polycondensation of L-Lactic Acid with Sn(II) Catalysts Activated by Various Proton Acids: A Direct Manufacturing Route to High Molecular Weight Poly(L-lactic acid),” J. Polymer Science: Part A: Polymer Chemistry, vol. 38: 1673-1679 (2000).;;Moreau et al., “Selective preparation of furfural from xylose over micro porous solid acid catalysts,” Industrial Crops and Products, vol. 7, pp. 95-99 (1998).;;Mosier et al., “Features of promising technologies for pretreatment of lignocellulosic biomass,” Bioresource Technology, vol. 96, pp. 673-686 (2005).;;MSDS of DOWEX™ MONOSPHERE™ 88. Dec. 15, 2015 retrieved online (2 pages)<https://web.archive.org/web/2015121517 4635/http:l/msdssearch .dow.com/PublishedliteratureDOWCOM/dh_0206/0901b80380206d8c.pdf?filepath=liquidseps/pdfs/noreg/177-01685.pdf&fromPage=GetDoc.>.;;MSDS of Purolite® C150S. Apr. 9, 2016. Retrieved on line (2 pages)<https://web.archive.org/web/20160409044617/http://purolite.com/Re1Id/619246/isvars/default/strong_acid_cationmacroporous.htm>.;;Mukhopadhyay, A., A Thesis entitled: “Bioconversion of Paper Mill Lignocellulosic Materials to Lacid Acid Using cellulase Enzyme Complex and Microbial Cultures,” prepared for Department of Grain Science and Industry College of Agriculture, Kansas State University, Manhattan Kansas (2009, 60 pages).;;Narayanan, N. et al., “L(+) lactic acid fermentation and its product polymerization,” Electr. J. of Biotechnol., vol. 7(2) (2004, 13 pages).;;Neureiter, M. et al., “Lignocellulose Feedstocks for the Production of Lactic Acid,” Chem. Biochem. Eng. Q., vol. 18(1):55-63 (2004).;;“An Introduction to Steam Boilers and Steam Raising,” by N.E.M. Business Solutions, Nov. 15, 2012. (23 pages) www.cip.ukcentre.com/steam.htm.;;“Biomass Conversion Technologies,” Chapter 5, EPA Combined Heat and Power Partnership : Biomass CHP Catalog, (32 pages) www.epa.gov (Accessed Jun. 12, 2014).;;“Biomass Technology Review,” Prepared for Biomass Power Association by McHale & Associates, Inc. Oct. 21, 2010 ( 52 pages).;;“DustBeater, DB8 and DB12 Models with MLC6 Control—User Guide,” for The Conair Group, Inc, Pittsburgh, PA 15202 www.conairnet.com (2002, 68 pages).;;“Guidelines for Ozone Mitigation at the APS,” Advanced Photon Source, (May 1994, 20 pages).;;“Holo-Flite Thermal Processor,” Metso Minerals Industries Inc. (2012, 8 pages).;;“Product Bulletin: Ozone Destruct Unit,” Corporate Consulting Service Instruments, Inc., Manufactured in Akron, Ohio 44301 USA http://www.ccsi-inc.com/pb-ozone-destruct.pdf (Accessed Jun. 12, 2014, 2 pages).;;“Recommendations for Geothermal Heating and Cooling Systems,” State of Ohio, Ohio Water Resources Council, State Coordinating Committee on Ground Water (Feb. 2012, 32 pages).;;“The advantage of physically separating airflow for each conveyor,” Air Flow Two Technology by Extru-Tech, Inc. www.extru-techinc.com (Accessed Jun. 12, 2014, 4 pages).;;“Thermal Degradation of Wood Components: A Review of the Literature,” U.S.D.A. Forest Service Research Paper, FPL 130 (May 1970, 29 pages).;;“TLA Model Tube Loaders, Hopper Loading, Feeding Bin and Direct Feed Configurations—User Guide,” for The Conair Group, Inc, Pittsburgh, PA 15202 www.conairnet.com (2003, 38 pages).;;“TLM Model Tube Loaders, Hopper Loading and Direct Feed Configurations with MLC2 Control—User Guide,” for The Conair Group, Inc, Pittsburgh, PA 15202 www.conairnet.com (2002, 45 pages).;;Abdel-Rahman, M. et al., “Efficient Homofermentative L-(+)-Lactic Acid Production from Xylose by a Novel Lactic Acid Bacterium, Enterococcus mundtii OU 25,” Appl. Environ. Microbial., vol. 77(5): 1892-1895 (Mar. 2011).;;Abdel-Rahman, M.A. et al., “Lactic Acid Production from Lignocellulose-Derived Sugars Using Lactic Acid Bacteria: Overview and Limits,” J. Biotechnol., vol. 156: 286-301 (2011).;;Ado, “Cellulase Production,” Renewable Biological Systems for Alternative Sustainable Energy Production, Miyamoto ed., FAQ Agricultural Services Bulletin, #128, Chapter 3.2, 13 pages (1997).;;Ahmed, J. and Varsheney, S.K., “Polylactides-Chemistry, Properties and Green Packaging Technology: A Review,” Intl. J. Food Properties, vol. 14(1): 37-58 (2011).;;Ahmed, J. et al., “Thermal Properties of Polylactides,” J. Thermal Analysis and Calorimetry, vol. 95(3): 957-964 (2009).;;Alfenore et al., “Improving ethanol production and viability of Saccharomyces cerevisiae by a vitamin feeding strategy during fed-batch process,” Applied Microbiology and Biotechnology, vol. 60, pp. 67-72 (2002).;;Anuar, H. and Zuraida, A., “Thermal Properties of Injection Moulded Polylactic Acid—Kenaf Fibre Biocomposite,” Malaysian Polymer J., vol. 6(1 ): 51-57 (2011).;;Author unknown, “The Case for Geothermal,” www.gladwell.com (Aug. 7, 2006, 10 pages).;;Awafo et al., “Effect of Irradiation, as a Pretreatment, on Bioconversion of Corn Stover into Protein-rich Mycelial Biomass of Pleurotus Sajor-Caju,” Radiation Physics and Chemistry, vol. 46, No. 4-6, pp. 1299-1302 (1995).;;Bak et al., “Improved enzymatic hydrolysis yield of rice straw using electron beam irradiation pretreatment,” Bioresource Technology, vol. 100, pp. 1285-1290 (2009).;;Baucher et al., “Lignin: Genetic Engineering and Impact on Pulping,” Critical Reviews in Biochemistry and Molecular Biology, vol. 38, No. 4, pp. 305-350 (2003).;;Belderok, H.J.M., Master Thesis entitled “Experimental Investigation and Modeling of the Pyrolysis of Biomass,” Eindhoven University of Technology, The Netherlands (Dec. 2007, 125 pages).;;BHS Sonthofen GmbH—BF Indexing Belt Filter “Gentle filtration of Sedimenting Media,” www.bhs-sonthofen.com 2012 (16 pages).;;BHS Sonthofen GmbH—RPF Rotary Pressure Filter “Precise Separation of Suspensions,” www.bhs-sonthofen.com 2012 (12 pages).;;Carter et al., “Removal and Recovery of Furfural, 5-Hydroxymethylfurfural, and Acetic Acid From Aqueous Solutions Using a Soluble Polyelectrolyte,” Biotechnology and Bioengineering, vol. 108, No. 9, pp. 2046-2052 (2011).;;Cellulose Ethanol (Cellulosic Ethanol), www.zfacts.com (Feb. 27, 2013, 4 pages).;;Chen and Dixon, “Lignin Modification Improves Fermentable Sugar Yields for Biofuel Production,” Nature Biotechnology, vol. 25, No. 7, pp. 759-761 (Jul. 2007).;;Chen, C.C. and Ju, L-K, “Coupled Lactic Acid Fermentation and Adsorption,” Appl. Microbial. Biotechnol., vol. 59: 170-174 (2002).;;Chunping et al., “Effect and aftereffect of g radiation pretreatment on enzymatic hydrolysis of wheat straw,” Bioresource Technology, vol. 99, pp. 6240-6245 (2008).;;Cleland, M.R., “Industrial Applications of Electron Accelerators.” Ion Beam Applications, Edgewood, NY 11717, USA http://cds.cern.ch/record/1005393/files/p383.pdf?version=1 (Accessed Jun. 12, 2014, 34 pages).;;Communication pursuant to Article 94(3) EPC dated Mar. 30, 2017 for European Patent Application No. 14 760 226.2 (7 pages).;;De Kerf et al., “Characterisation and Disintegration Properties of Irradiated Starch,” International Journal of Pharmaceutics, vol. 221, pp. 69-76 (Jun. 19, 2001).;;Dias et al. , “Modified versions of sulfated zirconia as catalysts for the conversion of xylose to furfural, ” Catalysis Letters, vol. 114, No. 3-4, pp. 151-160 (Apr. 2007).;;Dow, Dow Water & Process Solutions, Dowex Monosphere 88, Accessed from <http://www.dowwaterandprocess.com> on Jun. 4, 2015.;;Dutkiewicz, S. et al., “Synthesis of Poly(L(+) Lactic Acid) by Polycondensation Method in Solution,” Fibres & Textiles in Eastern Europe, vol. 11(4)(43): 66-70 (Dec. 2003).;;Edreder, E.A. et al., “Optimization of Batch Reactive Distillation Process: Production of Lactic Acid,” 20th European Symposium on Computer Aided Process Engineering—ESCAPE20, Ed. S. Pierucci and G. Buzzi Ferraris (2010, 6 pages).;;Eichenberger et al., “7.5 MeV High Average Power Linear Accelerator System for Food Irradiation Applications,” Proceedings of the International Symposium “New Frontier of Irradiated food and Non-Food Products”, 8 pages (Sep. 22-23, 2005).;;English language translation of Search Report for corresponding Chinese Patent Application No. 201480011018X, search completed Aug. 16, 2016 (2 pages).;;English Translation of Gromov, “VI Inter-University Conference on Electron Accelerators,” Atomnaya Energiya , vol. 21, No. 2, pp. 143-145 (Aug. 1966).;;Eriez Magnetics, “How to Choose and Use Vibratory Feeders and Conveyors, Complete guide to Vibratory Feeders and Conveyors,” 16 pages (2007).;;European Supplementary Search Report issued in EP 14760312.0, dated May 20, 2016 (6 pages).;;Extended European Search Report for European Patent Application No. 14759692.8 dated Jul. 18, 2016 (10 pages).;;Ezeji et al., “Fermentation of dried distillers' grains and solubles (DDGS) hydrolysates to solvents and value-added products by solventtogenic clostridia” Bioresourse Technology, 99, pp. 5232-5242, (2008).;;Fakhravar, S. et al., “Fermentative Lactic Acid from Deproteinized Whey Using Lactobacillus bulgaricus in Batch Culture,” World Applied Sciences Journal, vol. 17(9): 1083-1086 (2012).;;Fare, T.L. et al., “Effects of Atmospheric Ozone on Microarray Data Quality,” Analytical Chemistry (2003, pp. 1672-4675).;;Filter Cloth, by Kavon Filter Products Co., Feb. 26, 2012 (3 pages).;;Filter Cloth, by Suita Group, Feb. 26, 2013 (3 pages) www.filtercloths.cn.;;Garlotta, D., “A Literature Review of Poly(Lactic Acid),” J. Polymers and the Environ., vol. 9(2): 63-84 (2001).;;Jiang et al., “Production of Butyric Acid from Glucose and Xylose with Immobilized cells of Clostridium tyrobutyricum in a Fibrous-bed Bioreactor” Appl. Biochem. Biotechnol., 2010, vol. 160, pp. 350-359.;;Nagarale et al., “Recent developments on ion-exchange membranes and electro-membrane processes” Advances in Colloid and interface Science, 2006, vol. 119, pp. 97-130.;;Extended European Search Report for EP19164550.6 dated Oct. 7, 2019 (8 pages).",ACTIVE
73,US,A1,US 2017/0216775 A1,073-521-554-094-128,2017-08-03,2017,US 201715487565 A,2017-04-14,US 201715487565 A;;US 201414299010 A;;US 2014/0021815 W;;US 201361793336 P;;US 201361774773 P;;US 201361774731 P;;US 201361774723 P;;US 201361774780 P;;US 201361774775 P;;US 201361774684 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774761 P,2013-03-08,UPGRADING PROCESS STREAMS,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,XYLECO INC (2014-06-09),https://lens.org/073-521-554-094-128,Patent Application,yes,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,B01D61/44;;C12P7/10;;C12P7/56;;C13K13/00,,0,0,,,,ACTIVE
74,CN,A,CN 103906896 A,124-434-369-882-280,2014-07-02,2014,CN 201280054278 A,2012-08-24,US 2012/0052185 W;;US 201161556270 P;;US 201213443947 A,2011-11-06,Asymmetric radial spline seal for a gas turbine engine,"A shroud apparatus for a gas turbine engine includes: an annular shroud segment (26) having an arcuate bottom wall (52) defining an arcuate inner flowpath surface (62), spaced-apart forward and aft walls (54, 56) extending radially outward from the bottom wall (52), and spaced-apart side walls (58) extending radially outward from the bottom wall (52) and between the forward and aft walls (54, 56), each side wall (58) defining an end face (74) which includes: an axial slot (76) extending in a generally axial direction along the end face (74); a first radial slot (78) extending in a generally radial direction along the end face (74), and intersecting the axial slot (76); an axial spline seal (82) received in the axial slot (76); and a first radial spline seal (84) having an L-shape with radial and axial legs (88, 90), the radial leg (88) being substantially longer than the axial leg (90), wherein the radial leg (88) is received in the first radial slot (78), and the axial leg is received in the axial slot (76).",GEN ELECTRIC,STAPLETON DAVID SCOTT;;CEGLIO CHRISTOPHER MICHAEL;;CORREIA VICTOR HUGO SILVA,,https://lens.org/124-434-369-882-280,Patent Application,no,5,6,15,15,0,F01D11/005;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/11;;F05D2240/57;;F05D2240/57;;F05D2240/59;;F05D2240/59,F01D11/00,,0,0,,,,ACTIVE
75,US,A1,US 2013/0115065 A1,053-001-604-542-853,2013-05-09,2013,US 201213443947 A,2012-04-11,US 201213443947 A;;US 201161556270 P,2011-11-06,ASYMMETRIC RADIAL SPLINE SEAL FOR A GAS TURBINE ENGINE,"A shroud apparatus for a gas turbine engine includes: an annular shroud segment having an arcuate bottom wall defining an arcuate inner flowpath surface, spaced-apart forward and aft walls extending radially outward from the bottom wall, and spaced-apart side walls extending radially outward from the bottom wall and between the forward and aft walls, each side wall defining an end face which includes: an axial slot extending in a generally axial direction along the end face; a first radial slot extending in a generally radial direction along the end face, and intersecting the axial slot; an axial spline seal received in the axial slot; and a first radial spline seal having an L-shape with radial and axial legs, the radial leg being substantially longer than the axial leg, wherein the radial leg is received in the first radial slot, and the axial leg is received in the axial slot.",CORREIA VICTOR HUGO SILVA;;CEGLIO CHRISTOPHER MICHAEL;;STAPLETON DAVID SCOTT;;GEN ELECTRIC,CORREIA VICTOR HUGO SILVA;;CEGLIO CHRISTOPHER MICHAEL;;STAPLETON DAVID SCOTT,GENERAL ELECTRIC COMPANY (2012-04-06),https://lens.org/053-001-604-542-853,Patent Application,yes,11,19,15,15,0,F01D11/005;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/11;;F05D2240/57;;F05D2240/57;;F05D2240/59;;F05D2240/59,F04D29/40,415/182.1,0,0,,,,ACTIVE
76,AU,B2,AU 2014/225446 B2,131-226-631-476-964,2017-12-21,2017,AU 2014/225446 A,2014-03-07,US 201361774735 P;;US 201361793336 P;;US 201361774773 P;;US 201361774740 P;;US 201361774731 P;;US 201361774780 P;;US 201361774761 P;;US 201361774744 P;;US 201361774746 P;;US 201361774684 P;;US 201361774723 P;;US 201361774754 P;;US 201361774775 P;;US 201361774750 P;;US 201361774752 P;;US 2014/0021815 W,2013-03-08,Upgrading process streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials.. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. ] Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/131-226-631-476-964,Granted Patent,no,5,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,INACTIVE
77,EP,B1,EP 2890798 B1,140-806-816-813-178,2019-08-28,2019,EP 14760021 A,2014-03-07,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,METHOD FOR OBTAINING SACCHARIFIED BIOMASS WITH RADIATION AND ELECTRODIALYSIS,,XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,"XYLECO, INC. (2018-02-28)",https://lens.org/140-806-816-813-178,Granted Patent,yes,8,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,G01T7/08;;C10L9/08,,0,0,,,,ACTIVE
78,US,A1,US 2018/0193801 A1,023-314-637-152-092,2018-07-12,2018,US 201815913740 A,2018-03-06,US 201815913740 A;;US 201715487565 A;;US 201414299010 A;;US 2014/0021815 W;;US 201361793336 P;;US 201361774773 P;;US 201361774731 P;;US 201361774723 P;;US 201361774780 P;;US 201361774775 P;;US 201361774684 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774761 P,2013-03-08,UPGRADING PROCESS STREAMS,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,XYLECO INC (2014-06-09),https://lens.org/023-314-637-152-092,Patent Application,yes,3,2,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,B01D61/44;;C12P7/10;;C12P7/56;;C13K13/00,,0,0,,,,ACTIVE
79,DE,B,DE 1295013 B,120-919-873-899-823,1969-05-14,1969,DE P0035801 A,1965-01-02,GB 35764 A,1964-01-03,"Manuell einstellbarer, magnetischer Halbfestwertspeicher",,PLESSEY UK LTD,ALAN JONES;;WILLIAM SIMPSON ANTHONY;;CHRISTOPHER STAPLETON DAVID;;MILTON MASER,,https://lens.org/120-919-873-899-823,Patent Application,no,1,0,3,3,0,G11C17/02,G11C17/02,,0,0,,,,DISCONTINUED
80,AU,A1,AU 2014/265107 A1,158-978-718-313-799,2016-06-09,2016,AU 2014/265107 A,2014-11-21,AU 2014/265107 A,2014-11-21,APPARATUS FOR CONTROLLING POWER OUTPUT,"An apparatus (100) for controlling power output comprising: a controller (120) configured to adjust a power output of an inverter (14, 214, 215) of a power 5 generation system (200) which comprises a load (17) to which the power output (16, 216, 217) of the inverter is connected, said power generation system (200) being connected (18) to an electricity supply grid; and a detector (110) for providing input to the controller (120), the detector being adapted to detect the input (at 22) of the electricity supply grid to the power generation system (200); 10 wherein the controller (120) is adapted to adjust the power output of the inverter (14, 214, 215) downwards when the detected input power of the electricity supply grid to the power generation system is below a first, lower, predetermined threshold and to adjust the power output of the inverter upwards when the detected power input of the electricity supply grid to the power generation system 15 is above a second, higher, predetermined threshold. Figure 2 for publication System Power Turns On 1.Ceking Building Power Usage Inverter Disconnected 30 seconds elapsed while N imported flow >03kW disconnects 2lInverter Startup Period n 20 -mins Inverter Connected, Ye~s Raped t o minue lc .outu 60 seconds elapsed 5 seconds elapsed after inverter ramped to minimum 3 agtBn output. 3 agtBn No change to inverter output. Net export flow Net import flow >0kW 0.3kW Net export flow Net import flow <=OkW >= 0.3kW 4. Exported Power > 0 S.imported Pwr > 03kW Ramp inverter output Ramp inverter output UP DOWN at 20%/sec at 3%/sec .Fault -(:nverter Disconnected (Requires Power Cycle)",DBS IND QLD PTY LTD,STAPLETON DUANE;;TRULOFF JACOB;;BURNS DAVID;;BLACK MARCUS;;TAYLOR CHRISTOPHER,,https://lens.org/158-978-718-313-799,Patent Application,no,0,1,1,1,0,Y02B70/3225;;Y04S20/222,H02J5/00;;H02J3/14,,0,0,,,,DISCONTINUED
81,KR,A,KR 20150127050 A,074-033-967-911-601,2015-11-16,2015,KR 20157022633 A,2014-03-07,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,UPGRADING PROCESS STREAMS,"바이오매스(예컨대식물 바이오매스, 동물 바이오매스 및 도시 폐기물 바이오매스)를 가공처리하여 유용한 중간생성물 및 생성물, 예컨대, 에너지, 연료, 식품 또는 재료를 생산한다. 전기투석 또는 역극 전기투석을 이용해서 공정을 업그레이드하기 위한 시스템들, 방법들 및 장비가 기재되어 있다. 두서너 가지 예를 들면, 농산물 잔류물, 목재 바이오매스, 도시 폐기물, 오일시드/케이크 및 해초류를 비롯하여 많은 잠재적인 리그노셀룰로스 공급원료가 오늘날 입수 가능하다.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/074-033-967-911-601,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,B01J19/08;;C12P7/06;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/00;;E04B1/92;;G21F7/00;;H01J37/317,,0,0,,,,DISCONTINUED
82,CA,C,CA 2853622 C,190-431-695-270-757,2016-12-13,2016,CA 2853622 A,2012-08-24,US 201161556270 P;;US 201213443947 A;;US 2012/0052185 W,2011-11-06,ASYMMETRIC RADIAL SPLINE SEAL FOR A GAS TURBINE ENGINE,"A shroud apparatus for a gas turbine engine includes: an annular shroud segment (26) having an arcuate bottom wall (52) defining an arcuate inner flowpath surface(62), spaced-apart forward and aft walls (54, 56) extending radially outward from the bottom wall (52), and spaced-apart side walls (58) extending radially outward from the bottom wall (52) and between the forward and aft walls (54, 56), each side wall (58) defining an end face (74) which includes: an axial slot (76) extending in a generally axial direction along the end face (74); a first radial slot (78) extending in a generally radial direction along the end face (74), and intersecting the axial slot (76); an axial spline seal (82) received in the axial slot (76); and a first radial spline seal (84) having an L-shape with radial and axial legs (88, 90), the radial leg (88)being substantially longer than the axial leg (90), wherein the radial leg (88) is received in the first radial slot (78), and the axial leg is received in the axial slot (76).",GEN ELECTRIC,STAPLETON DAVID SCOTT;;CEGLIO CHRISTOPHER MICHAEL;;CORREIA VICTOR HUGO SILVA,,https://lens.org/190-431-695-270-757,Granted Patent,no,0,0,15,15,0,F01D11/005;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/11;;F05D2240/57;;F05D2240/57;;F05D2240/59;;F05D2240/59,F04D29/40,,0,0,,,,INACTIVE
83,WO,A3,WO 2013/074165 A3,000-714-888-417-17X,2013-08-15,2013,US 2012/0052185 W,2012-08-24,US 201161556270 P;;US 201213443947 A,2011-11-06,ASYMMETRIC RADIAL SPLINE SEAL FOR A GAS TURBINE ENGINE,"A shroud apparatus for a gas turbine engine includes: an annular shroud segment (26) having an arcuate bottom wall (52) defining an arcuate inner flowpath surface(62), spaced-apart forward and aft walls (54, 56) extending radially outward from the bottom wall (52), and spaced-apart side walls (58) extending radially outward from the bottom wall (52) and between the forward and aft walls (54, 56), each side wall (58) defining an end face (74) which includes: an axial slot (76) extending in a generally axial direction along the end face (74); a first radial slot (78) extending in a generally radial direction along the end face (74), and intersecting the axial slot (76); an axial spline seal (82) received in the axial slot (76); and a first radial spline seal (84) having an L-shape with radial and axial legs (88, 90), the radial leg (88)being substantially longer than the axial leg (90), wherein the radial leg (88) is received in the first radial slot (78), and the axial leg is received in the axial slot (76).",GEN ELECTRIC;;STAPLETON DAVID SCOTT;;CEGLIO CHRISTOPHER MICHAEL;;CORREIA VICTOR HUGO SILVA,STAPLETON DAVID SCOTT;;CEGLIO CHRISTOPHER MICHAEL;;CORREIA VICTOR HUGO SILVA,,https://lens.org/000-714-888-417-17X,Search Report,yes,5,0,15,15,0,F01D11/005;;F01D11/005;;F01D9/04;;F05D2240/11;;F05D2240/11;;F05D2240/57;;F05D2240/57;;F05D2240/59;;F05D2240/59,F01D11/00,,0,0,,,,PENDING
84,NZ,A,NZ 751363 A,073-648-863-439-108,2020-08-28,2020,NZ 75136314 A,2014-03-07,US 201361774684 P;;US 201361774773 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774775 P;;US 201361774780 P;;US 201361774761 P;;US 201361774723 P;;US 201361793336 P;;NZ 70611814 A,2013-03-08,Upgrading process streams,"Biomass (e.g., plant biomass, animal biomass, and municipal waste biomass) is processed to produce useful intermediates and products, such as energy, fuels, foods or materials. Systems, methods and equipment are described for upgrading process streams using electrodialysis or electrodialysis reversal. Many potential lignocellulosic feedstocks are available today, including agricultural residues, woody biomass, municipal waste, oilseeds/cakes and seaweed, to name a few.",XYLECO INC,MEDOFF MARSHALL;;MASTERMAN THOMAS CRAIG;;MUKHERJEE MAIA STAPLETON;;COOPER CHRISTOPHER,,https://lens.org/073-648-863-439-108,Patent Application,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10;;B01D61/44,,0,0,,,,PENDING
85,CU,B1,CU 24346 B1,157-808-906-675-510,2018-05-08,2018,CU 20150101 A,2014-03-07,US 201361774684 P;;US 201361774723 P;;US 201361774731 P;;US 201361774735 P;;US 201361774740 P;;US 201361774744 P;;US 201361774746 P;;US 201361774750 P;;US 201361774752 P;;US 201361774754 P;;US 201361774761 P;;US 201361774773 P;;US 201361774775 P;;US 201361774780 P;;US 201361793336 P;;US 2014/0021815 W,2013-03-08,MÉTODO PARA OBTENER AZÚCARES DERIVADOS DE LÍQUIDOS DE BIOMASA SACARIFICADOS,"<p>La invención describe un método para obtener azúcares derivados de líquidos de biomasa sacarificados. Este método consiste en pretratar un material celulósico o lignocelulósico para radiación por ionización. Posteriormente, el método consiste en sacarificar el material celulósico o lignocelulósico radiado para obtener líquidos de biomasa sacarificados. Finalmente, el método consiste en eliminar las sales, ácidos parcialmente ionizados o ácidos completamente ionizados, de los líquidos de biomasa sacarificada con un sistema de electrodiálisis, en donde utilizar un sistema de electrodiálisis comprende un primer paso de electrodiálisis y un segundo paso de electrodiálisis, en donde el segundo paso de electrodiálisis comprende usar una membrana bipolar. De esta forma la biomasa (por ejemplo, biomasa vegetal, biomasa animal y biomasa de desechos urbanos) es procesada para producir intermedios y productos útiles, tales como energía, combustibles, alimentos o materiales.</p>",XYLECO INC,COOPER CHRISTOPHER;;MASTERMAN THOMAS CRAIG;;MEDOFF MARSHALL;;MUKHERJEE MARIA STAPLETON,,https://lens.org/157-808-906-675-510,Unknown,no,0,0,393,589,0,C12P19/02;;C12P19/02;;C12P19/14;;C12P7/10;;C12P2201/00;;B01D53/02;;B01D53/46;;B01J19/085;;C08B1/00;;B01D15/02;;B01D53/32;;B01D61/44;;B01D61/445;;B65G27/00;;B65G53/04;;B65G53/40;;C07C29/149;;C07C31/12;;C10G1/00;;C10L1/023;;C10L1/026;;C10L9/08;;C12M47/00;;C12M47/10;;C12P7/04;;C12P7/06;;C12P7/10;;C12P7/52;;C12P7/56;;C12P19/02;;C12P19/14;;C13K1/02;;C13K13/002;;D21C9/007;;E04B1/92;;G21F7/00;;H01J37/317;;E04B2001/925;;H01J2237/31;;H01J2237/3165;;H01J2237/202;;Y02W10/37;;Y02W10/33;;Y02E50/30;;B01J2219/0879;;B01J2219/0869;;B01J2219/0886;;C10L2290/36;;C10L2200/0476;;C10L2200/0469;;C12P2203/00;;C12P2201/00;;G21K5/10;;Y02E50/10;;Y02E60/16;;Y02P20/133;;C12P2203/00;;C12M47/10;;C10L9/08;;C07C29/149;;Y02W10/33;;Y02W10/37;;Y02E50/30;;C10G1/00;;B01D15/02;;C13K1/02;;C13K13/002;;C12P19/02;;C12P19/14;;C12P7/10;;C12P7/52;;G21K5/10;;Y02W10/40;;Y02P20/133;;Y02E50/10;;B01J19/085;;B01D53/32;;B01J2219/0886;;C12M47/10;;C07C29/149;;Y02W10/33;;Y02W10/37;;H01J2237/31;;H01J2237/3165;;C12M47/00;;C12P2203/00;;C10L9/08;;Y02E50/30;;Y02E50/10;;Y02E60/16;;Y02P20/133;;B01D15/02;;E04B1/92;;E04B2001/925;;G21F7/00;;H01J37/317;;C13K1/02;;C13K13/002;;B65G53/40;;C12P19/02;;C12P7/06;;B01D61/44;;C12P19/14;;C12P7/10;;C12P7/52;;B65G27/00;;B65G53/04;;B01J2219/0879;;D21C9/007;;H01J2237/202;;B01J2219/0869;;C10G1/00;;C10L1/023;;C10L1/026;;C10L2200/0469;;C10L2200/0476;;C10L2290/36;;C12P7/04;;C12P2201/00;;B01D61/445;;C12P7/56;;C07C31/12,C12P7/10,,0,0,,,,PENDING
86,US,B1,US 6594231 B1,081-399-654-880-840,2003-07-15,2003,US 36932399 A,1999-08-06,GB 9910895 A,1999-05-12,Method and apparatus for configuration of stackable units in packet-based communications systems,"
    A stackable network unit comprises a down port and an up port, an arbitration path for data packets from the down port to the up port, a repeat path for data packets from the up port to the down port, a link detector for detecting tile absence of another operative unit connected to the down port to cause data packets on the return pat to bypass the down port and proceed on the arbitration path and for detecting the absence of another operative unit connected to the up port to cause data packets on the arbitration path to bypass the up port and proceed on the repeat path. 
",3COM CORP,BYHAM CHRISTOPHER;;LAW DAVID J;;STAPLETON NICHOLAS M;;TURNER EDWARD;;WALKER CHRISTOPHER;;WRIGHT DAVID,HEWLETT-PACKARD COMPANY (2010-04-28);;3COM CORPORATION (1999-07-29);;HEWLETT-PACKARD DEVELOPMENT COMPANY L.P (2003-01-31),https://lens.org/081-399-654-880-840,Granted Patent,yes,7,33,4,4,0,H04L12/44;;H04L12/44;;H04L12/437;;H04L12/437,H04L12/437;;H04L12/44,370/223;;370/219;;370/227,0,0,,,,EXPIRED
87,GB,B,GB 2350032 B,097-268-892-061-331,2001-04-11,2001,GB 9910895 A,1999-05-12,GB 9910895 A,1999-05-12,Method and apparatus for configuration of stackable units in packet-based communication systems,,3COM CORP,BYHAM CHRISTOPHER;;LAW DAVID JOHN;;STAPLETON NICHOLAS;;TURNER EDWARD;;WALKER CHRISTOPHER ALAN;;WRIGHT DAVID,,https://lens.org/097-268-892-061-331,Granted Patent,no,3,0,4,4,0,H04L12/44;;H04L12/44;;H04L12/437;;H04L12/437,H04L12/437;;H04L12/44,H4P PPG           PPG;;H4P PPJD          PPJD,0,0,,,,EXPIRED
88,GB,A,GB 2350032 A,014-462-776-344-375,2000-11-15,2000,GB 9910895 A,1999-05-12,GB 9910895 A,1999-05-12,Ring network formed from stackable units with self configuration system based on port connection status,"A stackable network hub unit comprises 'up' <B>12</B> and 'down' <B>11</B> ports with data paths <B>14,15</B> between them. Means are provided at each port to detect the presence of a link to another stackable unit and the type of link. If no unit is detected the port is bypassed and data packets are directed from one data path to the other, as per <B>UNITS 1</B> and <B>3</B>, and the ring network is thereby formed. A 'resilient' cable may be connected between the 'up' port of the top unit and the 'down' port of the bottom unit on the stack (Fig. 4) to allow a bidirectional ring to be formed, that can operate with one link of unit out of service. The network units contain configuring means which transmit configuration packets containing source unit identification and its 'down' port connection status data, ie. normal connection, resilient cable or no connection. A unit receiving the packet compares this 'down' port status data with its own 'down' port status according to the table. If it wins it transmits a new configuration packet with its own identifier and port status, if not it forwards the packet it received. When a unit receives a packet with its own identification it becomes the bottom of the stack and other units are numbered therefrom. This scheme allows hot configuration of the stack and can accommodate hub unit failure and incorrect use of connection cables.",3COM CORP,BYHAM CHRISTOPHER;;LAW DAVID JOHN;;STAPLETON NICHOLAS;;TURNER EDWARD;;WALKER CHRISTOPHER ALAN;;WRIGHT DAVID,,https://lens.org/014-462-776-344-375,Patent Application,no,3,20,4,4,0,H04L12/44;;H04L12/44;;H04L12/437;;H04L12/437,H04L12/437;;H04L12/44,H4P PPG           PPG;;H4P PPJD          PPJD,0,0,,,,EXPIRED
89,EP,A1,EP 3147462 A1,017-483-287-090-978,2017-03-29,2017,EP 16190927 A,2016-09-27,US 201514867137 A,2015-09-28,GAS TURBINE ENGINE SEALING ASSEMBLY WITH A SEAL HAVING A SHIELD MEMBER AND A SPRING MEMBER MADE OF DIFFERENT MATERIALS AND CORRESPONDING GAS TURBINE ENGINE,"In one aspect, the present disclosure is directed to a gas turbine sealing assembly (100) that includes a first static gas turbine wall and a second static gas turbine wall. A seal is disposed between the first static gas turbine wall and the second static gas turbine wall. The seal includes a shield wall (104) constructed from a first material that includes a first shield wall portion (114) and a second shield wall portion (116). A spring (102) constructed from a second material includes a first spring portion (120) and a second spring portion (122). The first shield wall portion (114) is adjacent to the first spring portion (120), and the second shield wall portion (116) is adjacent to the second spring portion (122).
",GEN ELECTRIC,FITZPATRICK DYLAN JAMES;;STAPLETON DAVID SCOTT;;BALDIGA JONATHAN DAVID;;TURA CHRISTOPHER PAUL,,https://lens.org/017-483-287-090-978,Patent Application,yes,7,0,7,7,0,F01D11/08;;F16J15/0893;;F05D2300/502;;F01D11/005;;F05D2240/55;;F16J15/027;;Y02T50/60;;F16J15/0893;;F05D2300/502;;Y02T50/60;;F01D11/005;;F05D2240/55;;F16J15/027,F01D11/00;;F16J15/08;;F16J15/10,,0,0,,,,DISCONTINUED
90,BE,A7,BE 1004181 A7,146-713-236-824-685,1992-10-06,1992,BE 9200510 A,1992-06-03,IE 921308 A,1992-04-23,PROCEDE ET APPAREIL DE REDUCTION DE LA TEMPERATURE D'UN COURANT DE GAZ DE FUMEE.,Un appareil (1) destiné à réduire adiabatiquement la température de gaz de fumée d'un courant de gaz de fumée comprend un conduit (3) pour le courant de gaz de fumée (20) et une sortie aval de gaz de fumée (23). Des gicleurs (28) situées dans le conduit (3) en position adjacente à l'entrée libère une pulvérisation d'eau de refroidissement dont la taille des gouttelettes est d'environ 40 microns dans le courant de gaz de fumée. Un étrangleur amont (35) formé par des éléments d'étrangleur (40) tubulaires parallèles et espacés provoque le mélange intime des gouttelettes d'eau avec les gaz de fumées du courant de gaz de fumée. L'étrangleur amont (35) comprend six éléments d'étrangleur (40) qui forment un étrangleur d'une porosité de 50% et qui cachent environ 60% de la suprficie de l'entrée des gaz de fumée (20).,SCHWAN LTD,REDINGTON MARTIN ANTHONY;;REDINGTON MARTIN LAURENCE;;STAPLETON ANTHONY WILLIAM;;SLATTERY GERARD CHRISTOPHER,,https://lens.org/146-713-236-824-685,Limited Patent,no,0,0,5,5,0,F28C3/06;;F23J15/06,F23J15/06;;F28C3/06,,0,0,,,,EXPIRED
91,CA,A1,CA 2941837 A1,008-559-192-882-421,2017-03-28,2017,CA 2941837 A,2016-09-15,US 201514867137 A,2015-09-28,ADVANCED STATIONARY SEALING CONCEPTS FOR AXIAL RETENTION OF CERAMIC MATRIX COMPOSITE SHROUDS,"In one aspect, the present disclosure is directed to a gas turbine sealing assembly that includes a first static gas turbine wall and a second static gas turbine wall. A seal is disposed between the first static gas turbine wall and the second static gas turbine wall. The seal includes a shield wall constructed from a first material that includes a first shield wall portion and a second shield wall portion. A spring constructed from a second material includes a first spring portion and a second spring portion. The first shield wall portion is adjacent to the first spring portion, and the second shield wall portion is adjacent to the second spring portion.",GEN ELECTRIC,FITZPATRICK DYLAN JAMES;;STAPLETON DAVID SCOTT;;BALDIGA JONATHAN DAVID;;TURA CHRISTOPHER PAUL,,https://lens.org/008-559-192-882-421,Patent Application,no,0,0,7,7,0,F01D11/08;;F16J15/0893;;F05D2300/502;;F01D11/005;;F05D2240/55;;F16J15/027;;Y02T50/60;;F16J15/0893;;F05D2300/502;;Y02T50/60;;F01D11/005;;F05D2240/55;;F16J15/027,F02C7/28;;F01D9/02,,0,0,,,,DISCONTINUED
92,GB,A,GB 2266362 A,005-724-093-714-972,1993-10-27,1993,GB 9308441 A,1993-04-23,IE 921308 A,1992-04-23,A method and apparatus for reducing the temperature of a flue gas stream,"Apparatus (1) for reducing the temperature of flue gases adiabatically in a flue gas stream comprises a duct (3) for the flue gas stream having an upstream flue gas inlet (20) and a downstream flue gas outlet (23). Nozzles (28) in the duct (3) adjacent the inlet (20) deliver a cooling water spray of droplet size which is not greater than 50 microns into the flue gas stream. An upstream baffle (35) formed by parallel spaced apart tubular baffle members (40) causes the water droplets to merge with the flue gases of the flue gas stream. The baffle (35) may comprise six baffle members (40) which form a baffle with a porosity of 50% and which occludes approximately 60% of the area of the flue gas inlet (20). Further baffle portions (36, 37) may be provided. <IMAGE>",SCHWAN LTD,REDINGTON MARTIN ANTHONY;;REDINGTON MARTIN LAURENCE;;STAPLETON ANTHONY WILLIAM;;SLATTERY GERARD CHRISTOPHER,,https://lens.org/005-724-093-714-972,Patent Application,no,5,0,5,5,0,F28C3/06;;F23J15/06,F23J15/06;;F28C3/06,F4K K11C          K11C;;U1S S1438,0,0,,,,EXPIRED
93,JP,A,JP 2017067070 A,081-363-123-957-330,2017-04-06,2017,JP 2016181101 A,2016-09-16,US 201514867137 A,2015-09-28,ADVANCED STATIONARY SEALING CONCEPTS FOR AXIAL RETENTION OF CERAMIC MATRIX COMPOSITE SHROUDS,"PROBLEM TO BE SOLVED: To provide advanced stationary sealing concepts for axial retention of ceramic matrix composite shrouds.SOLUTION: In one aspect, the present disclosure is directed to a gas turbine sealing assembly that includes a first static gas turbine wall and a second static gas turbine wall. A seal is disposed between the first static gas turbine wall and the second static gas turbine wall. The seal includes a shield wall constructed from a first material that includes a first shield wall portion and a second shield wall portion. A spring constructed from a second material includes a first spring portion and a second spring portion. The first shield wall portion is adjacent to the first spring portion, and the second shield wall portion is adjacent to the second spring portion.SELECTED DRAWING: Figure 1",GENERAL ELECTRIC CO GE,DYLAN JAMES FITZPATRICK;;DAVID SCOTT STAPLETON;;JONATHAN DAVID BALDIGA;;CHRISTOPHER PAUL TURA,,https://lens.org/081-363-123-957-330,Patent Application,no,6,1,7,7,0,F01D11/08;;F16J15/0893;;F05D2300/502;;F01D11/005;;F05D2240/55;;F16J15/027;;Y02T50/60;;F16J15/0893;;F05D2300/502;;Y02T50/60;;F01D11/005;;F05D2240/55;;F16J15/027,F01D11/00;;C09K3/10;;F01D25/24;;F02C7/28;;F16J15/08,,0,0,,,,PENDING
94,CN,A,CN 107035429 A,190-682-925-999-030,2017-08-11,2017,CN 201610857487 A,2016-09-28,US 201514867137 A,2015-09-28,Advanced Stationary Sealing Concepts For Axial Retention Of Ceramic Matrix Composite Shrouds,"In one aspect, the present disclosure is directed to a gas turbine sealing assembly that includes a first static gas turbine wall and a second static gas turbine wall. A seal is disposed between the first static gas turbine wall and the second static gas turbine wall. The seal includes a shield wall constructed from a first material that includes a first shield wall portion and a second shield wall portion. A spring constructed from a second material includes a first spring portion and a second spring portion. The first shield wall portion is adjacent to the first spring portion, and the second shield wall portion is adjacent to the second spring portion.",GEN ELECTRIC,JONATHAN DAVID BALDIGA;;CHRISTOPHER PAUL TURA;;DAVID SCOTT STAPLETON;;DYLAN JAMES FITZPATRICK,,https://lens.org/190-682-925-999-030,Patent Application,no,7,2,7,7,0,F01D11/08;;F16J15/0893;;F05D2300/502;;F01D11/005;;F05D2240/55;;F16J15/027;;Y02T50/60;;F16J15/0893;;F05D2300/502;;Y02T50/60;;F01D11/005;;F05D2240/55;;F16J15/027,F01D11/08,,0,0,,,,ACTIVE
95,US,A,US 1896006 A,002-898-936-465-099,1933-01-31,1933,US 43414230 A,1930-03-07,US 43414230 A,1930-03-07,Production of phosphoric acid,,MEMMINGER CHRISTOPHER G;;WAGGAMAN WILLIAM H;;GOOCH STAPLETON D;;KERSCHBAUM FRIEDRICH P,MEMMINGER CHRISTOPHER G;;WAGGAMAN WILLIAM H;;GOOCH STAPLETON D;;KERSCHBAUM FRIEDRICH P,,https://lens.org/002-898-936-465-099,Granted Patent,no,0,2,1,1,0,C01B25/20;;C01B25/20;;Y02P20/129;;Y02P20/129,C01B25/20,,0,0,,,,EXPIRED
96,US,A1,US 2017/0089212 A1,093-750-119-670-623,2017-03-30,2017,US 201514867137 A,2015-09-28,US 201514867137 A,2015-09-28,ADVANCED STATIONARY SEALING CONCEPTS FOR AXIAL RETENTION OF CERAMIC MATRIX COMPOSITE SHROUDS,"In one aspect, the present disclosure is directed to a gas turbine sealing assembly that includes a first static gas turbine wall and a second static gas turbine wall. A seal is disposed between the first static gas turbine wall and the second static gas turbine wall. The seal includes a shield wall constructed from a first material that includes a first shield wall portion and a second shield wall portion. A spring constructed from a second material includes a first spring portion and a second spring portion. The first shield wall portion is adjacent to the first spring portion, and the second shield wall portion is adjacent to the second spring portion.",GEN ELECTRIC,FITZPATRICK DYLAN JAMES;;STAPLETON DAVID SCOTT;;BALDIGA JONATHAN DAVID;;TURA CHRISTOPHER PAUL,GENERAL ELECTRIC COMPANY (2015-09-25),https://lens.org/093-750-119-670-623,Patent Application,yes,8,0,7,7,0,F01D11/08;;F16J15/0893;;F05D2300/502;;F01D11/005;;F05D2240/55;;F16J15/027;;Y02T50/60;;F16J15/0893;;F05D2300/502;;Y02T50/60;;F01D11/005;;F05D2240/55;;F16J15/027,F01D11/00;;F16J15/02,,0,0,,,,ACTIVE
97,IE,A1,IE 921308 A1,117-646-511-109-864,1993-11-03,1993,IE 921308 A,1992-04-23,IE 921308 A,1992-04-23,A method and apparatus for reducing the temperature of a¹flue gas stream,,SCHWAN LTD,STAPLETON ANTHONY WILLIAM;;SLATTERY GERARD CHRISTOPHER;;REDINGTON MARTIN ANTHONY;;REDINGTON MARTIN LAURENCE,,https://lens.org/117-646-511-109-864,Patent Application,no,0,0,5,5,0,F28C3/06;;F23J15/06,F23J15/06;;F28C3/06,,0,0,,,,DISCONTINUED
98,GB,B,GB 2266362 B,086-154-865-750-890,1995-12-13,1995,GB 9308441 A,1993-04-23,IE 921308 A,1992-04-23,A method and apparatus for reducing the temperature of a flue gas system,,SCHWAN LTD,REDINGTON MARTIN ANTHONY;;REDINGTON MARTIN LAURENCE;;STAPLETON ANTHONY WILLIAM;;SLATTERY GERARD CHRISTOPHER,,https://lens.org/086-154-865-750-890,Granted Patent,no,5,0,5,5,0,F28C3/06;;F23J15/06,F23J15/06;;F28C3/06,F4K K11C          K11C;;U1S S1438,0,0,,,,EXPIRED
99,US,B2,US 10794204 B2,125-933-537-719-216,2020-10-06,2020,US 201514867137 A,2015-09-28,US 201514867137 A,2015-09-28,Advanced stationary sealing concepts for axial retention of ceramic matrix composite shrouds,"In one aspect, the present disclosure is directed to a gas turbine sealing assembly that includes a first static gas turbine wall and a second static gas turbine wall. A seal is disposed between the first static gas turbine wall and the second static gas turbine wall. The seal includes a shield wall constructed from a first material that includes a first shield wall portion and a second shield wall portion. A spring constructed from a second material includes a first spring portion and a second spring portion. The first shield wall portion is adjacent to the first spring portion, and the second shield wall portion is adjacent to the second spring portion.",GEN ELECTRIC,FITZPATRICK DYLAN JAMES;;STAPLETON DAVID SCOTT;;BALDIGA JONATHAN DAVID;;TURA CHRISTOPHER PAUL,GENERAL ELECTRIC COMPANY (2015-09-25),https://lens.org/125-933-537-719-216,Granted Patent,yes,12,1,7,7,0,F01D11/08;;F16J15/0893;;F05D2300/502;;F01D11/005;;F05D2240/55;;F16J15/027;;Y02T50/60;;F16J15/0893;;F05D2300/502;;Y02T50/60;;F01D11/005;;F05D2240/55;;F16J15/027,F01D11/00;;F16J15/02;;F16J15/08,,3,0,,,"European Search Report and Opinion issued in connection with corresponding EP Application No. 16190927.0 dated Feb. 9, 2017.;;Canadian Office Action Corresponding to Application No. 2941837 dated Jun. 5, 2017.;;Chinese Office Action Corresponding to Application No. 201610857487.4 dated Jan. 29, 2019.",ACTIVE
100,US,A1,US 2015/0087004 A1,070-113-999-135-066,2015-03-26,2015,US 201414334408 A,2014-07-17,US 201414334408 A;;US 2013/0024450 W;;US 201261594084 P;;US 201313024450 A,2012-02-02,Microfabricated 3D Cell Culture System,"Device for 3D cell culture using an extracellular matrix including a substrate having at least one interior chamber, at least one opening providing access to the interior chamber for introduction of an extracellular matrix, and at least one channel disposed through at least a portion of the extra cellular matrix.",UNIV PENNSYLVANIA,CHEN CHRISTOPHER S;;NGUYEN DUC-HUY T;;STAPLETON SARAH C;;YANG MICHAEL T,THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (2015-01-28),https://lens.org/070-113-999-135-066,Patent Application,yes,4,19,1,2,0,C12N2513/00;;C12N2533/50;;G01N33/502;;C12M25/14;;C12N5/0068;;C12N2535/00;;G01N33/502;;C12N2513/00;;C12N2533/50;;C12M25/14,C12N5/00;;B29C65/70;;B29D22/00;;G01N33/50,435/29;;435/402;;156/245,0,0,,,,DISCONTINUED
101,WO,A1,WO 2013/116729 A1,003-576-125-570-893,2013-08-08,2013,US 2013/0024450 W,2013-02-01,US 201261594084 P,2012-02-02,MICROFABRICATED 3D CELL CULTURE SYSTEM,"Device for 3D cell culture using an extracellular matrix including a substrate having at least one interior chamber, at least one opening providing access to the interior chamber for introduction of an extracellular matrix, and at least one channel disposed through at least a portion of the extra cellular matrix.",UNIV PENNSYLVANIA,CHEN CHRISTOPHER S;;NGUYEN DUC-HUY T;;STAPLETON SARAH C;;YANG MICHAEL T,,https://lens.org/003-576-125-570-893,Patent Application,yes,4,9,1,2,0,C12M21/04;;C12M23/12;;C12M23/20;;C12M29/00,C12P21/04,,1,1,015-620-531-477-548,17969174;;10.1002/bit.21698;;pmc2796126,"NG ET AL.: ""A perfusable 3-D cell-matrix tissue culture chamber for in situ evaluation of nanoparticle vehicle penetration and transport"", BIOTECHNOLOGY AND BIOENGINEERING, vol. 99, no. 6, 29 October 2007 (2007-10-29), pages 1490 - 1501, XP009153051",PENDING
102,US,B2,US 8710821 B2,010-029-242-881-288,2014-04-29,2014,US 83738210 A,2010-07-15,US 83738210 A;;US 42484406 A,2006-06-16,Method for inhibiting thermal run-away,"A method for mitigating aliasing effects in a single phase power converter and mitigating aliasing effects and inhibiting thermal run-away in a multi-phase power converter at varying load transition rates. A single phase or multi-phase power converter having an on-time is provided and the frequency of the power converter is adjusted so that a load step period and the on time of the single phase power converter are in a temporal relationship. Alternatively, a load step rate is inhibited from locking onto a phase current of the single phase power converter by suspending an oscillator signal. In accordance with another alternative, a load step rate is inhibited from locking onto a phase current of the single phase power converter by suspending an oscillator signal and dithering an input signal to the oscillator.",MOYER OLE P;;HARRIMAN PAUL JAY;;RICE BENJAMIN M;;GASS CHRISTOPHER J;;STAPLETON MICHAEL A;;SEMICONDUCTOR COMPONENTS IND,MOYER OLE P;;HARRIMAN PAUL JAY;;RICE BENJAMIN M;;GASS CHRISTOPHER J;;STAPLETON MICHAEL A,SEMICONDUCTOR COMPONENTS INDUSTRIES L.L.C (2010-07-14),https://lens.org/010-029-242-881-288,Granted Patent,yes,13,0,2,15,0,H02M3/1584;;H02M3/1584;;H02M1/32;;H02M1/32,H02M3/156,323/288;;323/285,4,0,,,"2/3/4 Phase Buck Controller for VR10 and VR11 Pentium IV Processor Applications, Semiconductor Components Industries, LLC, Publication No. NCP5381, Rev. May 2, 2006. Retrieved from http://www.onsemi.com/pub/Collateral/NCP5381-D.PDF.;;MOSFET Driver with Dual Outputs for Synchronous Buck Converters, Semiconductor Components Industries, LLC, Publication No. NCP3418B, Rev. Mar. 5, 2006. Retrieved from http://www.onsemi.com/pub/Collateral/NCP3418B-D.PDF.;;Dual Bootstrapped 12 V MOSFET Driver with Output Disable, Semiconductor Components Industries, LLC, Publication No. NCP3418, Rev. May 12, 2006. Retrieved from http://www.onsemi.com/pub/Collateral/NCP3418-D.PDF.;;Dawson, Stephen, ""What is Dither?"" Ver. Aug. 21, 2003. Retrieved from http://www.hifi-writer.com/he/dydaudio/dither.htm.",ACTIVE
103,US,B2,US 7759918 B2,098-392-588-059-119,2010-07-20,2010,US 42484406 A,2006-06-16,US 42484406 A,2006-06-16,Method for inhibiting thermal run-away,"A method for method for inhibiting thermal run-away in a multi-phase power converter at varying load transition rates. A multi-phase power converter having an on-time is provided and the frequency of the multi-phase power converter is adjusted so that a load step period and the on time of the multi-phase power converter are in a temporal relationship. Alternatively, a load step rate is inhibited from locking onto a phase current of the multi-phase power converter by suspending an oscillator signal. In accordance with another alternative, a load step rate is inhibited from locking onto a phase current of the multi-phase power converter by suspending an oscillator signal and dithering an input signal to the oscillator.",SEMICONDUCTOR COMPONENTS IND,MOYER OLE P;;GASS CHRISTOPHER J;;HARRIMAN PAUL J;;RICE BENJAMIN M;;STAPLETON MICHAEL A,SEMICONDUCTOR COMPONENTS INDUSTRIES LLC (2006-06-28),https://lens.org/098-392-588-059-119,Granted Patent,yes,11,13,13,15,0,G05F1/455;;H02M1/32;;H02M1/32;;H02M3/04;;H02M3/1584;;H02M3/1584,G05F1/59;;G05F1/565,323/272;;323/284,4,0,,,"2/3/4 Phase Buck Controller for VR10 and VR11 Pentium IV Processor Applications, Semiconductor Components Industries, LLC, Publication No. NCP5381, Rev. 2, May 2006. Retrieved from http://www.onsemi.com/pub/Collateral/NCP5381-D.PDF.;;MOSFET Driver with Dual Outputs for Synchronous Buck Converters, Semiconductor Components Industries, LLC, Publication No. NCP3418B, Rev. 5, Mar. 2006. Retrieved from http://www.onsemi.com/pub/Collateral/NCP3418B-D.PDF.;;Dual Bootstrapped 12 V MOSFET Driver with Output Disable, Semiconductor Components Industries, LLC, Publication No. NCP3418, Rev. 12, May 2006. Retrieved from http://www.onsemi.com/pub/Collateral/NCP3418-D.PDF.;;Dawson, Stephen, ""What is Dither?"" Ver. 21, Aug. 2003. Retrieved from http://www.hifi-writer.com/he/dydaudio/dither.htm.",ACTIVE
104,US,A1,US 2010/0277961 A1,063-126-302-758-693,2010-11-04,2010,US 83738210 A,2010-07-15,US 83738210 A;;US 42484406 A,2006-06-16,METHOD FOR INHIBITING THERMAL RUN-AWAY,"A method for mitigating aliasing effects in a single phase power converter and mitigating aliasing effects and inhibiting thermal run-away in a multi-phase power converter at varying load transition rates. A single phase or multi-phase power converter having an on-time is provided and the frequency of the power converter is adjusted so that a load step period and the on time of the single phase power converter are in a temporal relationship. Alternatively, a load step rate is inhibited from locking onto a phase current of the single phase power converter by suspending an oscillator signal. In accordance with another alternative, a load step rate is inhibited from locking onto a phase current of the single phase power converter by suspending an oscillator signal and dithering an input signal to the oscillator.",MOYER OLE P;;HARRIMAN PAUL JAY;;RICE BENJAMIN M;;GASS CHRISTOPHER J;;STAPLETON MICHAEL A,MOYER OLE P;;HARRIMAN PAUL JAY;;RICE BENJAMIN M;;GASS CHRISTOPHER J;;STAPLETON MICHAEL A,SEMICONDUCTOR COMPONENTS INDUSTRIES L.L.C (2010-07-14),https://lens.org/063-126-302-758-693,Patent Application,yes,13,5,2,15,0,H02M3/1584;;H02M3/1584;;H02M1/32;;H02M1/32,H02M5/293,363/163,0,0,,,,ACTIVE
105,US,A1,US 2010/0327827 A1,173-144-232-984-659,2010-12-30,2010,US 83893210 A,2010-07-19,US 83893210 A;;US 42484406 A,2006-06-16,METHOD FOR BALANCING CURRENT,"A method for method for inhibiting thermal run-away in a multi-phase power converter at varying load transition rates. A multi-phase power converter having an on-time is provided and the frequency of the multi-phase power converter is adjusted so that a load step period and the on time of the multi-phase power converter are in a temporal relationship. Alternatively, a load step rate is inhibited from locking onto a phase current of the multi-phase power converter by suspending an oscillator signal. In accordance with another alternative, a load step rate is inhibited from locking onto a phase current of the multi-phase power converter by suspending an oscillator signal and dithering an input signal to the oscillator.",MOYER OLE P;;HARRIMAN PAUL JAY;;RICE BENJAMIN M;;GASS CHRISTOPHER J;;STAPLETON MICHAEL A,MOYER OLE P;;HARRIMAN PAUL JAY;;RICE BENJAMIN M;;GASS CHRISTOPHER J;;STAPLETON MICHAEL A,SEMICONDUCTOR COMPONENTS INDUSTRIES LLC (2006-06-28),https://lens.org/173-144-232-984-659,Patent Application,yes,18,4,13,15,0,G05F1/455;;H02M1/32;;H02M1/32;;H02M3/04;;H02M3/1584;;H02M3/1584,G05F1/00,323/272,0,0,,,,DISCONTINUED
106,AU,A1,AU 2019/426842 A1,075-311-488-669-997,2021-07-22,2021,AU 2019/426842 A,2019-12-11,US 201962797634 P;;US 2019/0065753 W,2019-01-28,Applicator for pesticides,A product applicator assembly (100) including a housing (102) having a first end and a second end; a dispensing force; a dispensing device (310) operatively attached to the dispensing force; at least one power source (400); a dispensing switch (120) operatively attached to the dispensing force; a data operator (112) electrically connected to an electrical power source. Also provided is a bait applicator and a method of using the applicator to apply bait.,DISCOVERY PURCHASER CORP,KO ALEXANDER;;REID BYRON;;CLEMENS DAVID;;LAMB WILSON CHRISTOPHER;;DEMERS MICHELLE H;;STAPLETON PAUL;;MOUGEY SPENCER,DISCOVERY PURCHASER CORPORATION (2023-08-03);;DISCOVERY PURCHASE CORPORATION (2023-02-16),https://lens.org/075-311-488-669-997,Patent Application,no,0,0,8,8,0,A01M1/2055;;A01M25/006;;B05C17/00593;;B05C17/0103;;B05B9/0838;;B05B9/01;;B05B9/0838;;B05C17/00593;;B05C17/0103;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;G06Q50/02;;A01M2200/01;;A01M1/04;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;A01M25/006;;A01M2200/01;;B05C17/0103,A01M1/20;;A01M17/00;;A01M25/00;;B05B9/08;;B05C17/005;;B05C17/01,,0,0,,,,PENDING
107,WO,A1,WO 2020/159627 A1,128-571-266-854-080,2020-08-06,2020,US 2019/0065753 W,2019-12-11,US 201962797634 P,2019-01-28,APPLICATOR FOR PESTICIDES,A product applicator assembly (100) including a housing (102) having a first end and a second end; a dispensing force; a dispensing device (310) operatively attached to the dispensing force; at least one power source (400); a dispensing switch (120) operatively attached to the dispensing force; a data operator (112) electrically connected to an electrical power source. Also provided is a bait applicator and a method of using the applicator to apply bait.,BAYER CROPSCIENCE LP,KO ALEXANDER;;REID BYRON;;CLEMENS DAVID;;LAMB WILSON CHRISTOPHER;;DEMERS MICHELLE H;;STAPLETON PAUL;;MOUGEY SPENCER,,https://lens.org/128-571-266-854-080,Patent Application,yes,10,0,8,8,0,A01M1/2055;;A01M25/006;;B05C17/00593;;B05C17/0103;;B05B9/0838;;B05B9/01;;B05B9/0838;;B05C17/00593;;B05C17/0103;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;G06Q50/02;;A01M2200/01;;A01M1/04;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;A01M25/006;;A01M2200/01;;B05C17/0103,A01M1/20;;A01M17/00;;A01M25/00;;B05B9/08;;B05C17/005;;B05C17/01,,0,0,,,,PENDING
108,EP,A1,EP 3917316 A1,132-367-054-534-161,2021-12-08,2021,EP 19839702 A,2019-12-11,US 201962797634 P;;US 2019/0065753 W,2019-01-28,APPLICATOR FOR PESTICIDES,,BAYER CROPSCIENCE LP,KO ALEXANDER;;REID BYRON;;CLEMENS DAVID A;;LAMB WILSON CHRISTOPHER;;DEMERS MICHELLE H;;STAPLETON PAUL;;MOUGEY SPENCER,DISCOVERY PURCHASER CORPORATION (2023-11-01),https://lens.org/132-367-054-534-161,Patent Application,yes,0,0,8,8,0,A01M1/2055;;A01M25/006;;B05C17/00593;;B05C17/0103;;B05B9/0838;;B05B9/01;;B05B9/0838;;B05C17/00593;;B05C17/0103;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;G06Q50/02;;A01M2200/01;;A01M1/04;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;A01M25/006;;A01M2200/01;;B05C17/0103,A01M1/20;;A01M17/00;;A01M25/00;;B05B9/08;;B05C17/005;;B05C17/01,,0,0,,,,PENDING
109,KR,A,KR 20210118827 A,174-975-788-462-614,2021-10-01,2021,KR 20217022157 A,2019-12-11,US 201962797634 P;;US 2019/0065753 W,2019-01-28,살충제용 어플리케이터,"제품 어플리케이터 조립체 (100) 로서, 제 1 단부 및 제 2 단부를 가진 하우징 (102); 분배력부; 상기 분배력부에 작동식으로 부착된 분배 디바이스 (310); 적어도 하나의 전력원 (400); 상기 분배력부에 작동식으로 부착된 분배 스위치 (120); 및 전기 전력원에 전기적으로 연결된 데이터 오퍼레이터 (112) 를 포함한다. 미끼 어플리케이터 및 이 어플리케이터를 사용하여 미끼를 도포하는 방법이 또한 제공된다.",BAYER CROPSCIENCE LP,KO ALEXANDER;;REID BYRON;;CLEMENS DAVID A;;LAMB WILSON CHRISTOPHER;;DEMERS MICHELLE H;;STAPLETON PAUL;;MOUGEY SPENCER,,https://lens.org/174-975-788-462-614,Patent Application,no,0,0,8,8,0,A01M1/2055;;A01M25/006;;B05C17/00593;;B05C17/0103;;B05B9/0838;;B05B9/01;;B05B9/0838;;B05C17/00593;;B05C17/0103;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;G06Q50/02;;A01M2200/01;;A01M1/04;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;A01M25/006;;A01M2200/01;;B05C17/0103,B05B9/08;;B05B9/01;;B05C17/005;;B05C17/01;;G06Q50/02,,0,0,,,,DISCONTINUED
110,US,A1,US 2022/0000093 A1,051-631-599-758-521,2022-01-06,2022,US 201917425860 A,2019-12-11,US 201917425860 A;;US 201962797634 P;;US 2019/0065753 W,2019-01-28,APPLICATOR FOR PESTICIDES,A product applicator assembly including a housing having a first end and a second end; a dispensing force; a dispensing device operatively attached to the dispensing force; at least one power source; a dispensing switch operatively attached to the dispensing force; a data operator electrically connected to an electrical power source. Also provided is a bait applicator and a method of using the applicator to apply bait.,BAYER CROPSCIENCE LP,KO ALEXANDER;;REID BYRON;;CLEMENS DAVID A;;LAMB WILSON CHRISTOPHER;;DEMERS MICHELLE H;;STAPLETON PAUL;;MOUGEY SPENCER,DISCOVERY PURCHASER CORPORATION (2023-01-12);;BAYER CROPSCIENCE LP (2020-06-25),https://lens.org/051-631-599-758-521,Patent Application,yes,17,0,8,8,0,A01M1/2055;;A01M25/006;;B05C17/00593;;B05C17/0103;;B05B9/0838;;B05B9/01;;B05B9/0838;;B05C17/00593;;B05C17/0103;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;G06Q50/02;;A01M2200/01;;A01M1/04;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;A01M25/006;;A01M2200/01;;B05C17/0103,A01M1/04;;A01M7/00;;A01M1/20;;A01M25/00,,0,0,,,,PENDING
111,CA,A1,CA 3127778 A1,098-028-284-579-130,2020-08-06,2020,CA 3127778 A,2019-12-11,US 201962797634 P;;US 2019/0065753 W,2019-01-28,APPLICATOR FOR PESTICIDES,A product applicator assembly (100) including a housing (102) having a first end and a second end; a dispensing force; a dispensing device (310) operatively attached to the dispensing force; at least one power source (400); a dispensing switch (120) operatively attached to the dispensing force; a data operator (112) electrically connected to an electrical power source. Also provided is a bait applicator and a method of using the applicator to apply bait.,BAYER CROPSCIENCE LP,KO ALEXANDER;;REID BYRON;;CLEMENS DAVID A;;LAMB WILSON CHRISTOPHER;;DEMERS MICHELLE H;;STAPLETON PAUL;;MOUGEY SPENCER,,https://lens.org/098-028-284-579-130,Patent Application,no,0,0,8,8,0,A01M1/2055;;A01M25/006;;B05C17/00593;;B05C17/0103;;B05B9/0838;;B05B9/01;;B05B9/0838;;B05C17/00593;;B05C17/0103;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;G06Q50/02;;A01M2200/01;;A01M1/04;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;A01M25/006;;A01M2200/01;;B05C17/0103,A01M1/20;;A01M17/00;;A01M25/00;;B05B9/08;;B05C17/005;;B05C17/01,,0,0,,,,PENDING
112,BR,A2,BR 112021009757 A2,145-551-768-122-769,2021-08-17,2021,BR 112021009757 A,2019-12-11,US 2019/0065753 W;;US 201962797634 P,2019-01-28,aplicador para pesticidas,uma montagem de aplicador de produto incluindo um alojamento tendo uma primeira extremidade e uma segunda extremidade; uma força de dispensar; um dispositivo dispensador operativamente fixado à força de dispensar; pelo menos uma fonte de energia; um comutador de dispensar operativamente fixado à força de dispensar; uma operadora de dados eletricamente conectado a uma fonte de energia elétrica. também é provido um aplicador de isca e um método de utilizar o aplicador para aplicar isca.,BAYER CROPSCIENCE LP,ALEXANDER KO;;BYRON REID;;DAVID A CLEMENS;;MICHELLE H DEMERS;;PAUL STAPLETON;;SPENCER MOUGEY;;WILSON CHRISTOPHER LAMB,DISCOVERY PURCHASER CORPORATION (US) (2023-10-03),https://lens.org/145-551-768-122-769,Patent Application,no,0,0,8,8,0,A01M1/2055;;A01M25/006;;B05C17/00593;;B05C17/0103;;B05B9/0838;;B05B9/01;;B05B9/0838;;B05C17/00593;;B05C17/0103;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;G06Q50/02;;A01M2200/01;;A01M1/04;;A01M1/2055;;A01M7/0032;;A01M7/0085;;A01M7/0089;;A01M25/006;;A01M2200/01;;B05C17/0103,A01M1/20;;A01M17/00;;A01M25/00;;B05B9/08;;B05C17/005;;B05C17/01,,0,0,,,,PENDING
113,US,B2,US 10570607 B2,043-257-122-531-55X,2020-02-25,2020,US 201916425242 A,2019-05-29,US 201916425242 A;;US 201815879145 A,2018-01-24,Acoustic shell for stage performances,"A method of erecting an acoustic shell for stage performances, the shell have frame defining a concave volume that is curved in two orthogonal planes and has an inner surface facing forwardly of a stage for a performance. A plurality of polygonal acoustic panels are positioned in the frame and spaced in rows and column along the inner surface, each panel having an outer acoustically active surface. The frame is formed of plural curved trusses each with a base for support on the stage and a peak. An oculus ring is connected to the peak of each arch and the bases of the arches are space along a bottom curve of the concave volume. The panels comprise plural adjacent blocks in rows and columns, each with a base and inner closed end, the length of each block being different for adjacent blocks.",CS INVENT LLC,STAPLETON CHRISTOPHER A;;CRONIN MICHAEL;;RODGERS BRUCE;;TRUSSELL TYE;;MCKINNEY JAMES;;GARRIOTT JOHN;;HUNT CLAYTON;;JUMPER MATT,CS INVENTIONS LLC (2018-01-10),https://lens.org/043-257-122-531-55X,Granted Patent,yes,19,1,3,3,0,E04B1/8236;;E04B1/3211;;E04B2001/8414;;E04B1/8404;;E04B2001/3217;;E04H3/22;;G10K11/162;;E04B1/34321;;G10K11/162;;E04B1/3211;;E04H3/22;;E04B1/8209;;E04B1/34326;;E04B2001/327;;E04B2001/0053;;E04B1/99;;E04B1/8404;;E04B1/8236;;E04B2001/3217;;E04B2001/8414,E04B1/34;;E04B1/00;;E04B1/32;;E04B1/343;;E04B1/82;;E04B1/99;;E04H3/22;;G10K11/16;;G10K11/162,,0,0,,,,ACTIVE
114,US,A1,US 2019/0277018 A1,046-425-874-668-97X,2019-09-12,2019,US 201916425242 A,2019-05-29,US 201916425242 A;;US 201815879145 A,2018-01-24,ACOUSTIC SHELL FOR STAGE PERFORMANCES,"A method of erecting an acoustic shell for stage performances, the shell have frame defining a concave volume that is curved in two orthogonal planes and has an inner surface facing forwardly of a stage for a performance. A plurality of polygonal acoustic panels are positioned in the frame and spaced in rows and column along the inner surface, each panel having an outer acoustically active surface. The frame is formed of plural curved trusses each with a base for support on the stage and a peak. An oculus ring is connected to the peak of each arch and the bases of the arches are space along a bottom curve of the concave volume. The panels comprise plural adjacent blocks in rows and columns, each with a base and inner closed end, the length of each block being different for adjacent blocks.",CS INVENT LLC,STAPLETON CHRISTOPHER A;;CRONIN MICHAEL;;RODGERS BRUCE;;TRUSSELL TYE;;MCKINNEY JAMES;;GARRIOTT JOHN;;HUNT CLAYTON;;JUMPER MATT,CS INVENTIONS LLC (2018-01-10),https://lens.org/046-425-874-668-97X,Patent Application,yes,0,0,3,3,0,E04B1/8236;;E04B1/3211;;E04B2001/8414;;E04B1/8404;;E04B2001/3217;;E04H3/22;;G10K11/162;;E04B1/34321;;G10K11/162;;E04B1/3211;;E04H3/22;;E04B1/8209;;E04B1/34326;;E04B2001/327;;E04B2001/0053;;E04B1/99;;E04B1/8404;;E04B1/8236;;E04B2001/3217;;E04B2001/8414,E04B1/343;;E04B1/32;;E04B1/99;;E04H3/22;;G10K11/162,,0,0,,,,ACTIVE
115,US,B1,US 10323403 B1,008-513-946-279-482,2019-06-18,2019,US 201815879145 A,2018-01-24,US 201815879145 A,2018-01-24,Acoustic shell for stage performances,"An acoustic shell for stage performances has a frame defining a concave volume that is curved in two orthogonal planes and has an inner surface facing forwardly of a stage for a performance. A plurality of polygonal acoustic panels are positioned in the frame and spaced in rows and column along the inner surface, each panel having an outer acoustically active surface. The frame is formed of plural curved trusses each with a base for support on the stage and a peak. An oculus ring is connected to the peak of each arch and the bases of the arches are space along a bottom curve of the concave volume. The panels comprise plural adjacent blocks in rows and columns, each with a base and inner closed end, the length of each block being different for adjacent blocks.",CS INVENT LLC,STAPLETON CHRISTOPHER A;;CRONIN MICHAEL;;RODGERS BRUCE;;TRUSSELL TYE;;MCKINNEY JAMES;;GARRIOTT JOHN;;HUNT CLAYTON;;JUMPER MATT,CS INVENTIONS LLC (2018-01-10),https://lens.org/008-513-946-279-482,Granted Patent,yes,15,2,3,3,0,E04B1/8236;;E04B1/3211;;E04B2001/8414;;E04B1/8404;;E04B2001/3217;;E04H3/22;;G10K11/162;;E04B1/34321;;G10K11/162;;E04B1/3211;;E04H3/22;;E04B1/8209;;E04B1/34326;;E04B2001/327;;E04B2001/0053;;E04B1/99;;E04B1/8404;;E04B1/8236;;E04B2001/3217;;E04B2001/8414,E04B1/34;;E04B1/00;;E04B1/32;;E04B1/343;;E04B1/82;;E04B1/99;;E04H3/22;;G10K11/16;;G10K11/162,,0,0,,,,ACTIVE
116,US,A1,US 2016/0244521 A1,095-514-967-065-096,2016-08-25,2016,US 201615048967 A,2016-02-19,US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDY;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GADY S,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/095-514-967-065-096,Patent Application,yes,0,22,71,71,1542,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;G01N33/574,,0,0,,,,ACTIVE
117,US,B1,US 6409555 B1,125-262-088-876-675,2002-06-25,2002,US 63412800 A,2000-08-08,US 63412800 A,2000-08-08,Device for generating a plume of water,"
    The invention features a device for generating a plume of water, the device including a) a first side wall, b) a second side wall extending at an angle to the first side wall, the first side wall and the second side wall defining a tapered channel, the channel including i) a first end, ii) a second end, and iii) a longitudinal extent extending between the first end and the second end, c) a first flange extending at an angle to the first side wall, and d) a second flange extending at an angle to the second side wall. 
",RAVE SPORTS INC,PLANTE THOMAS M;;SLAGLE MARY S;;NANOFF MICHAEL J;;OMVIG VALDIN C;;ROOT CHRISTOPHER M;;BRANDENHOFF MARK J;;STAPLETON ADAM;;LONGHENRY DANIEL P;;GARDNER H PETER,RAVE SPORTS INC (2000-11-15);;REVEL MATCH LLC (2009-10-16),https://lens.org/125-262-088-876-675,Granted Patent,yes,14,2,1,1,0,B63B1/32;;B63B17/00;;B63B2201/00;;Y02T70/10;;B63B1/32;;B63B2201/00;;B63B17/00;;Y02T70/10,B63B1/32;;B63B17/00,440/39;;441/71,0,0,,,,EXPIRED
118,WO,A9,WO 2016/134333 A9,162-336-075-832-527,2017-02-02,2017,US 2016/0018809 W,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S,,https://lens.org/162-336-075-832-527,Search Report,yes,0,5,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,0,0,,,,PENDING
119,US,A1,US 2017/0029504 A1,046-576-086-422-846,2017-02-02,2017,US 201615277980 A,2016-09-27,US 201615277980 A;;US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/046-576-086-422-846,Patent Application,yes,0,2,71,71,1542,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28,,0,0,,,,ACTIVE
120,US,A1,US 2017/0081408 A1,188-613-435-036-628,2017-03-23,2017,US 201615277978 A,2016-09-27,US 201615277978 A;;US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/188-613-435-036-628,Patent Application,yes,0,1,71,71,1542,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28,,0,0,,,,ACTIVE
121,WO,A1,WO 2016/134333 A1,113-347-296-892-140,2016-08-25,2016,US 2016/0018809 W,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S,,https://lens.org/113-347-296-892-140,Patent Application,yes,35,80,71,71,1542,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,122,93,003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;055-941-254-232-339;;010-801-824-793-588;;079-191-303-518-861;;061-453-882-230-419;;049-134-753-209-354;;017-150-654-990-340;;002-264-966-090-625;;001-400-252-595-282;;066-749-017-721-197;;097-637-621-469-520;;004-458-031-333-650;;033-955-564-406-161;;055-627-013-189-514;;024-929-137-199-30X;;003-752-183-823-430;;070-318-112-524-781;;032-624-544-479-82X;;010-916-105-450-247;;016-251-721-517-200;;085-727-974-637-837;;005-119-615-003-591;;005-219-687-670-471;;026-164-216-541-151;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;030-630-100-818-462;;089-633-612-001-004;;100-223-052-747-506;;121-584-957-679-398;;042-872-370-645-706;;035-349-760-749-850;;142-307-056-493-98X;;124-322-713-188-743;;089-720-692-037-167;;008-511-519-389-880;;083-886-311-552-950;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;042-688-967-632-553;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;028-786-751-528-732;;139-084-139-072-589;;098-407-145-404-736;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;010-671-144-023-106;;094-244-865-622-863;;041-285-260-595-960;;020-078-707-512-700;;091-430-503-250-222;;122-727-298-510-776;;073-606-695-370-555;;044-221-307-354-176;;012-887-646-978-442;;062-598-126-273-855;;074-067-544-364-744;;151-470-700-833-620;;106-520-098-512-752;;025-396-815-655-739;;014-570-797-947-747;;011-937-855-979-704;;122-368-017-221-205;;034-430-500-514-141;;093-205-912-594-570;;163-851-275-396-769;;028-247-833-970-169;;021-869-739-018-675;;056-250-961-306-88X;;044-560-677-600-211;;120-795-182-254-143;;134-851-929-212-139;;023-783-936-946-986;;004-963-265-392-765;;111-638-562-943-009;;008-355-672-565-201;;085-309-020-554-932;;003-082-950-776-533;;022-608-838-432-215;;007-041-645-879-370;;103-324-341-200-971,19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;10.1016/j.semcancer.2005.07.009;;16140545;;10.1146/annurev.immunol.23.021704.115611;;15771580;;15771565;;10.1146/annurev.immunol.23.021704.115839;;10.1158/1078-0432.ccr-07-0016;;17606736;;10.1016/0022-2836(87)90412-8;;3681981;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;11036658;;10.1016/s0076-6879(00)26070-9;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0165-2478(02)00019-6;;12008035;;11096108;;10.1074/jbc.m009483200;;10.1038/nri2761;;20414204;;11849310;;10.1046/j.0019-2805.2001.01341.x;;pmc1782638;;10.1002/bit.20151;;15352059;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;1201277;;10.1021/bi00696a021;;10.1038/nbt0792-779;;1368267;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;7897213;;10.4049/jimmunol.154.7.3310;;10.1016/0022-2836(92)90639-2;;1507232;;10.1093/nar/gks1370;;3382986;;10.1093/bioinformatics/4.1.11;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1038/348552a0;;2247164;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;2778836;;10.1093/jnci/81.19.1484;;10.1038/nrd3626;;22301798;;pmc3342842;;10.1158/0008-5472.can-11-3687;;22549946;;pmc2828349;;19197294;;10.1038/nri2506;;22330682;;10.1084/jem.20112275;;pmc3280881;;10.1093/jnci/djs033;;pmc3328421;;22395641;;22437871;;pmc3433802;;10.1038/nrc3258;;23207483;;10.1007/s00262-012-1378-2;;pmc6354242;;10.1038/nature11699;;23201688;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10.1016/s0171-2985(00)80072-8;;10834311;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10.1038/ni944;;12796776;;10.1016/s1074-7613(03)00152-3;;12818165;;10417377;;10.1126/science.285.5427.546;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;18600180;;10.1097/cji.0b013e3181826d89;;23386332;;10.1007/978-1-62703-296-4_1;;pmc2720162;;19264470;;10.1016/j.coi.2009.01.010;;19414738;;pmc3726306;;10.4049/jimmunol.0803771;;17304234;;10.1038/ni1443;;pmc3180079;;10.1155/2011/451694;;21960736;;10.1073/pnas.1015298108;;21576466;;pmc3107287;;pmc2669369;;10.1073/pnas.0809422106;;19332785;;10.4049/jimmunol.0901408;;19734216;;10.1128/jvi.00639-09;;19587053;;pmc2738247;;10.1038/nature04444;;16382236;;10.1186/cc10059;;21349174;;pmc3222003;;10.1189/jlb.0110037;;20483923;;pmc6607999;;pmc3220038;;21118528;;10.1186/cc9354;;10.1097/shk.0b013e3182168cce;;pmc3412306;;21368717;;10.1189/jlb.0410240;;20679071;;10.1007/s00134-012-2769-8;;23361625;;pmc7095153;;10.1097/ccm.0b013e3182741551;;23425819;;10.1272/jnms.79.4;;22398786;;22913335;;10.1089/sur.2012.126;;19050640;;10.1097/ccm.0b013e31819267fb;;10.1016/j.jss.2011.09.053;;22225756;;pmc3798159;;23427891;;10.1016/s1473-3099(13)70001-x;;23425441;;10.1186/cc12490;;pmc4056021;;pmc2914630;;10.4049/jimmunol.0903151;;20200277;;pmc2937828;;10.4049/jimmunol.0902307;;20026737;;10.1164/rccm.201204-0645oc;;22822024;;23118781;;10.1155/2012/720803;;pmc3483734;;21349771;;10.1016/j.clim.2011.01.009;;pmc2820677;;10.1093/bioinformatics/btp692;;20022975;;pmc3146043;;20436464;;10.1038/nbt.1621;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;25465800;;10.1016/j.ccell.2014.10.018;;10.1126/science.1129003;;pmc2267026;;16946036;;17141800;;10.1016/j.jim.2006.08.015,"GENE ID: ""PVRIG antibody -middle region Rabbit Polyclonal Antibody Catalog # AI13083 Specification PVRIG antibody -middle region -Product Information Application WB Primary Accession Q6DKI7 Other Accession NM_024070, NP_076975 Reactivity Human Predicted Human Host Rabbit Clonality Polyclonal Calculated MW 34k"", PHYSIOL. GENOMICS, 1 January 2006 (2006-01-01), pages 201 - 218, XP055273924, Retrieved from the Internet <URL:http://www.funakoshi.co.jp/data/datasheet/ABG/AI13083.pdf>;;N. STANIETSKY ET AL: ""The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 42, 20 October 2009 (2009-10-20), pages 17858 - 17863, XP055215810, ISSN: 0027-8424, DOI: 10.1073/pnas.0903474106;;XIN YU ET AL: ""The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells"", NATURE IMMUNOLOGY, vol. 10, no. 1, 1 January 2009 (2009-01-01), GB, pages 48 - 57, XP055273979, ISSN: 1529-2908, DOI: 10.1038/ni.1674;;ZHU YUWEN ET AL: ""Identification of CD112R as a novel checkpoint for human T cells"", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIV. PRESS, NEW YORK, NY, USA, vol. 213, no. 2, 8 February 2016 (2016-02-08), pages 167 - 176, XP009190107, ISSN: 1540-9538;;GALIT ROTMAN ET AL: ""Identification of novel immune checkpoints as targets for cancer immunotherapy"", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. Suppl 1, 7 November 2013 (2013-11-07), pages P135, XP021167082, ISSN: 2051-1426, DOI: 10.1186/2051-1426-1-S1-P135;;WANG: ""Immune Suppression by Tumor Specific CD4+ Regulatory T cells in Cancer"", SEMIN. CANCER. BIOL., vol. 16, 2006, pages 73 - 79, XP024908039, DOI: doi:10.1016/j.semcancer.2005.07.009;;GREENWALD ET AL.: ""The B7 Family Revisited"", ANN. REV. IMMUNOL., vol. 23, 2005, pages 515 - 48, XP002481408, DOI: doi:10.1146/annurev.immunol.23.021704.115611;;WATTS: ""TNF/TNFR Family Members in Co-stimulation of T Cell Responses"", ANN. REV. IMMUNOL., vol. 23, 2005, pages 23 - 68, XP008051583, DOI: doi:10.1146/annurev.immunol.23.021704.115839;;SADUM ET AL.: ""Immune Signatures of Murine and Human Cancers Reveal Unique Mechanisms of Tumor Escape and New Targets for Cancer Immunotherapy"", CLIN. CANC. RES., vol. 13, no. 13, 2007, pages 4016 - 4025, XP055248327, DOI: doi:10.1158/1078-0432.CCR-07-0016;;KABAT ET AL.: ""SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST"", 1991, NATIONAL INSTITUTES OF HEALTH;;CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;E. A. KABAT: ""SEQUENCES OF IMMUNOLOGICAL INTEREST"", NIH PUBLICATION, NO. 91-3242;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883;;TOMLINSON, METHODS ENZYMOL., vol. 326, 2000, pages 461 - 479;;HOLLIGER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 6444 - 6448;;JEFFERIS ET AL., IMMUNOL LETT, vol. 82, 2002, pages 57 - 65;;SHIELDS, R. L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;CHAN CA; CARTER PJ, NATURE REV IMMUNOL, vol. 10, 2010, pages 301 - 316;;AALBERSE, RC; SCHUURMAN J., IMMUNOLOGY, vol. 105, 2002, pages 9 - 19;;YAMANE-OHNUKI ET AL., BIOTECHNOL BIOENG, vol. 87, 2004, pages 614 - 22;;SHIELDS, R. L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;TARENTINO, A. L. ET AL., BIOCHEM., vol. 14, 1975, pages 5516 - 23;;MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779 - 783;;BARBAS ET AL., PROC. NAT. ACAD. SCI, USA, vol. 91, 1994, pages 3809 - 3813;;SHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155;;YELTON ET AL., J. IMMUNOL., vol. 155, 1995, pages 1994 - 2004;;JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 9;;HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896;;YE ET AL., NUCLEIC ACIDS RES., vol. 41, 2013, pages W34 - W40;;E. MEYERS; W. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17;;NEEDLEMAN; WUNSCH, J MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., JMOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;""Remington's Pharmaceutical Sciences"", 1980;;EPSTEIN ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 3688;;HWANG ET AL., PROC NATL ACAD SCI USA, vol. 77, 1980, pages 4030;;GABIZON ET AL., J NATIONAL CANCER INST, vol. 81, 1989, pages 1484;;GALLUZZI ET AL., NATURE REVIEWS - DRUG DISCOVERY, vol. 11, 2012, pages 215 - 233;;FACCIABENE A. ET AL., CANCER RES, vol. 72, no. 9, 2012, pages 2162 - 71;;BYRNE WL ET AL., CANCER RES., vol. 71, 2011, pages 691520;;GABRILOVICH DI; NAGARAJ S, NATURE REVIEWS, vol. 9, 2009, pages 162 - 174;;PARDOLL, J EXP MED., vol. 209, no. 2, 2012, pages 201 - 209;;MELLMAN I. ET AL., NATURE, vol. 480, 2011, pages 22 - 29;;SCHLOM J, JNATL CANCER INST, vol. 104, 2012, pages 599 - 613;;PALUCKA; BANCHEREAU, NAT. REV. CANCER, vol. 12, no. 4, pages 265 - 277;;RESTIFO ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 62, no. 4, 4 December 2012 (2012-12-04), pages 727 - 36;;SHI ET AL., NATURE, vol. 493, 2013, pages 111 - 115;;KEHRL, J. ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD, M.; O'GARRA, A., IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE, M. ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE, J. ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;ITO, N. ET AL., IMMUNOBIOLOGY, vol. 201, no. 5, 2000, pages 527 - 40;;WEINBERG, A. ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO, I. ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF, A. ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;WATANABE, N. ET AL., NAT IMMUNOL, vol. 4, 2003, pages 670 - 9;;SICA, G L ET AL., IMMUNITY, vol. 18, 2003, pages 849 - 61;;GREENBERG, R.; RIDDELL, S., SCIENCE, vol. 285, 1999, pages 546 - 51;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""ASCO Educational Book Spring"", 2000, article ""Development of Cancer Vaccines"", pages: 60 - 62;;LOGOTHETIS, C., ASCO EDUCATIONAL BOOK SPRING, 2000, pages 300 - 302;;KHAYAT, D.: ""ASCO Educational Book Spring"", 2000, pages: 414 - 428;;FOON, K.: ""ASCO Educational Book Spring"", 2000, pages: 730 - 738;;RESTIFO, N.; SZNOL, M. ET AL.: ""Cancer: Principles and Practice of Oncology"", 1997, article ""Cancer Vaccines"", pages: 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM, N ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT, R; SRIVASTAVA, P, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA, Y. ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE, F. ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER, A. ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;NEIGHBORS ET AL., JIMMUNOTHER, vol. 31, no. 7, 2008, pages 644 - 55;;GOODKIND ET AL., COMPUTERS AND CHEM. ENG., vol. 29, no. 3, 2005, pages 589;;HAN ET AL., BIOINFORM. BIOL. INSIGHTS 11/15/15, vol. 9, no. 1, pages 29 - 46;;CAMPO ET AL., NOD. PATHOL., vol. 26, no. 1, January 2013 (2013-01-01), pages S97 - S 110;;WANG ET AL.: ""Recent Advances in Capillary Electrophoresis-Based Proteomic Techniques for Biomarker Discovery, Methods"", MOL. BIOL., vol. 984, 2013, pages 1 - 12;;TAYLOR ET AL., BIOMED RES., vol. 2014, pages 8;;BECERK ET AL., MUTAT. RES, vol. 722, no. 2, 17 June 2011 (2011-06-17), pages 171 - 182;;CRAWFORD ET AL., CURR OPIN IMMUNOL., vol. 21, 2009, pages 179 - 186;;KAUFMANN ET AL., J IMMUNOL, vol. 182, 2009, pages 5891 - 5897;;SHARPE ET AL., NAT IMMUNOL, vol. 8, 2007, pages 239 - 245;;CRAWFORD ET AL., CURR OPIN IMMUNOL, vol. 21, 2009, pages 179 - 186;;HOFMEYER ET AL., J BIOMED BIOTECHNOL., vol. 2011;;BHADRA ET AL., PROC NATL. ACADSCI., vol. 108, no. 22, 2011, pages 9196 - 201;;HUANG ET AL., PNAS, vol. 106, 2009, pages 6303 - 6308;;RIVAS ET AL., J IMMUNOL., vol. 183, 2009, pages 4284 - 91;;GOLDEN-MASON ET AL., J VIROL., vol. 83, 2009, pages 9122 - 30;;VALU ET AL., NATURE, vol. 458, 2009, pages 206 - 210;;BARBER ET AL., NATURE, vol. 439, 2006, pages 682 - 7;;ZHANG ET AL., CRIT. CARE, vol. 15, 2011, pages R70;;BRAHMAMDAM ET AL., J. LEUKOC. BIOL., vol. 88, 2010, pages 233 - 240;;ZHANG ET AL., CRITICAL CARE, vol. 14, 2010, pages R220;;CHANG ET AL., CRITICAL CARE, vol. 17, 2013, pages R85;;INOUE ET AL., SHOCK, vol. 36, 2011, pages 38 - 44;;GOYERT; SILVER, J LEUK. BIOL., vol. 88, no. 2, 2010, pages 225 - 226;;DELLINGER ET AL.: ""International Guidelines for Management of Severe Sepsis and Septic Shock"", INTENSIVE CARE MED, vol. 39, 2013, pages 165 - 228, XP055286924, DOI: doi:10.1007/s00134-012-2769-8;;WITTEBOL ET AL., MEDIATORS OF INFLAMMATION, vol. 10, 2010;;GUNTUPALLI ET AL., CRIT CARE MED., vol. 41, no. 3, 2013, pages 706 - 716;;MATSUDA ET AL., J NIPPON MED SCH., vol. 79, 2012, pages 4 - 18;;HUSTON, SURG. INFECT., vol. 13, 2012, pages 187 - 193;;CINEL; OPAL, CRIT. CARE MED., vol. 37, 2009, pages 291 - 304;;WANNEMUEHLER ET AL., J. SURG. RES., vol. 173, 2012, pages 113 - 26;;HOTCHKISS ET AL., LANCET INFECT. DIS., vol. 13, 2013, pages 260 - 268;;PAYEN ET AL., CRIT CARE, vol. 17, 2013, pages 118;;UNSINGER ET AL., J. IMMUNOL., vol. 184, 2010, pages 3768 - 3779;;INOUE ET AL., J. IMMUNOL., vol. 184, 2010, pages 1401 - 1409;;MOUKTAROUDI ET AL., CRIT CARE., vol. 14, 2010, pages 17;;LEENTJENS ET AL., AM J RESPIR CRIT CARE MED, vol. 186, 2012, pages 838 - 845;;WU ET AL., CRITICAL CARE, vol. 17, 2013, pages R8;;RICHARD P. HAUGLAND: ""Molecular Probes Handbook"";;CLIN DEV IMMUNOL. 2012, 2012, pages 720803;;CLIN IMMUNOL., vol. 140, no. 2, August 2011 (2011-08-01), pages 167 - 76;;BO ET AL., BIOINFORMATICS, vol. 26, no. 4, 2010, pages 493 - 500;;TRAPNELL ET AL., NAT BIOTECHNOL., vol. 28, no. 5, May 2010 (2010-05-01), pages 511 - 5;;NOA STANIETSKY, JOURNAL OF IMMUNOLOGY, vol. 106, no. 42, pages 17858 - 17863;;ROBERT J JOHNSTON, CANCER CELL, vol. 26, no. 6, 8 December 2014 (2014-12-08), pages 923 - 937;;MORGAN ET AL., SCIENCE, vol. 314, 2006, pages 126 - 129;;DRAKE; KLAKAMP, JOURNAL OF IMMUNOL METHODS, vol. 318, 2007, pages 147 - 152",PENDING
122,EP,A1,EP 3295951 A1,198-175-498-788-283,2018-03-21,2018,EP 17192325 A,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;EP 16707603 A;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,"The present invention is directed to anti-PVRIG antibodies and methods of using same.
",COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/198-175-498-788-283,Patent Application,yes,43,0,71,71,1542,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,121,92,003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;055-941-254-232-339;;010-801-824-793-588;;079-191-303-518-861;;061-453-882-230-419;;049-134-753-209-354;;017-150-654-990-340;;002-264-966-090-625;;001-400-252-595-282;;066-749-017-721-197;;097-637-621-469-520;;004-458-031-333-650;;033-955-564-406-161;;055-627-013-189-514;;024-929-137-199-30X;;003-752-183-823-430;;070-318-112-524-781;;032-624-544-479-82X;;010-916-105-450-247;;016-251-721-517-200;;085-727-974-637-837;;005-119-615-003-591;;005-219-687-670-471;;026-164-216-541-151;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;030-630-100-818-462;;089-633-612-001-004;;100-223-052-747-506;;121-584-957-679-398;;042-872-370-645-706;;035-349-760-749-850;;142-307-056-493-98X;;124-322-713-188-743;;089-720-692-037-167;;083-886-311-552-950;;041-157-943-929-732;;007-470-431-271-066;;112-179-955-215-674;;007-709-585-201-038;;042-688-967-632-553;;056-422-417-058-69X;;005-022-447-377-963;;127-416-339-660-812;;028-786-751-528-732;;139-084-139-072-589;;098-407-145-404-736;;020-986-423-793-233;;087-879-787-031-413;;027-326-505-837-755;;061-757-907-136-641;;030-049-949-326-687;;090-774-193-364-453;;029-750-154-523-855;;010-671-144-023-106;;094-244-865-622-863;;041-285-260-595-960;;020-078-707-512-700;;091-430-503-250-222;;122-727-298-510-776;;073-606-695-370-555;;044-221-307-354-176;;012-887-646-978-442;;062-598-126-273-855;;074-067-544-364-744;;151-470-700-833-620;;106-520-098-512-752;;025-396-815-655-739;;014-570-797-947-747;;011-937-855-979-704;;122-368-017-221-205;;034-430-500-514-141;;093-205-912-594-570;;163-851-275-396-769;;028-247-833-970-169;;021-869-739-018-675;;056-250-961-306-88X;;044-560-677-600-211;;120-795-182-254-143;;134-851-929-212-139;;023-783-936-946-986;;004-963-265-392-765;;111-638-562-943-009;;008-355-672-565-201;;085-309-020-554-932;;003-082-950-776-533;;022-608-838-432-215;;007-041-645-879-370;;103-324-341-200-971,19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;10.1016/j.semcancer.2005.07.009;;16140545;;10.1146/annurev.immunol.23.021704.115611;;15771580;;15771565;;10.1146/annurev.immunol.23.021704.115839;;10.1158/1078-0432.ccr-07-0016;;17606736;;10.1016/0022-2836(87)90412-8;;3681981;;3140379;;10.1126/science.3140379;;10.1073/pnas.85.16.5879;;3045807;;pmc281868;;11036658;;10.1016/s0076-6879(00)26070-9;;8341653;;10.1073/pnas.90.14.6444;;pmc46948;;10.1016/s0165-2478(02)00019-6;;12008035;;11096108;;10.1074/jbc.m009483200;;10.1038/nri2761;;20414204;;11849310;;10.1046/j.0019-2805.2001.01341.x;;pmc1782638;;10.1002/bit.20151;;15352059;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;1201277;;10.1021/bi00696a021;;10.1038/nbt0792-779;;1368267;;10.1073/pnas.91.9.3809;;pmc43671;;8170992;;7897213;;10.4049/jimmunol.154.7.3310;;10.1016/0022-2836(92)90639-2;;1507232;;10.1093/nar/gks1370;;3382986;;10.1093/bioinformatics/4.1.11;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;10.1038/348552a0;;2247164;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;2778836;;10.1093/jnci/81.19.1484;;10.1038/nrd3626;;22301798;;pmc3342842;;10.1158/0008-5472.can-11-3687;;22549946;;pmc2828349;;19197294;;10.1038/nri2506;;22330682;;10.1084/jem.20112275;;pmc3280881;;10.1093/jnci/djs033;;pmc3328421;;22395641;;22437871;;pmc3433802;;10.1038/nrc3258;;10.1038/nature11699;;23201688;;2871125;;pmc2188095;;10.1084/jem.163.5.1037;;10.1016/0167-5699(92)90153-x;;1385707;;8910274;;10.1126/science.274.5291.1363;;9624003;;10.1038/30989;;10.1016/s0171-2985(00)80072-8;;10834311;;10657670;;10.4049/jimmunol.164.4.2160;;9176498;;10.1038/nm0697-682;;9930702;;10.1038/16717;;10.1038/ni944;;12796776;;10.1016/s1074-7613(03)00152-3;;12818165;;10417377;;10.1126/science.285.5427.546;;15470033;;10.4049/jimmunol.173.8.4919;;8097319;;pmc46336;;10.1073/pnas.90.8.3539;;10204484;;10.1016/s1074-7613(00)80028-x;;10.1126/science.7545313;;7545313;;9311915;;10.1126/science.278.5335.117;;9500607;;10.1038/nm0398-328;;10700237;;10.1038/73193;;18600180;;10.1097/cji.0b013e3181826d89;;23386332;;10.1007/978-1-62703-296-4_1;;pmc2720162;;19264470;;10.1016/j.coi.2009.01.010;;19414738;;pmc3726306;;10.4049/jimmunol.0803771;;17304234;;10.1038/ni1443;;pmc3180079;;10.1155/2011/451694;;21960736;;10.1073/pnas.1015298108;;21576466;;pmc3107287;;pmc2669369;;10.1073/pnas.0809422106;;19332785;;10.4049/jimmunol.0901408;;19734216;;10.1128/jvi.00639-09;;19587053;;pmc2738247;;10.1038/nature04444;;16382236;;10.1186/cc10059;;21349174;;pmc3222003;;10.1189/jlb.0110037;;20483923;;pmc6607999;;pmc3220038;;21118528;;10.1186/cc9354;;10.1097/shk.0b013e3182168cce;;pmc3412306;;21368717;;10.1189/jlb.0410240;;20679071;;10.1007/s00134-012-2769-8;;23361625;;pmc7095153;;10.1097/ccm.0b013e3182741551;;23425819;;10.1272/jnms.79.4;;22398786;;22913335;;10.1089/sur.2012.126;;19050640;;10.1097/ccm.0b013e31819267fb;;10.1016/j.jss.2011.09.053;;22225756;;pmc3798159;;23427891;;10.1016/s1473-3099(13)70001-x;;23425441;;10.1186/cc12490;;pmc4056021;;pmc2914630;;10.4049/jimmunol.0903151;;20200277;;pmc2937828;;10.4049/jimmunol.0902307;;20026737;;10.1164/rccm.201204-0645oc;;22822024;;23118781;;10.1155/2012/720803;;pmc3483734;;21349771;;10.1016/j.clim.2011.01.009;;pmc2820677;;10.1093/bioinformatics/btp692;;20022975;;pmc3146043;;20436464;;10.1038/nbt.1621;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;25465800;;10.1016/j.ccell.2014.10.018;;10.1126/science.1129003;;pmc2267026;;16946036;;17141800;;10.1016/j.jim.2006.08.015,"GENE ID: ""PVRIG antibody -middle region Rabbit Polyclonal Antibody Catalog # AI13083 Specification PVRIG antibody -middle region -Product Information Application WB Primary Accession Q6DKI7 Other Accession NM_024070, NP_076975 Reactivity Human Predicted Human Host Rabbit Clonality Polyclonal Calculated MW 34k"", PHYSIOL. GENOMICS, 1 January 2006 (2006-01-01), pages 201 - 218, XP055273924, Retrieved from the Internet <URL:http://www.funakoshi.co.jp/data/datasheet/ABG/AI13083.pdf>;;N. STANIETSKY ET AL: ""The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 42, 20 October 2009 (2009-10-20), pages 17858 - 17863, XP055215810, ISSN: 0027-8424, DOI: 10.1073/pnas.0903474106;;XIN YU ET AL: ""The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells"", NATURE IMMUNOLOGY, vol. 10, no. 1, 1 January 2009 (2009-01-01), GB, pages 48 - 57, XP055273979, ISSN: 1529-2908, DOI: 10.1038/ni.1674;;ZHU YUWEN ET AL: ""Identification of CD112R as a novel checkpoint for human T cells"", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIV. PRESS, NEW YORK, NY, USA, vol. 213, no. 2, 8 February 2016 (2016-02-08), pages 167 - 176, XP009190107, ISSN: 1540-9538;;GALIT ROTMAN ET AL: ""Identification of novel immune checkpoints as targets for cancer immunotherapy"", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. Suppl 1, 7 November 2013 (2013-11-07), pages P135, XP021167082, ISSN: 2051-1426, DOI: 10.1186/2051-1426-1-S1-P135;;WANG: ""Immune Suppression by Tumor Specific CD4+ Regulatory T cells in Cancer"", SEMIN. CANCER. BIOL., vol. 16, 2006, pages 73 - 79, XP024908039, DOI: doi:10.1016/j.semcancer.2005.07.009;;GREENWALD ET AL.: ""The B7 Family Revisited"", ANN. REV. IMMUNOL., vol. 23, 2005, pages 515 - 48, XP002481408, DOI: doi:10.1146/annurev.immunol.23.021704.115611;;WATTS: ""TNF/TNFR Family Members in Co-stimulation of T Cell Responses"", ANN. REV. IMMUNOL., vol. 23, 2005, pages 23 - 68, XP008051583, DOI: doi:10.1146/annurev.immunol.23.021704.115839;;SADUM ET AL.: ""Immune Signatures of Murine and Human Cancers Reveal Unique Mechanisms of Tumor Escape and New Targets for Cancer Immunotherapy"", CLIN. CANC. RES., vol. 13, no. 13, 2007, pages 4016 - 4025, XP055248327, DOI: doi:10.1158/1078-0432.CCR-07-0016;;KABAT ET AL.: ""SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST"", 1991, PUBLIC HEALTH SERVICE, NATIONAL INSTITUTES OF HEALTH, article 5TH EDITION;;CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;E. A. KABAT: ""SEQUENCES OF IMMUNOLOGICAL INTEREST"", part No. 91-3242 NIH, article 5 TH EDITION;;BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426;;HUSTON ET AL., PROC. NATL. ACAD. SCI. U.S.A, vol. 85, 1988, pages 5879 - 5883;;TOMLINSON, METHODS ENZYMOL., vol. 326, 2000, pages 461 - 479;;HOLLIGER ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 90, 1993, pages 6444 - 6448;;JEFFERIS ET AL., IMMUNOL LETT, vol. 82, 2002, pages 57 - 65;;SHIELDS, R. L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;CHAN CA; CARTER PJ, NATURE REV IMMUNOL, vol. 10, 2010, pages 301 - 316;;AALBERSE, RC; SCHUURMAN J., IMMUNOLOGY, vol. 105, 2002, pages 9 - 19;;YAMANE-OHNUKI ET AL., BIOTECHNOL BIOENG, vol. 87, 2004, pages 614 - 22;;SHIELDS, R. L. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;TARENTINO, A. L. ET AL., BIOCHEM., vol. 14, 1975, pages 5516 - 23;;MARKS ET AL., BIOTECHNOLOGY, vol. 10, 1992, pages 779 - 783;;BARBAS ET AL., PROC. NAT. ACAD. SCI, USA, vol. 91, 1994, pages 3809 - 3813;;SHIER ET AL., GENE, vol. 169, 1995, pages 147 - 155;;YELTON ET AL., J. IMMUNOL., vol. 155, 1995, pages 1994 - 2004;;JACKSON ET AL., J. IMMUNOL., vol. 154, no. 7, 1995, pages 3310 - 9;;HAWKINS ET AL., J. MOL. BIOL., vol. 226, 1992, pages 889 - 896;;YE ET AL., NUCLEIC ACIDS RES., vol. 41, 2013, pages W34 - W40;;E. MEYERS; W. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17;;NEEDLEMAN; WUNSCH, J MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., JMOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883;;MCCAFFERTY ET AL., NATURE, vol. 348, 1990, pages 552 - 554;;A. OSAL.: ""Remington's Pharmaceutical Sciences"", 1980, article 16TH EDITION;;EPSTEIN ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 3688;;HWANG ET AL., PROC NATL ACAD SCI USA, vol. 77, 1980, pages 4030;;GABIZON ET AL., J NATIONAL CANCER INST, vol. 81, 1989, pages 1484;;GALLUZZI ET AL., NATURE REVIEWS - DRUG DISCOVERY, vol. 11, 2012, pages 215 - 233;;FACCIABENE A. ET AL., CANCER RES, vol. 72, no. 9, 2012, pages 2162 - 71;;BYRNE WL. ET AL., CANCER RES., vol. 71, 2011, pages 691520;;GABRILOVICH DI.; NAGARAJ S, NATURE REVIEWS, vol. 9, 2009, pages 162 - 174;;PARDOLL, J EXP MED., vol. 209, no. 2, 2012, pages 201 - 209;;MELLMAN I. ET AL., NATURE, vol. 480, 2011, pages 22 - 29;;SCHLOM J, J NATL CANCER INST, vol. 104, 2012, pages 599 - 613;;PALUCKA; BANCHEREAU, NAT. REV. CANCER, vol. 12, no. 4, pages 265 - 277;;RESTIFO ET AL., CANCER IMMUNOL. IMMUNOTHER., vol. 62, no. 4, 2013, pages 727 - 36;;SHI ET AL., NATURE, vol. 493, 2013, pages 111 - 115;;KEHRL, J. ET AL., J. EXP. MED., vol. 163, 1986, pages 1037 - 1050;;HOWARD, M.; O'GARRA, A., IMMUNOLOGY TODAY, vol. 13, 1992, pages 198 - 200;;HAHNE, M. ET AL., SCIENCE, vol. 274, 1996, pages 1363 - 1365;;RIDGE, J. ET AL., NATURE, vol. 393, 1998, pages 474 - 478;;ITO, N. ET AL., IMMUNOBIOLOGY, vol. 201, no. 5, 2000, pages 527 - 40;;WEINBERG, A. ET AL., IMMUNOL, vol. 164, 2000, pages 2160 - 2169;;MELERO, I. ET AL., NATURE MEDICINE, vol. 3, 1997, pages 682 - 685;;HUTLOFF, A. ET AL., NATURE, vol. 397, 1999, pages 262 - 266;;WATANABE, N. ET AL., NAT IMMUNOL, vol. 4, 2003, pages 670 - 9;;SICA, G L ET AL., IMMUNITY, vol. 18, 2003, pages 849 - 61;;GREENBERG, R.; RIDDELL, S., SCIENCE, vol. 285, 1999, pages 546 - 51;;HE ET AL., J. IMMUNOL., vol. 173, 2004, pages 4919 - 28;;ROSENBERG, S.: ""Development of Cancer Vaccines"", 2000, ASCO EDUCATIONAL BOOK SPRING, pages: 60 - 62;;RESTIFO, N.; SZNOL, M. ET AL.: ""Cancer: Principles and Practice of Oncology"", 1997, article CHAPTER 61FIFTH EDITION: ""Cancer Vaccines"", pages: 3023 - 3043;;DRANOFF ET AL., PROC. NATL. ACAD. SCI U.S.A., vol. 90, 1993, pages 3539 - 43;;ROSENBERG, S A, IMMUNITY, vol. 10, 1999, pages 281 - 7;;KIM, N ET AL., SCIENCE, vol. 266, 1994, pages 2011 - 2013;;SUOT, R; SRIVASTAVA, P, SCIENCE, vol. 269, 1995, pages 1585 - 1588;;TAMURA, Y. ET AL., SCIENCE, vol. 278, 1997, pages 117 - 120;;NESTLE, F. ET AL., NATURE MEDICINE, vol. 4, 1998, pages 328 - 332;;KUGLER, A. ET AL., NATURE MEDICINE, vol. 6, 2000, pages 332 - 336;;NEIGHBORS ET AL., JIMRNUNOTHER., vol. 31, no. 7, 2008, pages 644 - 55;;GOODKIND ET AL., COMPUTERS AND CHEM. ENG., vol. 29, no. 3, 2005, pages 589;;HAN ET AL., BIOINFORM. BIOL. INSIGHTS, vol. 9, no. 1, 15 November 2015 (2015-11-15), pages 29 - 46;;CAMPO ET AL., NOD. PATHOL., vol. 26, no. 1, January 2013 (2013-01-01), pages S97 - S 110;;WANG ET AL.: ""Recent Advances in Capillary Electrophoresis-Based Proteomic Techniques for Biomarker Discovery"", METHODS. MOL. BIOL., vol. 984, 2013, pages 1 - 12;;TAYLOR ET AL., BIOMED RES., vol. 2014, pages 8;;BECERK ET AL., MUTAT. RES, vol. 722, no. 2, 17 June 2011 (2011-06-17), pages 171 - 182;;CRAWFORD ET AL., CURR OPIN IMMUNOL., vol. 21, 2009, pages 179 - 186;;KAUFMANN ET AL., J IMMUNOL, vol. 182, 2009, pages 5891 - 5897;;SHARPE ET AL., NAT IMMUNOL, vol. 8, 2007, pages 239 - 245;;CRAWFORD ET AL., CURR OPIN IMMUNOL, vol. 21, 2009, pages 179 - 186;;HOFMEYER ET AL., J BIOMED BIOTECHNOL., vol. 2011;;BHADRA ET AL., PROC NATL. ACAD SCI., vol. 108, no. 22, 2011, pages 9196 - 201;;HUANG ET AL., PNAS, vol. 106, 2009, pages 6303 - 6308;;RIVAS ET AL., J IMMUNOL., vol. 183, 2009, pages 4284 - 91;;GOLDEN-MASON ET AL., J VIROL., vol. 83, 2009, pages 9122 - 30;;VALU ET AL., NATURE, vol. 458, 2009, pages 206 - 210;;BARBER ET AL., NATURE, vol. 439, 2006, pages 682 - 7;;DUNCAN; MILLER, PLOS ONE, vol. 6, no. e1, 2011, pages 8548;;ZHANG ET AL., CRIT. CARE, vol. 15, 2011, pages R70;;BRAHMAMDAM ET AL., J. LEUKOC. BIOL., vol. 88, 2010, pages 233 - 240;;ZHANG ET AL., CRITICAL CARE, vol. 14, 2010, pages R220;;CHANG ET AL., CRITICAL CARE, vol. 17, 2013, pages R85;;INOUE ET AL., SHOCK, vol. 36, 2011, pages 38 - 44;;GOYERT; SILVER, J LEUK. BIOL., vol. 88, no. 2, 2010, pages 225 - 226;;DELLINGER ET AL.: ""International Guidelines for Management of Severe Sepsis and Septic Shock"", INTENSIVE CARE MED, vol. 39, 2013, pages 165 - 228, XP055286924, DOI: doi:10.1007/s00134-012-2769-8;;WITTEBOLE ET AL., MEDIATORS OF INFLAMMATION, vol. 10, 2010;;GUNTUPALLI ET AL., CRIT CARE MED., vol. 41, no. 3, 2013, pages 706 - 716;;MATSUDA ET AL., J NIPPON MED SCH., vol. 79, 2012, pages 4 - 18;;HUSTON, SURG. INFECT., vol. 13, 2012, pages 187 - 193;;CINEL; OPAL, CRIT. CARE MED., vol. 37, 2009, pages 291 - 304;;WANNEMUEHLER ET AL., J. SURG. RES., vol. 173, 2012, pages 113 - 26;;HOTCHKISS ET AL., LANCET INFECT. DIS., vol. 13, 2013, pages 260 - 268;;PAYEN ET AL., CRIT CARE, vol. 17, 2013, pages 118;;UNSINGER ET AL., J. IMMUNOL., vol. 184, 2010, pages 3768 - 3779;;INOUE ET AL., J. IMMUNOL., vol. 184, 2010, pages 1401 - 1409;;MOUKTAROUDI ET AL., CRIT CARE, vol. 14, 2010, pages 17;;LEENTJENS ET AL., AM J RESPIR CRIT CARE MED, vol. 186, 2012, pages 838 - 845;;WU ET AL., CRITICAL CARE, vol. 17, 2013, pages R8;;RICHARD P. HAUGLAND: ""Molecular Probes Handbook"", article 6TH EDITION;;CLIN DEV IMMUNOL., vol. 2012, 2012, pages 720803;;CLIN IMMUNOL., vol. 140, no. 2, August 2011 (2011-08-01), pages 167 - 76;;BO ET AL., BIOINFORMATICS, vol. 26, no. 4, 2010, pages 493 - 500;;TRAPNELL ET AL., NAT BIOTECHNOL., vol. 28, no. 5, May 2010 (2010-05-01), pages 511 - 5;;G. QUINONES, NEW TECHNOLOGIES & FRONTIERS, Retrieved from the Internet <URL:https://www.yumpu.com/en/document/view/7263720/sunday-december-4-late-abstracts-1-molecular-biology-of-the-/l 33>;;NOA STANIETSKY, JOURNAL OF IMMUNOLOGY, vol. 106, no. 42, pages 17858 - 17863;;ROBERT J JOHNSTON, CANCER CELL, vol. 26, no. 6, 8 December 2014 (2014-12-08), pages 923 - 937;;MORGAN ET AL., SCIENCE, vol. 314, 2006, pages 126 - 129;;DRAKE; KLAKAMP, JOURNAL OF IMMUNOL METHODS, vol. 318, 2007, pages 147 - 152",ACTIVE
123,US,B2,US 11795220 B2,189-105-447-271-241,2023-10-24,2023,US 202016904510 A,2020-06-17,US 202016904510 A;;US 202016748695 A;;US 201615277980 A;;US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,Anti-PVRIG antibodies and methods of use,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/189-105-447-271-241,Granted Patent,yes,64,0,71,71,1543,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;C07K7/06;;C12N15/113;;G01N33/574,,76,47,047-792-343-788-48X;;025-407-244-777-265;;054-003-322-293-460;;057-692-130-684-50X;;025-120-068-045-330;;045-264-222-464-815;;030-386-130-285-706;;088-434-716-536-224;;009-863-107-597-216;;016-291-551-264-744;;055-865-733-704-493;;038-569-018-972-189;;028-947-110-430-895;;006-568-097-103-41X;;003-204-276-209-117;;022-608-838-432-215;;102-726-320-965-671;;006-574-964-805-278;;027-447-792-135-350;;020-748-493-197-572;;117-415-470-543-112;;042-171-846-329-572;;016-022-019-007-80X;;062-418-979-939-961;;089-252-860-702-185;;020-855-322-534-259;;035-971-661-796-491;;020-883-295-175-85X;;124-685-610-132-547;;042-879-791-960-298;;014-257-447-295-055;;080-252-306-108-27X;;060-310-971-679-125;;165-758-558-422-687;;052-579-262-928-039;;082-735-005-968-62X;;003-082-950-776-533;;057-307-040-432-890;;033-159-791-900-680;;051-707-000-800-833;;059-976-981-060-663;;047-792-343-788-48X;;001-377-831-676-789;;093-693-174-712-525;;001-485-358-549-255;;026-314-498-200-929;;100-399-671-580-29X,10.1016/j.cell.2012.02.034;;pmc3310896;;22424219;;10.1182/blood-2010-08-300954;;21406724;;16831868;;10.1074/jbc.m602359200;;10.1084/jem.20030788;;pmc2194180;;12913096;;10.1016/0378-1119(91)90244-6;;1916287;;10.1002/9783527682423.ch4;;pmc4295550;;10.3389/fonc.2014.00385;;25642417;;22285893;;10.1016/j.coi.2012.01.009;;22095633;;10.1002/jso.22150;;1512548;;10.1084/jem.176.3.855;;pmc2119366;;10.1128/mcb.5.12.3610;;10.1128/mcb.5.12.3610-3616.1985;;pmc369192;;3915782;;10.4049/jimmunol.172.7.3994;;15034010;;28978021;;pmc5620161;;10.18632/oncotarget.18004;;10.1073/pnas.192461099;;12218188;;pmc129438;;26870003;;pmc4740385;;10.3389/fmicb.2016.00022;;25465800;;10.1016/j.ccell.2014.10.018;;pmc3128994;;10.4049/jimmunol.1003081;;21199897;;10.1038/321522a0;;3713831;;20957455;;10.1007/s10059-010-0138-4;;10.1016/j.humpath.2015.01.003;;25704805;;pmc4371526;;25213377;;10.1126/science.1255904;;10.1158/1538-7445.am2017-581;;10.1200/jco.2017.35.15_suppl.3074;;10.1126/science.271.5256.1734;;8596936;;22427644;;pmc3324669;;10.4049/jimmunol.1103627;;1748994;;10.1016/0022-2836(91)90498-u;;pmc7038785;;30659055;;10.1158/2326-6066.cir-18-0460;;10.4161/viru.26153;;pmc5359721;;23979029;;21991385;;pmc3186807;;10.1371/journal.pone.0025908;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;10.1016/j.ccell.2014.11.016;;25490444;;10.1634/theoncologist.2014-0422;;26069281;;pmc4492230;;pmc166236;;12826605;;10.1073/pnas.1533209100;;10.1080/02648725.2013.801235;;24568279;;16405301;;22437872;;10.1038/nrc3236;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;7584144;;10.1016/1074-7613(95)90125-6;;22658127;;pmc3544539;;10.1056/nejmoa1200690;;12079396;;10.1016/s0022-2836(02)00264-4;;10.1016/0022-1759(86)90001-3;;2420900;;10.1016/j.cell.2012.02.034;;pmc3310896;;22424219;;16926269;;10.1152/physiolgenomics.00284.2005;;pmc4346487;;25676064;;10.1038/emm.2014.114;;pmc4003259;;10.1038/cmi.2009.108;;20081873;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091,"Weiner et al., 2012, Cell. vol. 148: 1081-4.;;U.S. Appl. No. 15/048,967, 2016-0244521, U.S. Pat. No. 10,227,408, filed Feb. 19, 2016, Aug. 25, 2016, Mar. 12, 2019.;;U.S. Appl. No. 15/277,978, 2017-0081408, U.S. Pat. No. 9,714,289, filed Sep. 27, 2016, Mar. 23, 2017, Jul. 25, 2017.;;U.S. Appl. No. 15/277,980, 2017-0029504, U.S. Pat. No. 11,220,542, filed Sep. 27, 2016, Feb. 2, 2017, Jan. 22, 2022.;;U.S. Appl. No. 15/896,040, 2018-0244774, U.S. Pat. No. 10,351,625, filed Feb. 13, 2018, Aug. 30, 2018, Jul. 16, 2019.;;U.S. Appl. No. 16/748,695, 2020-0148769, U.S. Pat. No. 11,623,955, filed Jan. 21, 2020, May 14, 2020, Apr. 11, 2023.;;U.S. Appl. No. 15/048,975, 2017-0088607, U.S. Pat. No. 10,550,173, filed Feb. 19, 2016, Mar. 30, 2017, Feb. 4, 2020.;;U.S. Appl. No. 16/775,133, 2020-0385445, filed Jan. 28, 2020, Dec. 10, 2020.;;U.S. Appl. No. 15/680,187, 2018-0305456, U.S. Pat. No. 10,751,415, filed Aug. 17, 2017, Oct. 25, 2018, Aug. 25, 2020.;;U.S. Appl. No. 15/795,135, 2018-0169238, U.S. Pat. No. 10,124,061, filed Oct. 26, 2017, Jun. 21, 2018, Nov. 13, 2018.;;U.S. Appl. No. 15/937,784, 2018-0280506, U.S. Pat. No. 10,213,505, filed Mar. 27, 2018, Oct. 4, 2018, Feb. 26, 2019.;;U.S. Appl. No. 16/904,511, 2021-0000952, filed Jun. 17, 2020, Jan. 7, 2021.;;U.S. Appl. No. 15/996,369, 2019-0010246, U.S. Pat. No. 11,225,523, filed Jun. 1, 2018, Jan. 10, 2019, Jan. 18, 2022.;;U.S. Appl. No. 17/544,852, 2023-0070685, filed Dec. 7, 2021, Mar. 9, 2023.;;U.S. Appl. No. 16/428,856, 2019-0382477, filed May 31, 2019, Dec. 19, 2019.;;Gene ID: PVRIG antibody—middle region, Rabbit Polyclonal Antibody Catalog #AI13083, retrieved from the internet: URL:http://www.funakoshi.co.jp/data/datasheet/ABG/AH3083.pdf.;;Sep. 1, 2012 (Sep. 1, 2012), pp. 286-293, XP002759705.;;Apr. 2, 2018 (Apr. 2, 2018), XP055605563, Retrieved from the Internet.;;Alvarez M., et al., Increased Antitumor Effects Using IL-2 with Anti-TGF-β Reveals Competition between Mouse NK and CD8 T Cells. J Immunol 2014; 193:1709-1716; Prepublished online Jul. 7, 2014.;;Anonymous: “Medimnune to Develop Compugen Imnuno-Oncology Antibodies”, Genetic Engineering and Biotechnology News.;;Ardolino, M., et al., “DNAM-1 Ligand Expression on Ag-Stimulated T Lymphocytes is Mediated by ROS-Dependent Activation of DNA-Damage Response: Relevance for NK-T Cell Interaction,” Blood, v. 117, No. 18, p. 4778 (May 5, 2011).;;Bachelet, I., et al., “Mast Cell Costimulation by CD226/CD112 (DNAM-1/Nectin-2) A Novel Interface in the Allergic Process”, J. of Biol. Chem., v. 281, n. 37, p. 27190-27196, Sep. 15, 2006.;;Bottino, C., et al., “Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule”, J. Exp. Med., v. 198, No. 4, p. 557-567, Aug. 18, 2003.;;Breitling, F., et al., “A Surface Expression Vector for Antibody Screening”, Gene, 104 (1991) 147-153.;;Brüggemann, M., et al., “Handbook of Therapeutic Antibodies”, Second Edition, p. 77-87, Ch. 4, Transgenic animals derived by DNA Microinjection, 2014.;;Callahan, M.K., et al., “CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic,” Frontiers in Oncology, v. 4, article 385, p. 2 (Jan. 2015).;;Chan, C.J., et al., “Receptors that Interact with Nectin and Netin-Like Proteins in the Immunosurveillance and Immunotherapy of Cancer”, Current Opinion in Immun. 2012, 24:246-251.;;Chen Y et al: Decreased expression of V-set and immunoglobulin domain containing 1 (VSIGI) is associated with poor prognosis in primary gastric cancer, J. of Surgical Oncology, v. 106, n. 3, p. 286-293 (Sep. 1, 2012).;;Chen et al., 1992, Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen., J. Exp. Med. vol. 176: 855-866.;;Compugen, TriNet Census.;;Eran et al., “Discovery and Development of COM701, a Therapeutic Antibody Targeting the Novel Inmune Checkpoint PVRIG.”, POS, Jun. 4, 2017 (Jun. 4, 2017), p. 169, XP055506726.;;Evan, G.I., et al., “Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product”, Mol. Cell. Biol., Dec. 1985, vol. 5, p. 3610-3616.;;Fuchs, A., et al., “Cutting Edge: CD96 (Tactile) Promotes NK Cell-Target Cell Adhesion by Interactng ith the Poliovirus Receptor (CD155),” J. Immunol. 2004; 172:3994-3998.;;He et al., Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., Oncotarget. May 19, 2017;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection Sep. 15, 2017.;;Iwai, Y., et al., “Involvement of PD-L1 on Tumor Cells in the Escape from Host Immune System and Tumor Immunotherapy by PD-L1 Bockade,” PNAS, v. 99, n. 19, p. 12293-12297, Sep. 17, 2002.;;Janda et al., Ig Constant Region Effects on Variable Region Structure and Function., Front Microbiol. Feb. 4, 2016;7:22. doi: 10.3389/fmicb.2016.00022. eCollection 2016.;;Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Joller, “Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions”, J. of Immun. 2011; 186:1338-1342.;;Jones, P.T., et al., “Replacing the Complementarity-Determining regions in a Human Antibody with Thse from a Mouse,” Nature, v. 321, May 29, 1986.;;Journal of Surgical Oncology, New York, NY, US, vol. 106 , No. 3.;;Kim et al: 11 Extracellular domain of V-set and immunoglobulin domain containing 1 (VSIGI) interacts with sertoli cell membrane protein, while its PDZ-binding motif forms a complex with Z0-1, Molecules and Cells, vol. 30, No. 5, Oct. 14, 2010 (Oct. 14, 2010), pp. 443-448, XP055344846.;;Kim et al., Gastric-type expression signature in serrated pathway-associated colorectal tumors., Human Pathology vol. 46, Issue 5, May 2015, pp. 643-656.;;Kuehn, H.S., et al., “Immune Dysregulation in Human Subjects with heterozygous Germline Mutations in CTLA4,” Science, v. 345, issue 6204, p. 1623.;;Levy et al., Abstract 581: Discovery and development of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG., Cancer Research, Apr. 1, 2017 (Apr. 1, 2017), p. 581, XP055506734.;;Liang et al., “Discovery of COM701, a therapeutic antibody targeting the novel imnune checkpoint PVRIG, for the treatment of cancer”, Journal of Clinical Oncology, American Society of Clinical Oncology, US , vol. 35, No. 15 suppl May 20, 2017 (May 20, 2017), p. 3074.;;Leach, D.R., et al., “Enhancement of Antitumor Immunity by CTLA-4 Blockade,” Scinece, v. 271, Mar. 22, 1996.;;Lozano, E., “The TIGIT/CD226 Axis Regulates Human T Cell Function”, J. of Immun., 2012; 188:3869-3875.;;Marks, J.D., et al., “By-Passing Immunization: Human Antibodies form V-Gene Libraries Displayed on Phage,” J. Mol. Bio. (1991) 222, 581-597.;;Murter, B., et al., “Mouse PVRIG has CD8+ T Cell-Specifric Coinhibitory Functions and Dampens Antitumor Immunity”, Cancer Immun. Res., Jan. 18, 2019; DOI: 10.1158/2326-6066.CIR-18-0460.;;Nosanchuk JD., The interdependence of antibody C and V regions on specificity and affinity: significant implications for the engineering of therapeutic antibodies., Virulence. Aug. 15, 2013;4(6):439-40. doi: 10.4161/viru.26153.;;Oidovsambuu et al. (2011) Adhesion Protein VSIGI is Required for the Proper Differentiation of Glandular Gastric Epithelia. PLoS ONE 6(10): e25908. doi: 10.1371/journal.pone.0025908.;;Ophir et al., “Discovery and Development of COM701, a Therapeutic Antibody Targeting the Novel Inmune Checkpoint PVRIG.”, Pos, Jun. 4, 2017 (Jun. 4, 2017), p. 169, XP055506726.;;Orentas et al., Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Pauken, K.E., et al., “TIGIT and CD226: Tipping the Balance Between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit”, Cancer Cell 26, Dec. 8, 2014.;;Pennock et al., “The Evolving Role of Inmune Checkpoint Inhibitors in Cancer Treatment.”, The Oncologist, Jun. 11, 2015 (Jun. 11, 2015), pp. 812-822, XP055320470.;;Phan, G.Q., “Cancer Regression and Autoimmunity Induced by Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma”, PNAS v. 100, n. 14, p. 8372-8377, Jul. 8, 2003.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.;;R&D Systems Catalog, Oct. 13, 2015 (Oct. 13, 2015), pp. 1-2.;;R&d Systems: 11 Human VSIGI Antibody, Catalog No. MAB4818.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): P135.;;Safdari, Y., “Antibody Humanization Methods—A review and Update”, Biotech, and Gen. Eng. Rev., v. 29, n. 2, p. 175-186, 2013.;;Scanlan et al : 11 Gl ycoprotein 1-47 A34, a novel t arget for antibody-based cancer inrnunotherapy, Cancer Immunity, Academy of Cancer Immunology, Ch, vol. 6, Jan. 1, 2006.;;Scott et al., Antibody therapy of cancer., 2012, Nature Reviews, vol. 12: 278-287.;;Shaffer, A. “Novel Immune Checkpoint Identified as Promising Target for Blockade Strategies”, Targeted Oncology, Nov. 1, 2016. Found on Sep. 7, 2021, https://www.targetedonc.com/view/novel-immune-checkpoint-identified-as-promising-target-for-blockade-strategies.;;Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.;;Tivol, E. A., “Loss of CTLA-4 Leads to Massive Lymphoproliferation and Fatal Multiorgan Tissue Destruction, Revealing a Critical Negative Regulatory Role of CTLA-4”, Immunity, v. 3, 541-547, Nov. 1995.;;Topalian, S.L., “Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer,” N. Engl. J. Med, 366;26, Jun. 28, 2012.;;URL:https://www.genengnews.com/topics/drug-discovery/medimnune-to-develop-compugen-imnuno-oncology-antibodies/[retrieved on Jul. 15, 2019].;;Vajdos et al., 2002, Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis, J. Mol. Biol. vol. 320: 415-428.;;Walter, G., “Production and Use of Antibodies Against Synthetic Peptides”, J. of Immun. Methods, 88 (1986) 149-161.;;Weiner et al., Antibody-based immunotherapy of cancer., Cell. Mar. 1, 2012;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034.;;Wilson et al., Comparative analysis of the paired immunoglobulin-like receptor (PILR) locus in six mammalian genomes: duplication, conversion, and the birth of new genes. Physiol Genomics. 2006;27(3):201-218. doi:10.1152/physiolgenomics.00284.2005.;;Yoon, S.R., et al., “Understanding of Molecular Mechanisms in Natural Killer Cell Therapy,” Experimental & Molecular Med., (2015) 47, e141; doi:10.1038;emm.2014.114.;;Xu, Z., “A Novel Interface Consisting of Homologous Immunoglobulin Superfamily Members with Multiple Functions”, Cellular & Molecular Immunology (2010) 7, 11-19.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.",ACTIVE
124,US,A1,US 2020/0148769 A1,083-349-192-946-119,2020-05-14,2020,US 202016748695 A,2020-01-21,US 202016748695 A;;US 201615277980 A;;US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/083-349-192-946-119,Patent Application,yes,0,0,71,71,1543,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;C07K7/06;;G01N33/574,,0,0,,,,ACTIVE
125,US,B2,US 11220542 B2,106-730-826-459-976,2022-01-11,2022,US 201615277980 A,2016-09-27,US 201615277980 A;;US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,Anti-PVRIG antibodies and methods of use,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/106-730-826-459-976,Granted Patent,yes,23,1,71,71,1543,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;C07K7/06;;C12N15/113;;G01N33/574,,17,13,051-707-000-800-833;;016-291-551-264-744;;003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;022-608-838-432-215;;042-879-791-960-298;;028-947-110-430-895;;082-735-005-968-62X;;047-792-343-788-48X;;020-883-295-175-85X;;003-204-276-209-117;;001-377-831-676-789,12079396;;10.1016/s0022-2836(02)00264-4;;1512548;;10.1084/jem.176.3.855;;pmc2119366;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;25465800;;10.1016/j.ccell.2014.10.018;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;28978021;;pmc5620161;;10.18632/oncotarget.18004;;22437872;;10.1038/nrc3236;;10.1016/j.cell.2012.02.034;;pmc3310896;;22424219;;10.4161/viru.26153;;pmc5359721;;23979029;;26870003;;pmc4740385;;10.3389/fmicb.2016.00022;;16926269;;10.1152/physiolgenomics.00284.2005,"Vajdos et al., 2002, J. Mol. Biol. vol. 320: 415-428.;;Chen et al., 1992, J. Exp. Med. vol. 176: 855-866.;;Gene ID: PVRIG antibody—middle region, Rabbit Polyclonal Antibody Catalog #AI13083, retrieved from the internet: URL:http://www.funakoshi.co.jp/data/datasheet/ABG/AI13083.pdf.;;Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): P135.;;Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Orentas et al., Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.;;He et al., Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., Oncotarget. May 19, 2017;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection Sep. 15, 2017.;;Scott et al., Antibody therapy of cancer., 2012, Nature Reviews, vol. 12: 278-287.;;Weiner et al., Antibody-based immunotherapy of cancer., Cell. Mar. 16, 2012;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034.;;Nosanchuk JD., The interdependence of antibody C and V regions on specificity and affinity: significant implications for the engineering of therapeutic antibodies., Virulence. Aug. 15, 2013;4(6):439-40. doi: 10.4161/viru.26153.;;Janda et al., Ig Constant Region Effects on Variable Region Structure and Function., Front Microbiol. Feb. 4, 2016;7:22. doi: 10.3389/fmicb.2016.00022. eCollection 2016.;;U.S. Appl. No. 15/937,784, 2018-0280506, U.S. Pat. No. 10,213,505, filed Mar. 27, 2018, Oct. 4, 2018, Feb. 26, 2019.;;Wilson et al., Comparative analysis of the paired immunoglobulin-like receptor (PILR) locus in six mammalian genomes: duplication, conversion, and the birth of new genes. Physiol Genomics. 2006;27(3):201-218. doi:10.1152/physiolgenomics.00284.2005.",ACTIVE
126,US,B2,US 10351625 B2,018-918-641-880-056,2019-07-16,2019,US 201815896040 A,2018-02-13,US 201815896040 A;;US 201615277980 A;;US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,Anti-PVRIG antibodies and methods of use,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/018-918-641-880-056,Granted Patent,yes,22,0,71,71,1543,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K39/395;;C07K7/06;;C07K16/28;;C12N15/113;;G01N33/574,,17,10,028-947-110-430-895;;082-735-005-968-62X;;047-792-343-788-48X;;003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;022-608-838-432-215;;042-879-791-960-298;;020-883-295-175-85X;;003-204-276-209-117,28978021;;pmc5620161;;10.18632/oncotarget.18004;;22437872;;10.1038/nrc3236;;10.1016/j.cell.2012.02.034;;pmc3310896;;22424219;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;25465800;;10.1016/j.ccell.2014.10.018;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;10.4161/viru.26153;;pmc5359721;;23979029;;26870003;;pmc4740385;;10.3389/fmicb.2016.00022,"He et al., 2017, Oncotarget, vol. 8: 67129-67139.;;Scott et al., 2012, Nature Reviews, vol. 12: 278-287.;;Weiner et al., 2012, Cell. vol. 148: 1081-1084.;;Gene ID: PVRIG antibody—middle region, Rabbit Polyclonal Antibody Catalog #Al13083, retrieved from the internet: URL:http://www.funakoshi.co.jp/data/datasheet/ABG/Al13083.pdf.;;Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): P135.;;Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Orentas et al., Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.;;Nosanchuk JD., The interdependence of antibody C and V regions on specificity and affinity: significant implications for the engineering of therapeutic antibodies., Virulence. Aug. 15, 2013;4(6):439-40. doi: 10.4161/viru.26153.;;Janda et al., Ig Constant Region Effects on Variable Region Structure and Function., Front Microbiol. Feb. 4, 2016;7:22. doi: 10.3389/fmicb.2016.00022. eCollection 2016.;;U.S. Appl. No. 15/048,967, 2016-0244521, filed Feb. 19, 2016, Aug. 25, 2016.;;U.S. Appl. No. 15/277,978, 2017-0081408, U.S. Pat. No. 9,714,289, filed Sep. 27, 2016, Mar. 23, 2017, Jul. 25, 2017.;;U.S. Appl. No. 15/277,980, 2017-0029504, filed Sep. 27, 2016, Feb. 2, 2017.;;U.S. Appl. No. 15/896,040, filed Feb. 13, 2018.",ACTIVE
127,ES,T3,ES 2786651 T3,165-955-777-006-889,2020-10-13,2020,ES 16707603 T,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,Anticuerpos anti-PVRIG y métodos de uso,"Un anticuerpo anti-PVRIG (Proteína que Contiene Dominio de Inmunoglobulina Relacionada con Receptor de Virus de la Polio) para uso en el tratamiento de cáncer, donde el anticuerpo activa células T y/o células NK.",COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/165-955-777-006-889,Granted Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,0,0,,,,ACTIVE
128,SI,T1,SI 3258951 T1,051-226-780-031-977,2020-07-31,2020,SI 201630706 T,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W;;EP 16707603 A,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/051-226-780-031-977,Granted Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/00;;C12N15/00,,0,0,,,,ACTIVE
129,MX,A,MX 2020009461 A,125-089-795-533-448,2021-02-17,2021,MX 2020009461 A,2017-08-18,US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE.,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,DASSA LIAT;;KUMAR SANDEEP;;GOZLAN YOSI;;SAMEAH-GREENWALD SHIRLEY;;TIRAN ZOHAR;;VAKNIN ILAN;;LIANG SPENCER;;CHAN CHRISTOPHER;;WHITE MARK;;STAPLETON LANCE;;DRAKE ANDREW W;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/125-089-795-533-448,Patent Application,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;A61K38/00;;C07K14/00;;C12N15/113,,0,0,,,,PENDING
130,EP,B1,EP 3295951 B1,148-626-930-749-213,2020-04-22,2020,EP 17192325 A,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;EP 16707603 A;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/148-626-930-749-213,Granted Patent,yes,5,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61P35/00;;C07K16/28,,5,0,,,"Gene Id: ""PVRIG antibody -middle region Rabbit Polyclonal Antibody Catalog # AI13083 Specification PVRIG antibody -middle region -Product Information Application WB Primary Accession Q6DKI7 Other Accession NM_024070, NP_076975 Reactivity Human Predicted Human Host Rabbit Clonality Polyclonal Calculated MW 34k"", Physiol. Genomics, 1 January 2006 (2006-01-01), pages 201-218, XP055273924, Retrieved from the Internet: URL:http://www.funakoshi.co.jp/data/datash eet/ABG/AI13083.pdf;;N. STANIETSKY ET AL: ""The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 42, 20 October 2009 (2009-10-20), pages 17858-17863, XP055215810, ISSN: 0027-8424, DOI: 10.1073/pnas.0903474106;;XIN YU ET AL: ""The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells"", NATURE IMMUNOLOGY, vol. 10, no. 1, 1 January 2009 (2009-01-01), pages 48-57, XP055273979, GB ISSN: 1529-2908, DOI: 10.1038/ni.1674;;ZHU YUWEN ET AL: ""Identification of CD112R as a novel checkpoint for human T cells"", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIV. PRESS, NEW YORK, NY, USA, vol. 213, no. 2, 8 February 2016 (2016-02-08), pages 167-176, XP009190107, ISSN: 1540-9538;;GALIT ROTMAN ET AL: ""Identification of novel immune checkpoints as targets for cancer immunotherapy"", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. Suppl 1, 7 November 2013 (2013-11-07), page P135, XP021167082, ISSN: 2051-1426, DOI: 10.1186/2051-1426-1-S1-P135",ACTIVE
131,PL,T3,PL 3258951 T3,065-235-181-229-183,2020-07-27,2020,PL 16707603 T,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;EP 16707603 A;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,SAMEAH-GREENWALD SHIRLEY;;WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/065-235-181-229-183,Patent Application,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,0,0,,,,PENDING
132,MX,A,MX 2017010667 A,148-761-802-926-328,2018-08-15,2018,MX 2017010667 A,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE.,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,GAD S COJOCARU;;LIAT DASSA;;MARK WHITE;;SANDEEP KUMAR;;CHRISTOPHER CHAN;;SPENCER LIANG;;LANCE STAPLETON;;ANDREW W DRAKE;;YOSI GOZLAN;;SHIRLEY SAMEAH-GREENWALD;;ZOHAR TIRAN;;LEONARD PRESTA;;RICHARD THEOLIS;;ILAN VAKNIN,,https://lens.org/148-761-802-926-328,Patent Application,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,0,0,,,,ACTIVE
133,DK,T3,DK 3295951 T3,167-062-946-197-87X,2020-07-20,2020,DK 17192325 T,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;EP 16707603 A,2015-02-19,ANTI-PVRIG-ANTISTOFFER OG FREMGANGSMÅDER FOR ANVENDELSE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/167-062-946-197-87X,Granted Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61P35/00;;C07K16/28,,0,0,,,,ACTIVE
134,RU,C2,RU 2732042 C2,002-731-850-314-914,2020-09-10,2020,RU 2017132214 A,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USING,"FIELD: medicine.SUBSTANCE: group of inventions concerns application an anti-PVRIG antibody (a human poliovirus-related protein-containing protein containing an immunoglobulin domain), activating T-cells and/or NK cells, for treating cancer, characterized by the expression of PVRIG and/or PVRL2. Group of inventions also relates to a method of activating T-cells of a patient suffering from cancer, characterized by expression of PVRIG and/or PVRL2, comprising administering to patient PVRIG antibodies; a composition of expression vectors for expressing the anti-PVRIG antibody; a host cell for expressing the anti-PVRIG antibody, containing said composition of expression vectors.EFFECT: group of inventions provides treating cancer characterized by expression of PVRIG and/or PVRL2.58 cl, 103 dwg, 5 tbl, 29 ex",COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/002-731-850-314-914,Granted Patent,no,3,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K39/395;;A61P35/00,,1,1,067-816-127-236-532,24555932;;10.1089/mab.2013.0074,"CHEN Y., et al., Development and characterization of monoclonal antibodies against pancreatic cancer marker hippocalcin-like 1 protein.Monoclon Antib Immunodiagn Immunother. 2014 Feb;33(1):20-7. doi: 10.1089/mab.2013.0074.",ACTIVE
135,HU,T2,HU E049032 T2,051-813-445-306-423,2020-08-28,2020,HU E16707603 A,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/051-813-445-306-423,Amended Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28,,0,0,,,,PENDING
136,US,A1,US 2021/0188974 A1,041-148-780-866-030,2021-06-24,2021,US 202016904510 A,2020-06-17,US 202016904510 A;;US 202016748695 A;;US 201615277980 A;;US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/041-148-780-866-030,Patent Application,yes,1,0,71,71,1543,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;C07K7/06;;G01N33/574,,1,1,047-792-343-788-48X,10.1016/j.cell.2012.02.034;;pmc3310896;;22424219,"Weiner et al., 2012, Cell. Vol 148: 1081-4.",ACTIVE
137,US,B2,US 9714289 B2,041-531-164-143-906,2017-07-25,2017,US 201615277978 A,2016-09-27,US 201615277978 A;;US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,Anti-PVRIG antibodies and methods of use,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/041-531-164-143-906,Granted Patent,yes,17,10,71,71,1542,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K39/395;;C07K7/06;;C07K16/28;;C12N15/113;;G01N33/574,,7,5,003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;022-608-838-432-215;;042-879-791-960-298,19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;25465800;;10.1016/j.ccell.2014.10.018;;24959420;;pmc4050364;;10.3389/fonc.2014.00134,"Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): P135.;;Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Orentas et al., Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.",ACTIVE
138,AU,A1,AU 2020/264349 A1,040-043-780-588-23X,2020-12-03,2020,AU 2020/264349 A,2020-11-05,AU 2020/264349 A;;AU 2016/219835 A;;US 201562141120 P;;US 201562118208 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,Anti-PVRIG antibodies and methods of use,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/040-043-780-588-23X,Patent Application,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;A61K38/00;;C07K14/00;;C12N15/113,,0,0,,,,PENDING
139,EP,B1,EP 3258951 B1,176-017-110-643-01X,2020-01-29,2020,EP 16707603 A,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/176-017-110-643-01X,Granted Patent,yes,14,2,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,20,18,100-399-671-580-29X;;089-252-860-702-185;;042-879-791-960-298;;003-082-950-776-533;;093-693-174-712-525;;057-692-130-684-50X;;038-569-018-972-189;;102-726-320-965-671;;025-407-244-777-265;;001-485-358-549-255;;054-003-322-293-460;;022-608-838-432-215;;035-971-661-796-491;;014-257-447-295-055;;003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;088-434-716-536-224,10.1084/jem.20150785;;26755705;;pmc4749091;;22427644;;pmc3324669;;10.4049/jimmunol.1103627;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;pmc4346487;;25676064;;10.1038/emm.2014.114;;10.1084/jem.20030788;;pmc2194180;;12913096;;10.4049/jimmunol.172.7.3994;;15034010;;pmc3128994;;10.4049/jimmunol.1003081;;21199897;;10.1182/blood-2010-08-300954;;21406724;;pmc4003259;;10.1038/cmi.2009.108;;20081873;;16831868;;10.1074/jbc.m602359200;;25465800;;10.1016/j.ccell.2014.10.018;;pmc7038785;;30659055;;10.1158/2326-6066.cir-18-0460;;10.1016/j.ccell.2014.11.016;;25490444;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;22285893;;10.1016/j.coi.2012.01.009,"ZHU ET AL.: ""Identification of CD 112R as a novel checkpoint for human T cells"", J. EXP. MED., vol. 213, no. 2, 11 January 2016 (2016-01-11), pages 167 - 176, XP055314642, DOI: 10.1084/jem.20150785;;LOZANO E; DOMINGUEZ-VILLAR M; KUCHROO V; HAFLER D A: ""The TIGIT/ CD 226 axis regulates human T cell function"", J. IMMUNOL., vol. 188, 16 March 2012 (2012-03-16), pages 3869, XP055557788;;RIMAS J ORENTAS; JESSICA NORDLUND; JIANBIN HE; SIVASISH SINDIRI; CRYSTAL MACKALL; TERRY J FRY; JAVED KHAN: ""Bioinformatic Description of Immunotherapy Targets for Pediatric T- Cell Leukemia and the Impact of Normal Gene Sets Used for Comparison"", FRONTIERS ONCOL, vol. 4, no. 134, 10 June 2014 (2014-06-10), pages 1 - 11, XP055397613;;STANIETSKY ET AL.: ""The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity"", PNAS, vol. 106, no. 42, 20 October 2009 (2009-10-20), pages 17858, XP055215810, DOI: 10.1073/pnas.0903474106;;YOON SUK RAN , TAE-DON KIM, AND INPYO CHOI: ""Understanding of molecular mechanisms in natural killer cell therapy"", EXPERIMENTAL & MOLECULAR MEDICINE, vol. 47, no. 2, 13 February 2015 (2015-02-13), pages e141, XP055748040;;BOTTINO ET AL.: ""Identification of PVR ( CD 165) and Nectin-2 ( CD 112) as Cell Surface Ligands for the Human DNAM-1 ( CD 226) Activating Molecule"", J. EXP. MED., vol. 198, no. 4, 11 August 2003 (2003-08-11), pages 557, XP055011690, DOI: 10.1084/jem.20030788;;FUCHS ET AL.: ""Cutting edge: CD 96 (tactile) promotes NK cell -target cell adhesion by interacting with the poliovirus receptor ( CD 165"", J. IMMUNOL., vol. 172, 1 April 2004 (2004-04-01), pages 3994, XP055344481, DOI: 10.4049/jimmunol.172.7.3994;;JOLLER N; HAFLER J P; BRYNEDAL B; KASSAM N; SPOERL S; LEVIN S D; SHARPE A H; KUCHROO V K: ""Cutting Edge: TIGIT Has T Cell -Intrinsic Inhibitory Functions"", J. IMMUNOL., vol. 186, no. 3, 3 January 2011 (2011-01-03), pages 1338 - 1342, XP055319470;;QUINONES ET AL.: ""High-throughput cellular assays using a well-less plate format"", POSTER ABSTRACT NO. 2205 (NEW TECHNOLOGIES AND FRONTIERS), 2011 AMERICAN SOCIETY FOR CELL BIOLOGY (ASCB) ANNUAL MEETING, DENVER , CO, 3 December 2011 (2011-12-03), pages 1 - 3, XP055748047;;ARDOLINO ET AL.: ""DNAM-1 ligand expression on Ag-stimulated T lymphocytes is mediated by ROS-dependent activation of DNA- damage response: relevance for NK-T cell interaction"", BLOOD, vol. 11718, 5 May 2011 (2011-05-05), pages 4778, XP055748054;;XU ZHUWEI, ET ALBOQUAN JIN: ""A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions"", CELLULAR & MOLECULAR IMMUNOLOGY, vol. 7, 18 January 2010 (2010-01-18), pages 11 - 19, XP055748061;;BACHELET ET AL.: ""Mast Cell Costimulation by CD 226/ CD 112 (DNAM- 1/Nectin-2): a novel interface in the allergic process"", J. BIOL. CHEM., vol. 281, 15 September 2006 (2006-09-15), pages 27190, XP055223948, DOI: 10.1074/jbc.M602359200;;JOHNSTON ET AL.: ""The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD 8+ T Cell Effector Function"", CANCER CELL, vol. 26, no. 6, 8 December 2014 (2014-12-08), pages 923, XP029111576, DOI: 10.1016/j.ccell.2014.10.018;;BENJAMIN MURTER, XIAOYU PAN, ERAN OPHIR, ZOYA ALTEBER, MEIR AZULAY, RUPASHREE SEN, OFER LEVY, LIAT DASSA, ILAN VAKNIN, TAL FRIDMAN: ""Mouse PVRIG Has CD 8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity"", CANCER IMMUNOL. RES., vol. 7, no. 2, 18 January 2019 (2019-01-18), pages 244, XP055748070;;PAUKEN ET AL.: ""TIGIT and CD 226: Tipping the Balance Between Costimulatory and Coinhibitory Molecules to Augment the Cancer Immunotherapy Toolkit"", CANCER CELL, vol. 26, 8 December 2014 (2014-12-08), pages 785, XP029111585, DOI: 10.1016/j.ccell.2014.11.016;;GENE ID.: ""PVRIG antibody -middle region Rabbit Polyclonal Antibody Catalog # AI13083 Specification PVRIG antibody -middle region -Product Information Application WB Primary Accession Q6DKI7 Other Accession NM_024070, NP_076975 Reactivity Human Predicted Human Host Rabbit Clonality Polyclonal Calculated MW 34k"", PHYSIOL. GENOMICS, 1 January 2006 (2006-01-01), pages 201 - 218, XP055273924;;STANIETSKY, N. ET AL.: ""The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity"", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS, vol. 106, no. 42, 20 October 2009 (2009-10-20), pages 17858 - 17863, XP055215810;;XIN YU; KRISTIN HARDEN; LINO C GONZALEZ; MICHELLE FRANCESCO; EUGENE CHIANG; BRYAN IRVING; IRENE TOM; SINISA IVELJA; CANIO J REFINO: ""The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells"", NATURE IMMUNOLOGY., vol. 10, no. 1, 1 January 2009 (2009-01-01), pages 48 - 57, XP055273979;;ZHU YUWEN ET AL.: ""Identification of CD112R as a novel checkpoint for human T cells"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 213, no. 2, 8 February 2016 (2016-02-08), pages 167 - 176, XP002763687;;CHRISTOPHER J CHAN; DANIEL M ANDREWS; MARK J SMYTH: ""Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer"", CURRENT OPINION IN IMMUNOLOGY, vol. 24, 28 January 2012 (2012-01-28), pages 246 - 251, XP055147483",ACTIVE
140,LT,T,LT 3295951 T,008-392-440-630-070,2020-09-25,2020,LT 17192325 T,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/008-392-440-630-070,Unknown,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61P35/00;;C07K16/28,,0,0,,,,PENDING
141,CA,A1,CA 2976926 A1,100-244-480-814-392,2016-08-25,2016,CA 2976926 A,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/100-244-480-814-392,Patent Application,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;C12N15/13;;C12P21/08,,0,0,,,,PENDING
142,AU,B2,AU 2016/219835 B2,135-817-125-491-774,2020-12-03,2020,AU 2016/219835 A,2016-02-19,US 201562141120 P;;US 201562118208 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,Anti-PVRIG antibodies and methods of use,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/135-817-125-491-774,Granted Patent,no,1,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;A61K38/00;;C07K14/00;;C12N15/113,,0,0,,,,ACTIVE
143,SG,A,SG 11201706583P A,013-235-684-325-250,2017-09-28,2017,SG 11201706583P A,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/013-235-684-325-250,Unknown,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,0,0,,,,PENDING
144,HR,T1,HR P20200572 T1,023-774-002-247-191,2020-08-21,2020,HR P20200572 T,2020-04-09,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;EP 16707603 A;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/023-774-002-247-191,Granted Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,0,0,,,,ACTIVE
145,EP,A1,EP 3258951 A1,080-104-311-648-153,2017-12-27,2017,EP 16707603 A,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/080-104-311-648-153,Patent Application,yes,0,1,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,0,0,,,,ACTIVE
146,HU,T2,HU E049791 T2,126-229-384-366-006,2020-10-28,2020,HU E17192325 A,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/126-229-384-366-006,Amended Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61P35/00;;C07K16/28,,0,0,,,,PENDING
147,US,B2,US 11623955 B2,123-699-361-726-264,2023-04-11,2023,US 202016748695 A,2020-01-21,US 202016748695 A;;US 201615277980 A;;US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,Anti-PVRIG antibodies and methods of use,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/123-699-361-726-264,Granted Patent,yes,61,1,71,71,1543,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;C07K7/06;;C12N15/113;;G01N33/574,,39,22,003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;022-608-838-432-215;;042-879-791-960-298;;028-947-110-430-895;;082-735-005-968-62X;;047-792-343-788-48X;;020-883-295-175-85X;;003-204-276-209-117;;016-022-019-007-80X;;042-171-846-329-572;;080-252-306-108-27X;;042-171-846-329-572;;051-707-000-800-833;;016-291-551-264-744;;052-579-262-928-039;;009-863-107-597-216;;027-447-792-135-350;;124-685-610-132-547;;001-377-831-676-789;;020-748-493-197-572,19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;25465800;;10.1016/j.ccell.2014.10.018;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;28978021;;pmc5620161;;10.18632/oncotarget.18004;;22437872;;10.1038/nrc3236;;10.1016/j.cell.2012.02.034;;pmc3310896;;22424219;;10.4161/viru.26153;;pmc5359721;;23979029;;26870003;;pmc4740385;;10.3389/fmicb.2016.00022;;10.1200/jco.2017.35.15_suppl.3074;;10.1158/1538-7445.am2017-581;;10.1634/theoncologist.2014-0422;;26069281;;pmc4492230;;10.1158/1538-7445.am2017-581;;12079396;;10.1016/s0022-2836(02)00264-4;;1512548;;10.1084/jem.176.3.855;;pmc2119366;;16405301;;22095633;;10.1002/jso.22150;;20957455;;10.1007/s10059-010-0138-4;;21991385;;pmc3186807;;10.1371/journal.pone.0025908;;16926269;;10.1152/physiolgenomics.00284.2005;;10.1016/j.humpath.2015.01.003;;25704805,"Gene ID: PVRIG antibody—middle region, Rabbit Polyclonal Antibody Catalog #AI13083, retrieved from the internet: URL:http://www.funakoshi.co.jp/data/datasheet/ABG/AI13083.pdf.;;Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): P135.;;Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Orentas et al., Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.;;He et al., Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., Oncotarget. May 19, 2017;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection Sep. 15, 2017.;;Scott et al., Antibody therapy of cancer., 2012, Nature Reviews, vol. 12: 278-287.;;Weiner et al., Antibody-based immunotherapy of cancer., Cell. Mar. 16, 2012;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034.;;Nosanchuk JD., The interdependence of antibody C and V regions on specificity and affinity: significant implications for the engineering of therapeutic antibodies., Virulence. Aug. 15, 2013;4(6):439-40. doi: 10.4161/viru.26153.;;Janda et al., Ig Constant Region Effects on Variable Region Structure and Function., Front Microbiol. Feb. 4, 2016;7:22. doi: 10.3389/fmicb.2016.00022. eCollection 2016.;;Liang et al., “Discovery of COM701, a therapeutic antibody targeting the novel imnune checkpoint PVRIG, for the treatment of cancer”, Journal of Clinical Oncology, American Society of Clinical Oncology, US , vol. 35, No. 15 suppl May 20, 2017 (May 20, 2017), p. 3074.;;Anonymous: “Medimnune to Develop Compugen Imnuno-Oncology Antibodies”, Genetic Engineering and Biotechnology News, Apr. 2, 2018 (Apr. 2, 2018), XP055605563, Retrieved from the Internet: URL:https://www.genengnews.com/topics/drug -discovery/medimnune-to-develop-compugen-i mnuno-oncology-antibodies/[retrieved on Jul. 15, 2019].;;Levy et al., Abstract 581: Discovery and development of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG., Cancer Research, 1 Apr. 1, 2017 (Apr. 1, 2017), p. 581, XP055506734.;;Pennock et al., “The Evolving Role of Inmune Checkpoint Inhibitors in Cancer Treatment.”, The Oncologist, Jun. 11, 2015 (Jun. 11, 2015), pp. 812-822, XP055320470.;;OPHIR ERAN, OFER LEVY, SUDIPTO GANGULY, MAYA KOTTURI, ILAN VAKNIN, LIAT DASSA, MEIR AZULAY, ZOYA ALTEBER, SARAH WHELAN, KYLE HANSE: ""Discovery and Development of COM701, a Therapeutic Antibody Targeting the Novel Immune Checkpoint PVRIG"", 4 June 2017 (2017-06-04), pages 169, XP055506726;;Vajdos et al., 2002, Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis, J. Mol. Biol. vol. 320: 415-428.;;Chen et al., 1992, Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen., J. Exp. Med. vol. 176: 855-866.;;Alvarez M., et al., Increased Antitumor Effects Using IL-2 with Anti-TGF-β Reveals Competition between Mouse NK and CD8 T Cells. J Immunol 2014; 193:1709-1716; Prepublished online Jul. 7, 2014.;;Scanlan et al : 11 Gl ycoprotein 1-47 A34, a novel t arget for antibody-based cancer inrnunotherapy, Cancer Immunity, Academy of Cancer Immunology, CH, vol. 6, Jan. 1, 2006.;;R&d Systems: 11 Human VSIGl Antibody, Catalog No. MAB4818 R&D Systems Catalog, Oct. 13, 2015 (Oct. 13, 2015), pp. 1-2.;;CHEN Y, PAN K, LI S, XIA J, WANG W, CHEN J, ZHAO J, Lü L, WANG D, PAN Q, WANG Q, LI Y, HE J, LI Q.: ""Decreased expression of V-set and immunoglobulin domain containing 1 (VSIG1) is associated with poor prognosis in primary gastric cancer."", JOURNAL OF SURGICAL ONCOLOGY, NEW YORK, NY, US, vol. 106, no. 3, 1 September 2012 (2012-09-01), US , pages 286 - 293, XP002759705, ISSN: 0022-4790, DOI: 10.1002/jso.22150;;EKYUNE KIM, YOUNGJEON LEE, JI-SU KIM, BONG-SEOK SONG, SUN-UK KIM, JAE-WON HUH, SANG-RAE LEE, SANG-HYUN KIM, YONGGEUN HONG, KYU-TAE: ""Extracellular domain of V-set and immunoglobulin domain containing 1 (VSIG1) interacts with sertoli cell membrane protein, while its PDZ-binding motif forms a complex with ZO-1"", MOLECULES AND CELLS, SEOUL, KR, vol. 30, no. 5, 1 November 2010 (2010-11-01), KR , pages 443 - 448, XP055344846, ISSN: 1016-8478, DOI: 10.1007/s10059-010-0138-4;;Oidovsambuu et al. (2011) Adhesion Protein VSIG1 Is Required for the Proper Differentiation of Glandular Gastric Epithelia. PLoS ONE 6(10): e25908. doi:10.1371/journal.pone.0025908.;;Wilson et al., Comparative analysis of the paired immunoglobulin-like receptor (PILR) locus in six mammalian genomes: duplication, conversion, and the birth of new genes. Physiol Genomics. 2006;27(3):201-218. doi:10.1152/physiolgenomics.00284.2005.;;Kim et al., Gastric-type expression signature in serrated pathway-associated colorectal tumors., Human Pathology vol. 46, Issue 5, May 2015, pp. 643-656.;;U.S. Appl. No. 15/048,967, 2016-0244521, U.S. Pat. No. 10,227,408, filed Feb. 19, 2016, Aug. 25, 2016, Mar. 12, 2019.;;U.S. Appl. No. 15/277,978, 2017-0081408, U.S. Pat. No. 9,714,289, filed Sep. 27, 2016, Mar. 23, 2017, Jul. 25, 2017.;;U.S. Appl. No. 15/277,980, 2017-0029504, filed Sep. 27, 2016, Feb. 2, 2017.;;U.S. Appl. No. 15/896,040, 2018-0244774, U.S. Pat. No. 10,351,625, filed Feb. 13, 2018, Aug. 30, 2018, Jul. 16, 2019.;;U.S. Appl. No. 15/048,975, 2017-0088607, filed Feb. 19, 2016, Mar. 30, 2017.;;U.S. Appl. No. 16/775,133, filed Jan. 28, 2020.;;U.S. Appl. No. 15/680,187, 2018-0305456, filed Aug. 17, 2017, Oct. 25, 2018.;;U.S. Appl. No. 15/795,135, 2018-0169238, U.S. Pat. No. 10,124,061, filed Oct. 26, 2017, Jun. 21, 2018, Nov. 13, 2018.;;U.S. Appl. No. 15/937,784, 2018-0280506, U.S. Pat. No. 10,213,505, filed Mar. 27, 2018, Oct. 4, 2018, Feb. 26, 2019.;;U.S. Appl. No. 15/996,369, 2019-0010246, filed Jun. 1, 2018, Jan. 10, 2019.;;U.S. Appl. No. 16/428,856, 2019-0382477, filed May 31, 2019, Dec. 19, 2019.",ACTIVE
148,US,B2,US 10227408 B2,020-086-320-437-275,2019-03-12,2019,US 201615048967 A,2016-02-19,US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,Anti-PVRIG antibodies and methods of use,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/020-086-320-437-275,Granted Patent,yes,21,3,71,71,1543,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/00;;C07K7/06;;C07K16/28;;C12N15/113;;C12P21/08;;G01N33/574,,15,8,003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;022-608-838-432-215;;042-879-791-960-298;;028-947-110-430-895;;082-735-005-968-62X;;047-792-343-788-48X,19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;25465800;;10.1016/j.ccell.2014.10.018;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;28978021;;pmc5620161;;10.18632/oncotarget.18004;;22437872;;10.1038/nrc3236;;10.1016/j.cell.2012.02.034;;pmc3310896;;22424219,"U.S. Appl. No. 15/277,978, 2017-0081408, U.S. Pat. No. 9,714,289, Granted, filed Sep. 27, 2016, Mar. 23, 2017, Jul. 25, 2017.;;U.S. Appl. No. 15/277,980, 2017-0029504, Published, filed Sep. 27, 2016, Feb. 2, 2017.;;U.S. Appl. No. 15/896,040, Pending, filed Feb. 13, 2018.;;Gene Id: PVRIG antibody—middle region, Rabbit Polyclonal Antibody Catalog #Al13083, retrieved from the internet: URL:http://www.funakoshi.co.jp/data/datasheet/ABG/Al13083.pdf.;;Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): P135.;;Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Orentas et al., Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.;;U.S. Appl. No. 15/048,975, filed Feb. 19, 2016.;;He et al., Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., Oncotarget. May 19, 2017;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection Sep. 15, 2017.;;Scott et al., Antibody therapy of cancer., 2012, Nature Reviews, vol. 12: 278-287.;;Weiner et al., Antibody-based immunotherapy of cancer., Cell. Mar. 16, 2012;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034.",ACTIVE
149,AU,A1,AU 2016/219835 A1,025-426-501-496-207,2017-09-14,2017,AU 2016/219835 A,2016-02-19,US 201562141120 P;;US 201562118208 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,Anti-PVRIG antibodies and methods of use,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/025-426-501-496-207,Patent Application,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K14/00;;A61K38/00;;C07K16/28;;C12N15/113,,0,0,,,,ACTIVE
150,KR,A,KR 20170137067 A,092-618-604-674-068,2017-12-12,2017,KR 20177026353 A,2016-02-19,US 201562141120 P;;US 201562118208 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,항-PVRIG 항체 및 사용 방법,본 발명은 항-PVRIG 항체 및 이의 사용 방법에 관한 것이다.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/092-618-604-674-068,Patent Application,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;G01N33/574,,0,0,,,,ACTIVE
151,SI,T1,SI 3295951 T1,109-519-802-576-09X,2020-10-30,2020,SI 201630837 T,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;EP 17192325 A,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/109-519-802-576-09X,Granted Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61P35/00;;C07K16/00,,0,0,,,,ACTIVE
152,US,A1,US 2018/0244774 A1,139-838-215-621-390,2018-08-30,2018,US 201815896040 A,2018-02-13,US 201815896040 A;;US 201615277980 A;;US 201615048967 A;;US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,COMPUGEN LTD (2016-03-08);;COMPUGEN USA INC (2017-02-22),https://lens.org/139-838-215-621-390,Patent Application,yes,2,1,71,71,1543,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,C07K16/28;;C07K7/06;;G01N33/574,,0,0,,,,ACTIVE
153,PL,T3,PL 3295951 T3,143-838-553-686-546,2020-10-05,2020,PL 17192325 T,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;EP 17192325 A;;EP 16707603 A;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/143-838-553-686-546,Patent Application,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61P35/00;;C07K16/28,,0,0,,,,PENDING
154,HK,A1,HK 1247568 A1,084-961-566-322-077,2018-09-28,2018,HK 18107128 A,2018-05-31,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/084-961-566-322-077,Patent Application,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K/;;C07K/;;C12N/,,0,0,,,,PENDING
155,ZA,B,ZA 201706323 B,133-065-569-178-584,2020-05-27,2020,ZA 201706323 A,2017-09-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,MARK WHITE;;SANDEEP KUMAR;;CHRISTOPHER CHAN;;SPENCER LIANG;;LANCE STAPLETON;;ANDREW W DRAKE;;YOSI GOZLAN;;IIAN VAKNIN;;SHIRLEY SAMEAH-GREENWALD;;LIAT DASSA;;ZOHAR TIRAN;;GAD S COJOCARU;;LEONARD PRESTA;;RICHARD THEOLIS,,https://lens.org/133-065-569-178-584,Granted Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,,,0,0,,,,ACTIVE
156,DK,T3,DK 3258951 T3,024-601-673-273-957,2020-04-06,2020,DK 16707603 T,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTISTOFFER OG FREMGANGSMÅDER FOR ANVENDELSE,,COMPUGEN LTD,PRESTA LEONARD;;THEOLIS RICHARD;;WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S,,https://lens.org/024-601-673-273-957,Granted Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,0,0,,,,ACTIVE
157,ES,T3,ES 2806800 T3,019-498-569-402-882,2021-02-18,2021,ES 17192325 T,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,Anticuerpos anti-PVRIG y métodos de uso,"Un anticuerpo anti-PVRIG (proteína que contiene dominio de inmunoglobulina relacionada con receptor del poliovirus) que comprende i) el dominio variable de cadena pesada de SEQ ID NO: 1434 y ii) el dominio variable de cadena ligera de SEQ ID NO: 1453, para uso en el tratamiento del cáncer mediante la activación de células T en un paciente.",COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/019-498-569-402-882,Granted Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61P35/00;;C07K16/28,,0,0,,,,ACTIVE
158,HR,T1,HR P20201066 T1,016-098-671-116-418,2021-02-05,2021,HR P20201066 T,2020-07-07,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;EP 17192325 A,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/016-098-671-116-418,Granted Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61P35/00;;C07K16/28,,0,0,,,,ACTIVE
159,HK,A1,HK 1247569 A1,116-409-962-323-40X,2018-09-28,2018,HK 18107129 A,2018-05-31,US 201562118208 P;;US 201562141120 P;;US 201562235823 P,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/116-409-962-323-40X,Patent Application,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K/;;C07K/;;C12N/,,0,0,,,,PENDING
160,CY,T1,CY 1122970 T1,006-736-124-072-293,2021-10-29,2021,CY 201100381 T,2020-04-27,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-PVRIG ΚΑΙ ΜΕΘΟΔΟΙ ΧΡΗΣΗΣ,Η παρούσα εφεύρεση απευθύνεται σε αντισώματα αντι-ΡVRIG και μεθόδους χρήσης των ιδίων.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/006-736-124-072-293,Granted Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,0,0,,,,ACTIVE
161,LT,T,LT 3258951 T,057-361-344-228-036,2020-05-11,2020,LT 16707603 T,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/057-361-344-228-036,Unknown,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K38/00;;C07K14/00;;C07K16/28;;C12N15/113,,0,0,,,,PENDING
162,CN,A,CN 107580500 A,092-862-424-321-075,2018-01-12,2018,CN 201680023677 A,2016-02-19,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;US 2016/0018809 W,2015-02-19,ANTI-PVRIG ANTIBODIES AND METHODS OF USE,The present invention is directed to anti-PVRIG antibodies and methods of using same.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/092-862-424-321-075,Patent Application,no,3,9,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61K39/395;;A61P35/00;;C07K16/28;;C12N15/13;;G01N33/574,,5,0,,,"NOA STANIETSKY 等: ""The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity"", 《PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES》;;XIN YU等: ""The Surface Protein TIGIT Suppresses T Cell Activation by Promoting the Generation of Mature Immunoregulatory Dendritic Cells"", 《NATURE IMMUNOLOGY》;;CRISTINA BOTTINO等: ""Identification of PVR (CD155) and Nectin-2 (CD112) as Cell Surface Ligands for the Human DNAM-1 (CD226) Activating Molecule"", 《THE JOURNAL OF EXPERIMENTAL MEDICINE》;;YUWEN ZHU等: ""Identification of CD112R as a novel checkpoint for human T cells"", 《THE JOURNAL OF EXPERIMENTAL MEDICINE》;;ABGENT: ""Gene ID:“PVRIG antibody -middle region Rabbit Polyclonal Antibody Catalog#AI13083”"", 《HTTP://WWW.FUNAKOSHI.CO.JP/DATA/DATASHEET/ABG/AI13083.PDF》",ACTIVE
163,CY,T1,CY 1123259 T1,128-735-143-798-777,2021-12-31,2021,CY 201100669 T,2020-07-21,US 201562118208 P;;US 201562141120 P;;US 201562235823 P;;EP 16707603 A;;US 2016/0018809 W,2015-02-19,ΑΝΤΙΣΩΜΑΤΑ ANTI-PVRIG ΚΑΙ ΜΕΘΟΔΟΙ ΧΡΗΣΗΣ,Η παρούσα εφεύρεση απευθύνεται σε αντισώματα αντι-PVRIG και μεθόδους χρήσης των ιδίων.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/128-735-143-798-777,Granted Patent,no,0,0,71,71,0,C07K16/2803;;G01N33/57484;;C07K2317/565;;C07K2317/76;;C07K2317/33;;C07K2317/34;;C07K2317/70;;C07K2317/56;;C12N2310/14;;C07K2317/21;;G01N2333/47;;C07K2317/92;;A61K2039/505;;C07K2317/55;;C07K2317/53;;C07K2317/74;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/76;;C07K2317/92;;G01N33/57484;;A61P35/00;;A61P35/02;;A61P37/04;;A61P43/00;;C07K16/2803;;A61P35/00;;C07K2317/21;;C07K2317/55;;C07K2317/74;;C07K2319/32;;G01N2333/47;;A61P43/00;;C07K2317/53;;C07K2317/70;;C07K2319/30;;C12N2310/14;;A61P35/02;;C07K2317/33;;C07K2317/56;;C07K2317/76;;C07K7/06;;G01N33/57484;;A61P37/04;;C07K2317/34;;C07K2317/565;;C07K2317/92;;C12N15/1138;;A61K39/395;;C07K16/2803;;G01N33/57484;;C07K2317/21;;C07K2317/33;;C07K2317/34;;C07K2317/53;;C07K2317/55;;C07K2317/56;;C07K2317/565;;C07K2317/74;;C07K2317/76;;A61K39/395;;A61P35/00;;C07K2317/33;;C07K2317/70;;C07K2317/74;;C07K2319/30;;C07K2319/32;;C07K7/06;;C12N15/1138;;C12N2310/14;;C07K16/2803;;C07K2317/21;;C07K2317/55;;C07K2317/565;;C07K2317/76;;C07K2317/92;;G01N33/57484;;G01N2333/47;;C07K2317/34;;C07K2317/53;;C07K2317/56,A61P35/00;;C07K16/28,,0,0,,,,ACTIVE
164,US,B2,US 10550173 B2,121-213-925-552-891,2020-02-04,2020,US 201615048975 A,2016-02-19,US 201615048975 A;;US 201562118235 P;;US 201562141168 P,2015-02-19,PVRIG polypeptides and methods of treatment,The present invention is directed to PVRIG polypeptides and their uses.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;TOPORIK AMIR;;KLIGER YOSSEF;;LEVY OFER;;MACHLENKIN ARTHUR;;NEMZER SERGEY;;BENITA YAIR;;NOVIK AMIT,COMPUGEN LTD (2016-03-04),https://lens.org/121-213-925-552-891,Granted Patent,yes,25,2,12,12,1589,G01N33/5011;;G01N33/574;;G01N2500/02;;C07K7/06;;C07K14/70503;;C07K16/2803;;C07K16/2818;;A61K2039/507;;C07K2317/74;;C12N15/1138;;C12N2310/14;;A61P35/00;;A61P37/00;;Y02A50/30;;G01N33/574;;G01N33/5011;;C12N15/1138;;C07K16/2818;;C07K7/06;;C12N2310/14;;C07K16/2803;;C07K2317/74;;G01N2500/02;;C07K14/70503;;A61K2039/507;;Y02A50/30;;C07K16/1009;;C07K2319/30;;G01N33/502;;G01N33/505;;G01N2333/70596;;G01N2500/10,C07K16/28;;C07K16/10;;G01N33/50;;G01N33/53,,14,8,003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;022-608-838-432-215;;042-879-791-960-298;;028-947-110-430-895;;082-735-005-968-62X;;047-792-343-788-48X,19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;25465800;;10.1016/j.ccell.2014.10.018;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;28978021;;pmc5620161;;10.18632/oncotarget.18004;;22437872;;10.1038/nrc3236;;10.1016/j.cell.2012.02.034;;pmc3310896;;22424219,"Quinones et al. Molecular Biology of the Cell (2011) 22(24): 2205.;;Gene ID: PVRIG antibody—middle region, Rabbit Polyclonal Antibody Catalog #Al13083, retrieved from the internet: URL:http://www.funakoshi.co.jp/data/datasheet/ABG/Al13083.pdf.;;Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): p. 135.;;Johnston et al., The innnnunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Orentas et al., Bioinformatics description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.;;He et al., Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., Oncotarget. May 19, 2017;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection Sep. 15, 2017.;;Scott et al., Antibody therapy of cancer., 2012, Nature Reviews, vol. 12: 278-287.;;Weiner et al., Antibody-based immunotherapy of cancer., Cell. Mar. 16, 2012;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034.;;U.S. Appl. No. 15/277,978, 2017-0081408, U.S. Pat. No. 9,714,289, filed Sep. 27, 2016, Mar. 23, 2017, Jul. 25, 2017.;;U.S. Appl. No. 15/277,980, 2017-0029504, filed Feb. 2, 2017.",ACTIVE
165,WO,A2,WO 2016/134335 A2,022-964-983-047-541,2016-08-25,2016,US 2016/0018811 W,2016-02-19,US 201562118235 P;;US 201562141168 P,2015-02-19,PVRIG POLYPEPTIDES AND METHODS OF TREATMENT,The present invention is directed to PVRIG polypeptides and their uses.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;LEVY OFER;;MACHLENKIN ARTHUR;;TOPORIK AMIR;;KLIGER YOSSEF;;NEMZER SERGEY;;NOVIK AMIT;;BENITA YAIR,,https://lens.org/022-964-983-047-541,Patent Application,yes,27,34,12,12,1588,G01N33/5011;;G01N33/574;;G01N2500/02;;C07K7/06;;C07K14/70503;;C07K16/2803;;C07K16/2818;;A61K2039/507;;C07K2317/74;;C12N15/1138;;C12N2310/14;;A61P35/00;;A61P37/00;;Y02A50/30;;G01N33/574;;G01N33/5011;;C12N15/1138;;C07K16/2818;;C07K7/06;;C12N2310/14;;C07K16/2803;;C07K2317/74;;G01N2500/02;;C07K14/70503;;A61K2039/507;;Y02A50/30;;C07K16/1009;;C07K2319/30;;G01N33/502;;G01N33/505;;G01N2333/70596;;G01N2500/10,G01N33/574,,27,23,055-941-254-232-339;;010-801-824-793-588;;079-191-303-518-861;;061-453-882-230-419;;097-637-621-469-520;;004-458-031-333-650;;033-955-564-406-161;;024-929-137-199-30X;;003-752-183-823-430;;070-318-112-524-781;;032-624-544-479-82X;;026-744-100-669-883;;051-940-176-386-905;;029-667-686-534-996;;089-633-612-001-004;;004-963-265-392-765;;111-638-562-943-009;;008-355-672-565-201;;085-309-020-554-932;;003-082-950-776-533;;022-608-838-432-215;;007-041-645-879-370;;103-324-341-200-971,10.1016/j.semcancer.2005.07.009;;16140545;;10.1146/annurev.immunol.23.021704.115611;;15771580;;15771565;;10.1146/annurev.immunol.23.021704.115839;;10.1158/1078-0432.ccr-07-0016;;17606736;;10.1016/s0165-2478(02)00019-6;;12008035;;11096108;;10.1074/jbc.m009483200;;10.1038/nri2761;;20414204;;10.1002/bit.20151;;15352059;;11986321;;10.1074/jbc.m202069200;;10.1038/6179;;10052355;;1201277;;10.1021/bi00696a021;;pmc363152;;10.1128/mcb.8.1.466-472.1988;;2827008;;10.1128/mcb.8.1.466;;10.1073/pnas.77.7.4216;;pmc349802;;6933469;;6292436;;10.1016/0022-2836(82)90103-6;;6933450;;pmc349762;;10.1073/pnas.77.7.4030;;23118781;;10.1155/2012/720803;;pmc3483734;;21349771;;10.1016/j.clim.2011.01.009;;pmc2820677;;10.1093/bioinformatics/btp692;;20022975;;pmc3146043;;20436464;;10.1038/nbt.1621;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;25465800;;10.1016/j.ccell.2014.10.018;;10.1126/science.1129003;;pmc2267026;;16946036;;17141800;;10.1016/j.jim.2006.08.015,"WANG: ""Immune Suppression by Tumor Specific CD4+ Regulatory T cells in Cancer"", SEMIN. CANCER. BIOL., vol. 16, 2006, pages 73 - 79, XP024908039, DOI: doi:10.1016/j.semcancer.2005.07.009;;GREENWALD ET AL.: ""The B7 Family Revisited"", ANN. REV. IMMUNOL., vol. 23, 2005, pages 515 - 548, XP002481408, DOI: doi:10.1146/annurev.immunol.23.021704.115611;;WATTS: ""TNF/TNFR Family Members in Co-stimulation of T Cell Responses"", ANN. REV. IMMUNOL., vol. 23, 2005, pages 23 - 68, XP008051583, DOI: doi:10.1146/annurev.immunol.23.021704.115839;;SADUM ET AL.: ""Immune Signatures of Murine and Human Cancers Reveal Unique Mechanisms of Tumor Escape and New Targets for Cancer Immunotherapy"", CLIN. CANC. RES., vol. 13, no. 13, 2007, pages 4016 - 4025, XP055248327, DOI: doi:10.1158/1078-0432.CCR-07-0016;;JEFFERIS ET AL., IMMUNOL LETT, vol. 82, 2002, pages 57 - 65;;SHIELDS, R. L. ET AL., J BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;CHAN CA; CARTER PJ, NATURE REV IMMUNOL, vol. 10, 2010, pages 301 - 316;;YAMANE-OHNUKI ET AL., BIOTECHNOL BIOENG, vol. 87, 2004, pages 614 - 622;;SHIELDS, R. L. ET AL., J BIOL. CHEM., vol. 277, 2002, pages 26733 - 26740;;UMANA ET AL., NAT. BIOTECH., vol. 17, 1999, pages 176 - 180;;TARENTINO, A. L. ET AL., BIOCHEM., vol. 14, 1975, pages 5516 - 5523;;GOEDDEL: ""Methods in Enzymology"", vol. 185, 1990, ACADEMIC PRESS, article ""Gene Expression Technology"";;TAKEBE, Y. ET AL., MOL. CELL. BIOL., vol. 8, 1988, pages 466 - 472;;URLAUB; CHASIN, PROC. NATL. ACAD. SCI. USA, vol. 77, 1980, pages 4216 - 4220;;R. J. KAUFMAN; P. A. SHARP, MOL. BIOL., vol. 159, 1982, pages 601 - 621;;""Current Protocols in Molecular Biology"", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE;;A. OSAL: ""Remington's Pharmaceutical Sciences. 16th ed."", 1980;;EPSTEIN ET AL., PROC NATL ACAD SCI USA, vol. 82, 1985, pages 3688;;HWANG ET AL., PROC NATL ACAD SCI USA, vol. 77, 1980, pages 4030;;CLIN DEV IMMUNOL., 2012, pages 720803;;CLIN IMMUNOL., vol. 140, no. 2, August 2011 (2011-08-01), pages 167 - 176;;BO ET AL., BIOINFORMATICS, vol. 26, no. 4, 2010, pages 493 - 500;;TRAPNELL ET AL., NAT BIOTECHNOL., vol. 28, no. 5, May 2010 (2010-05-01), pages 511 - 515;;NOA STANIETSKY, JOURNAL OF IMMUNOLOGY, vol. 106, no. 42, pages 17858 - 17863;;ROBERT J JOHNSTON, CANCER CELL, vol. 26, no. 6, 8 December 2014 (2014-12-08), pages 923 - 937;;MORGAN ET AL., SCIENCE, vol. 314, 2006, pages 126 - 129;;DRAKE; KLAKAMP, JOURNAL OF IMMUNOL METHODS, vol. 318, 2007, pages 147 - 152",PENDING
166,DK,T3,DK 3259597 T3,103-180-114-775-126,2022-05-09,2022,DK 16711051 T,2016-02-19,US 201562118235 P;;US 201562141168 P;;US 2016/0018811 W,2015-02-19,PVRIG-POLYPEPTIDER OG FREMGANGSMÅDER TIL BEHANDLING,,COMPUGEN LTD,NEMZER SERGEY;;NOVIK AMIT;;BENITA YAIR;;WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;LEVY OFER;;MACHLENKIN ARTHUR;;TOPORIK AMIR;;KLIGER YOSSEF,,https://lens.org/103-180-114-775-126,Granted Patent,no,0,0,12,12,0,G01N33/5011;;G01N33/574;;G01N2500/02;;C07K7/06;;C07K14/70503;;C07K16/2803;;C07K16/2818;;A61K2039/507;;C07K2317/74;;C12N15/1138;;C12N2310/14;;A61P35/00;;A61P37/00;;Y02A50/30;;G01N33/574;;G01N33/5011;;C12N15/1138;;C07K16/2818;;C07K7/06;;C12N2310/14;;C07K16/2803;;C07K2317/74;;G01N2500/02;;C07K14/70503;;A61K2039/507;;Y02A50/30;;C07K16/1009;;C07K2319/30;;G01N33/502;;G01N33/505;;G01N2333/70596;;G01N2500/10,G01N33/574;;A61P35/00;;A61P37/00;;C07K14/00;;C07K16/00;;G01N33/50,,0,0,,,,ACTIVE
167,US,A1,US 2024/0025973 A1,179-293-872-882-527,2024-01-25,2024,US 202318460523 A,2023-09-01,US 202318460523 A;;US 202016775133 A;;US 201615048975 A;;US 201562141168 P;;US 201562118235 P,2015-02-19,PVRIG POLYPEPTIDES AND METHODS OF TREATMENT,The present invention is directed to PVRIG polypeptides and their uses.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;TOPORIK AMIR;;KLIGER YOSSEF;;LEVY OFER;;MACHLENKIN ARTHUR;;NEMZER SERGEY;;BENITA YAIR;;NOVIK AMIT,,https://lens.org/179-293-872-882-527,Patent Application,yes,0,0,12,12,0,G01N33/5011;;G01N33/574;;G01N2500/02;;C07K7/06;;C07K14/70503;;C07K16/2803;;C07K16/2818;;A61K2039/507;;C07K2317/74;;C12N15/1138;;C12N2310/14;;A61P35/00;;A61P37/00;;Y02A50/30;;G01N33/574;;G01N33/5011;;C12N15/1138;;C07K16/2818;;C07K7/06;;C12N2310/14;;C07K16/2803;;C07K2317/74;;G01N2500/02;;C07K14/70503;;A61K2039/507;;Y02A50/30;;C07K16/1009;;C07K2319/30;;G01N33/502;;G01N33/505;;G01N2333/70596;;G01N2500/10,C07K16/10;;C07K7/06;;C07K14/705;;C07K16/28;;C12N15/113;;G01N33/50;;G01N33/574,,0,0,,,,PENDING
168,EP,B1,EP 3259597 B1,152-665-683-118-516,2022-04-06,2022,EP 16711051 A,2016-02-19,US 201562118235 P;;US 201562141168 P;;US 2016/0018811 W,2015-02-19,PVRIG POLYPEPTIDES AND METHODS OF TREATMENT,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;LEVY OFER;;MACHLENKIN ARTHUR;;TOPORIK AMIR;;KLIGER YOSSEF;;NEMZER SERGEY;;NOVIK AMIT;;BENITA YAIR,,https://lens.org/152-665-683-118-516,Granted Patent,yes,1,0,12,12,0,G01N33/5011;;G01N33/574;;G01N2500/02;;C07K7/06;;C07K14/70503;;C07K16/2803;;C07K16/2818;;A61K2039/507;;C07K2317/74;;C12N15/1138;;C12N2310/14;;A61P35/00;;A61P37/00;;Y02A50/30;;G01N33/574;;G01N33/5011;;C12N15/1138;;C07K16/2818;;C07K7/06;;C12N2310/14;;C07K16/2803;;C07K2317/74;;G01N2500/02;;C07K14/70503;;A61K2039/507;;Y02A50/30;;C07K16/1009;;C07K2319/30;;G01N33/502;;G01N33/505;;G01N2333/70596;;G01N2500/10,G01N33/574;;A61P35/00;;A61P37/00;;C07K14/00;;C07K16/00;;G01N33/50,,5,3,100-399-671-580-29X;;013-122-792-588-081;;051-218-620-433-15X,10.1084/jem.20150785;;26755705;;pmc4749091;;10.4049/jimmunol.170.3.1257;;12538684;;24872026;;10.1158/2326-6066.cir-14-0040,"ZHU ET AL.: ""Identification of CD 112R as a novel checkpoint for human T cells"", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 213, no. 2, 8 February 2016 (2016-02-08), NEW YORK, NY, USA, pages 167 - 176, XP055314642, DOI: 10.1084/jem.20150785;;QUINONES ET AL.: ""2205 High-Throughput Cellular Assays Using A Well-Less Plate Format"", ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY, 7 December 2011 (2011-12-07), XP093014465;;QUINONES, ET AL.: ""High-throughput cellular assays using a well-less plate format"", POSTER ABSTRACT NO. 2205 (NEW TECHNOLOGIES AND FRONTIERS), 2011 AMERICAN SOCIETY FOR CELL BIOLOGY (ASCB) ANNUAL MEETING, DENVER , CO, 3 December 2011 (2011-12-03), pages 1 - 3, XP055748047, [retrieved on 20201109];;BROWN ET AL.: ""Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1"", J IMMUNOL, vol. 170, no. 3, 1 February 2003 (2003-02-01), pages 1257 - 1266, XP002973918;;WANG ET AL.: ""In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates"", CANCER IMMUNOL RES, vol. 2, no. 9, 1 September 2014 (2014-09-01), pages 846 - 856, XP055563054, DOI: 10.1158/2326-6066.CIR-14-0040",ACTIVE
169,WO,A9,WO 2016/134335 A9,039-283-672-785-524,2016-10-13,2016,US 2016/0018811 W,2016-02-19,US 201562118235 P;;US 201562141168 P,2015-02-19,PVRIG POLYPEPTIDES AND METHODS OF TREATMENT,The present invention is directed to PVRIG polypeptides and their uses.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;LEVY OFER;;MACHLENKIN ARTHUR;;TOPORIK AMIR;;KLIGER YOSSEF;;NEMZER SERGEY;;NOVIK AMIT;;BENITA YAIR,,https://lens.org/039-283-672-785-524,Search Report,yes,0,1,12,12,0,G01N33/5011;;G01N33/574;;G01N2500/02;;C07K7/06;;C07K14/70503;;C07K16/2803;;C07K16/2818;;A61K2039/507;;C07K2317/74;;C12N15/1138;;C12N2310/14;;A61P35/00;;A61P37/00;;Y02A50/30;;G01N33/574;;G01N33/5011;;C12N15/1138;;C07K16/2818;;C07K7/06;;C12N2310/14;;C07K16/2803;;C07K2317/74;;G01N2500/02;;C07K14/70503;;A61K2039/507;;Y02A50/30;;C07K16/1009;;C07K2319/30;;G01N33/502;;G01N33/505;;G01N2333/70596;;G01N2500/10,G01N33/574,,0,0,,,,PENDING
170,WO,A3,WO 2016/134335 A3,025-644-465-276-420,2016-11-03,2016,US 2016/0018811 W,2016-02-19,US 201562118235 P;;US 201562141168 P,2015-02-19,PVRIG POLYPEPTIDES AND METHODS OF TREATMENT,The present invention is directed to PVRIG polypeptides and their uses.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;LEVY OFER;;MACHLENKIN ARTHUR;;TOPORIK AMIR;;KLIGER YOSSEF;;NEMZER SERGEY;;NOVIK AMIT;;BENITA YAIR,,https://lens.org/025-644-465-276-420,Search Report,yes,3,0,12,12,0,G01N33/5011;;G01N33/574;;G01N2500/02;;C07K7/06;;C07K14/70503;;C07K16/2803;;C07K16/2818;;A61K2039/507;;C07K2317/74;;C12N15/1138;;C12N2310/14;;A61P35/00;;A61P37/00;;Y02A50/30;;G01N33/574;;G01N33/5011;;C12N15/1138;;C07K16/2818;;C07K7/06;;C12N2310/14;;C07K16/2803;;C07K2317/74;;G01N2500/02;;C07K14/70503;;A61K2039/507;;Y02A50/30;;C07K16/1009;;C07K2319/30;;G01N33/502;;G01N33/505;;G01N2333/70596;;G01N2500/10,G01N33/574;;A61P35/00;;A61P37/00;;C07K14/00;;C07K16/00;;G01N33/50,,3,1,100-399-671-580-29X,10.1084/jem.20150785;;26755705;;pmc4749091,"ZHU YUWEN ET AL: ""Identification of CD112R as a novel checkpoint for human T cells"", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIV. PRESS, NEW YORK, NY, USA, vol. 213, no. 2, 8 February 2016 (2016-02-08), pages 167 - 176, XP009190107, ISSN: 1540-9538;;GALIT ROTMAN ET AL: ""Identification of novel immune checkpoints as targets for cancer immunotherapy"", JOURNAL FOR IMMUNOTHERAPY OF CANCER, BIOMED CENTRAL LTD, LONDON, UK, vol. 1, no. Suppl 1, 7 November 2013 (2013-11-07), pages P135, XP021167082, ISSN: 2051-1426, DOI: 10.1186/2051-1426-1-S1-P135;;GENE ID: ""PVRIG antibody -middle region Rabbit Polyclonal Antibody Catalog # AI13083 Specification PVRIG antibody -middle region -Product Information Application WB Primary Accession Q6DKI7 Other Accession NM_024070, NP_076975 Reactivity Human Predicted Human Host Rabbit Clonality Polyclonal Calculated MW 34k"", PHYSIOL. GENOMICS, 1 January 2006 (2006-01-01), pages 201 - 218, XP055273924, Retrieved from the Internet <URL:http://www.funakoshi.co.jp/data/datasheet/ABG/AI13083.pdf>",PENDING
171,EP,A2,EP 3259597 A2,055-265-126-007-603,2017-12-27,2017,EP 16711051 A,2016-02-19,US 201562118235 P;;US 201562141168 P;;US 2016/0018811 W,2015-02-19,PVRIG POLYPEPTIDES AND METHODS OF TREATMENT,,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN IIAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;LEVY OFER;;MACHLENKIN ARTHUR;;TOPORIK AMIR;;KLIGER YOSSEF;;NEMZER SERGEY;;NOVIK AMIT;;BENITA YAIR,,https://lens.org/055-265-126-007-603,Patent Application,yes,0,1,12,12,0,G01N33/5011;;G01N33/574;;G01N2500/02;;C07K7/06;;C07K14/70503;;C07K16/2803;;C07K16/2818;;A61K2039/507;;C07K2317/74;;C12N15/1138;;C12N2310/14;;A61P35/00;;A61P37/00;;Y02A50/30;;G01N33/574;;G01N33/5011;;C12N15/1138;;C07K16/2818;;C07K7/06;;C12N2310/14;;C07K16/2803;;C07K2317/74;;G01N2500/02;;C07K14/70503;;A61K2039/507;;Y02A50/30;;C07K16/1009;;C07K2319/30;;G01N33/502;;G01N33/505;;G01N2333/70596;;G01N2500/10,G01N33/574;;A61P35/00;;A61P37/00;;C07K14/00;;C07K16/00;;G01N33/50,,0,0,,,,ACTIVE
172,US,A1,US 2020/0385445 A1,090-205-059-298-74X,2020-12-10,2020,US 202016775133 A,2020-01-28,US 202016775133 A;;US 201615048975 A;;US 201562141168 P;;US 201562118235 P,2015-02-19,PVRIG POLYPEPTIDES AND METHODS OF TREATMENT,The present invention is directed to PVRIG polypeptides and their uses.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;TOPORIK AMIR;;KLIGER YOSSEF;;LEVY OFER;;MACHLENKIN ARTHUR;;NEMZER SERGEY;;BENITA YAIR;;NOVIK AMIT,COMPUGEN LTD (2016-03-08),https://lens.org/090-205-059-298-74X,Patent Application,yes,2,0,12,12,1589,G01N33/5011;;G01N33/574;;G01N2500/02;;C07K7/06;;C07K14/70503;;C07K16/2803;;C07K16/2818;;A61K2039/507;;C07K2317/74;;C12N15/1138;;C12N2310/14;;A61P35/00;;A61P37/00;;Y02A50/30;;G01N33/574;;G01N33/5011;;C12N15/1138;;C07K16/2818;;C07K7/06;;C12N2310/14;;C07K16/2803;;C07K2317/74;;G01N2500/02;;C07K14/70503;;A61K2039/507;;Y02A50/30;;C07K16/1009;;C07K2319/30;;G01N33/502;;G01N33/505;;G01N2333/70596;;G01N2500/10,C07K16/10;;C07K7/06;;C07K14/705;;C07K16/28;;C12N15/113;;G01N33/50;;G01N33/574,,0,0,,,,ACTIVE
173,US,B2,US 11795209 B2,089-897-737-701-361,2023-10-24,2023,US 202016775133 A,2020-01-28,US 202016775133 A;;US 201615048975 A;;US 201562141168 P;;US 201562118235 P,2015-02-19,PVRIG polypeptides and methods of treatment,The present invention is directed to PVRIG polypeptides and their uses.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;TOPORIK AMIR;;KLIGER YOSSEF;;LEVY OFER;;MACHLENKIN ARTHUR;;NEMZER SERGEY;;BENITA YAIR;;NOVIK AMIT,COMPUGEN LTD (2016-03-08),https://lens.org/089-897-737-701-361,Granted Patent,yes,66,0,12,12,1589,G01N33/5011;;G01N33/574;;G01N2500/02;;C07K7/06;;C07K14/70503;;C07K16/2803;;C07K16/2818;;A61K2039/507;;C07K2317/74;;C12N15/1138;;C12N2310/14;;A61P35/00;;A61P37/00;;Y02A50/30;;G01N33/574;;G01N33/5011;;C12N15/1138;;C07K16/2818;;C07K7/06;;C12N2310/14;;C07K16/2803;;C07K2317/74;;G01N2500/02;;C07K14/70503;;A61K2039/507;;Y02A50/30;;C07K16/1009;;C07K2319/30;;G01N33/502;;G01N33/505;;G01N2333/70596;;G01N2500/10,G01N33/53;;A61K39/00;;C07K7/06;;C07K14/705;;C07K16/10;;C07K16/28;;C12N15/113;;G01N33/50;;G01N33/574,,33,24,003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;022-608-838-432-215;;042-879-791-960-298;;028-947-110-430-895;;082-735-005-968-62X;;047-792-343-788-48X;;020-883-295-175-85X;;003-204-276-209-117;;016-022-019-007-80X;;042-171-846-329-572;;080-252-306-108-27X;;051-707-000-800-833;;016-291-551-264-744;;052-579-262-928-039;;009-863-107-597-216;;027-447-792-135-350;;124-685-610-132-547;;001-377-831-676-789;;020-748-493-197-572;;001-400-252-595-282;;013-122-792-588-081;;051-218-620-433-15X,19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;25465800;;10.1016/j.ccell.2014.10.018;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;28978021;;pmc5620161;;10.18632/oncotarget.18004;;22437872;;10.1038/nrc3236;;10.1016/j.cell.2012.02.034;;pmc3310896;;22424219;;10.4161/viru.26153;;pmc5359721;;23979029;;26870003;;pmc4740385;;10.3389/fmicb.2016.00022;;10.1200/jco.2017.35.15_suppl.3074;;10.1158/1538-7445.am2017-581;;10.1634/theoncologist.2014-0422;;26069281;;pmc4492230;;12079396;;10.1016/s0022-2836(02)00264-4;;1512548;;10.1084/jem.176.3.855;;pmc2119366;;16405301;;22095633;;10.1002/jso.22150;;20957455;;10.1007/s10059-010-0138-4;;21991385;;pmc3186807;;10.1371/journal.pone.0025908;;16926269;;10.1152/physiolgenomics.00284.2005;;10.1016/j.humpath.2015.01.003;;25704805;;11036658;;10.1016/s0076-6879(00)26070-9;;10.4049/jimmunol.170.3.1257;;12538684;;24872026;;10.1158/2326-6066.cir-14-0040,"Gene ID: PVRIG antibody—middle region, Rabbit Polyclonal Antibody Catalog #AI13083, retrieved from the internet: URL:http://www.funakoshi.co.jp/data/datasheet/ABG/AI13083.pdf.;;Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci USA. Oct. 20, 2009;106(42):17858-63.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): P135.;;Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Orentas et al., Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.;;He et al., Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., Oncotarget. May 19, 2017;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection Sep. 15, 2017.;;Scott et al., Antibody therapy of cancer., 2012, Nature Reviews, vol. 12: 278-287.;;Weiner et al., Antibody-based immunotherapy of cancer., Cell. Mar. 16, 2012;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034.;;Nosanchuk JD., The interdependence of antibody C and V regions on specificity and affinity: significant implications for the engineering of therapeutic antibodies., Virulence. Aug. 15, 2013;4(6):439-40. doi: 10.4161/viru.26153.;;Janda et al., Ig Constant Region Effects on Variable Region Structure and Function., Front Microbiol. Feb. 4, 2016;7:22. doi: 10.3389/fmicb.2016.00022. eCollection 2016.;;Liang et al., “Discovery of COM701, a therapeutic antibody targeting the novel imnune checkpoint PVRIG, for the treatment of cancer”, Journal of Clinical Oncology, American Society of Clinical Oncology, US , vol. 35, No. 15 suppl May 20, 2017 (May 20, 2017), p. 3074.;;Anonymous: “Medimnune to Develop Compugen Imnuno-Oncology Antibodies”, Genetic Engineering and Biotechnology News, Apr. 2, 2018 (Apr. 2, 2018), XP055605563, Retrieved from the Internet: url:https://www.genengnews.com/topics/drug -discover/medimnune-to-develop-compugen-i mnuno-oncolgy-antibodies/[retrieved on Jul. 15, 2019].;;Levy et al., Abstract 581: Discovery and development of COM701, a therapeutic antibody targeting the novel immune checkpoint PVRIG., Cancer Research, 1 Apr. 1, 2017 (Apr. 1, 2017), p. 581, XP055506734.;;Pennock et al., “The Evolving Role of Inmune Checkpoint Inhibitors in Cancer Treatment.”, The Oncologist, Jun. 11, 2015 (Jun. 11, 2015), pp. 812-822, XP055320470.;;Ophir et al., “Discovery and Development of COM701, a Therapeutic Antibody Targeting the Novel Inmune Checkpoint PVRIG.”, POS, Jun. 4, 2017 (Jun. 4, 2017), p. 169, XP055506726.;;Vajdos et al., 2002, Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis, J. Mol. Biol. vol. 320: 415-428.;;Chen et al., 1992, Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen., J. Exp. Med. vol. 176: 855-866.;;Alvarez M., et al., Increased Antitumor Effects Using IL-2 with Anti-TGF-β Reveals Competition between Mouse NK and CD8 T Cells. J Immunol 2014; 193:1709-1716; Prepublished online Jul. 7, 2014.;;Scanlan et al : 11 Gl ycoprotein 1-47 A34, a novel t arget for antibody-based cancer inrnunotherapy, Cancer Immunity, Academy of Cancer Immunology, CH, vol. 6, Jan. 1, 2006.;;R&d Systems: 11 Human VSIGI Antibody, Catalog No. MAB4818 R&D Systems Catalog, Oct. 13, 2015 (Oct. 13, 2015), pp. 1-2.;;Chen Y et al: Decreased expression of V-set and immunoglobulin domain containing 1 (VSIGI) is associated with poor prognosis in primary gastric cancer, Journal of Surgical Oncology, New York, NY, US, vol. 106 , No. 3, Sep. 1, 2012 (Sep. 1, 2012), pp. 286-293, XP002759705.;;Kim et al: 11 Extracellular domain of V-set and immunoglobulin domain containing 1 (VSIGI) interacts with sertoli cell membrane protein, while its PDZ-binding motif forms a complex with Z0-1, Molecules and Cells, vol. 30, No. 5, Oct. 14, 2010 (Oct. 14, 2010), pp. 443-448, XP055344846.;;Oidovsambuu et al. (2011) Adhesion Protein VSIGI Is Required for the Proper Differentiation of Glandular Gastric Epithelia. PLoS ONE 6(10): e25908. doi:10.1371/journal.pone.0025908.;;Wilson et al., Comparative analysis of the paired immunoglobulin-like receptor (PILR) locus in six mammalian genomes: duplication, conversion, and the birth of new genes. Physiol Genomics. 2006;27(3):201-218. doi:10.1152/physiolgenomics.00284.2005.;;Kim et al., Gastric-type expression signature in serrated pathway-associated colorectal tumors., Human Pathology vol. 46, Issue 5, May 2015, pp. 643-656.;;Tomlinson et. al., Methods for generating multivalent and bispecific antibody fragments., 2000, Methods Enzymol. 326:461-479.;;Brown, et al., “Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1”, J. Immunol, Feb. 1, 2003, 170(3): pp. 1257-1266.;;Quinones et al., “2205 High-Throughput Cellular Assays Using A Well-Less Plate Format”, Poster presented at the Annual Meeting of the American Society for Cell Biology (ASCB Dec. 3-7, 2011).;;Quinones et al., “2205 High-Throughput Cellular Assays Using a Well-Less Plate Format”, Abstract, published Monday Dec. 5, 2011.;;Wang, et al., “In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivoi Toxicology in Non-Human Primates”, Cancer Immun. Res., Sep. 1, 2014, 2(9): pp. 943-856.",ACTIVE
174,US,A1,US 2017/0088607 A1,026-068-201-310-801,2017-03-30,2017,US 201615048975 A,2016-02-19,US 201615048975 A;;US 201562118235 P;;US 201562141168 P,2015-02-19,PVRIG POLYPEPTIDES AND METHODS OF TREATMENT,The present invention is directed to PVRIG polypeptides and their uses.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;TOPORIK AMIR;;KLIGER YOSSEF;;LEVY OFER;;MACHLENKIN ARTHUR;;NEMZER SERGEY;;BENITA YAIR;;NOVIK AMIT,COMPUGEN LTD (2016-03-04),https://lens.org/026-068-201-310-801,Patent Application,yes,6,4,12,12,1588,G01N33/5011;;G01N33/574;;G01N2500/02;;C07K7/06;;C07K14/70503;;C07K16/2803;;C07K16/2818;;A61K2039/507;;C07K2317/74;;C12N15/1138;;C12N2310/14;;A61P35/00;;A61P37/00;;Y02A50/30;;G01N33/574;;G01N33/5011;;C12N15/1138;;C07K16/2818;;C07K7/06;;C12N2310/14;;C07K16/2803;;C07K2317/74;;G01N2500/02;;C07K14/70503;;A61K2039/507;;Y02A50/30;;C07K16/1009;;C07K2319/30;;G01N33/502;;G01N33/505;;G01N2333/70596;;G01N2500/10,C07K16/10;;G01N33/50,,1,0,,,Quinones et al. Molecular Biology of the Cell (2011) 22(24): 2205.,ACTIVE
175,HU,T2,HU E048313 T2,196-415-130-852-483,2020-07-28,2020,HU E17797429 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/196-415-130-852-483,Amended Patent,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,PENDING
176,LT,T,LT 3347379 T,026-948-506-779-817,2020-05-11,2020,LT 17797429 T,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/026-948-506-779-817,Unknown,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,PENDING
177,SG,A,SG 11201901077R A,004-006-214-513-761,2019-03-28,2019,SG 11201901077R A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/004-006-214-513-761,Unknown,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,PENDING
178,US,B2,US 11701424 B2,013-226-743-974-10X,2023-07-18,2023,US 202016904511 A,2020-06-17,US 202016904511 A;;US 201715680187 A;;US 201662417217 P;;US 201762513775 P;;US 201762477974 P;;US 201762513916 P;;US 201762538561 P;;US 201662376334 P;;US 201762513771 P;;US 201662376335 P,2016-08-17,"Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,COMPUGEN LTD (2017-09-03);;COMPUGEN USA INC (2017-10-16),https://lens.org/013-226-743-974-10X,Granted Patent,yes,53,0,50,52,612,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/00;;A61K39/00;;A61K39/395;;A61P35/00;;C07K16/28,,14,12,016-291-551-264-744;;028-947-110-430-895;;003-204-276-209-117;;022-608-838-432-215;;020-883-295-175-85X;;042-879-791-960-298;;082-735-005-968-62X;;003-082-950-776-533;;051-707-000-800-833;;047-792-343-788-48X;;026-314-498-200-929;;100-399-671-580-29X,1512548;;10.1084/jem.176.3.855;;pmc2119366;;28978021;;pmc5620161;;10.18632/oncotarget.18004;;26870003;;pmc4740385;;10.3389/fmicb.2016.00022;;25465800;;10.1016/j.ccell.2014.10.018;;10.4161/viru.26153;;pmc5359721;;23979029;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;22437872;;10.1038/nrc3236;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;12079396;;10.1016/s0022-2836(02)00264-4;;10.1016/j.cell.2012.02.034;;pmc3310896;;22424219;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091,"Chen et al., 1992, Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen., J. Exp. Med. vol. 176: 855-866.;;He et al., Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., Oncotarget. May 19, 2017;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection Sep. 15, 2017.;;Janda et al., Ig Constant Region Effects on Variable Region Structure and Function., Front Microbiol. Feb. 4, 2016;7:22. doi: 10.3389/fmicb.2016.00022. eCollection 2016.;;Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Nosanchuk JD., The interdependence of antibody C and V regions on specificity and affinity: significant implications for the engineering of therapeutic antibodies., Virulence. Aug. 15, 2013;4(6):439-40. doi: 10.4161/viru.26153.;;Orentas et al., Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): p. 135.;;Scott et al., Antibody therapy of cancer., 2012, Nature Reviews, vol. 12: 278-287.;;Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.;;Vajdos et al., 2002, Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis, J. Mol. Biol. vol. 320: 415-428.;;Weiner et al., Antibody-based immunotherapy of cancer., Cell. Mar. 16, 2012;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.",ACTIVE
179,ES,T3,ES 2774320 T3,108-141-361-920-087,2020-07-20,2020,ES 17797429 T,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"Anticuerpos anti-TIGIT, anticuerpos anti-PVRIG y combinaciones de los mismos",Una composición que comprende un dominio de unión a antígeno que se une a TIGIT humano (SEQ ID NO:97) que comprende: a) un dominio pesado variable que comprende la SEQ ID NO: 160; y b) un dominio ligero variable que comprende la SEQ ID NO: 165.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/108-141-361-920-087,Granted Patent,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,ACTIVE
180,US,B2,US 10213505 B2,015-787-101-918-416,2019-02-26,2019,US 201815937784 A,2018-03-27,US 201815937784 A;;US 201715795135 A;;US 201715680187 A;;US 201662376335 P;;US 201662417217 P;;US 201762513775 P;;US 201762477974 P;;US 201762513916 P;;US 201762538561 P;;US 201662376334 P;;US 201762513771 P,2016-08-17,"Anti-TIGIT anibodies, anti-PVRIG antibodies and combinations thereof",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,COMPUGEN LTD (2017-09-03);;COMPUGEN USA INC (2017-10-16),https://lens.org/015-787-101-918-416,Granted Patent,yes,53,5,50,52,612,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/00;;A61K39/00;;A61K39/395;;C07K16/28,,13,10,020-883-295-175-85X;;003-204-276-209-117;;003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;022-608-838-432-215;;042-879-791-960-298;;028-947-110-430-895;;082-735-005-968-62X;;047-792-343-788-48X,10.4161/viru.26153;;pmc5359721;;23979029;;26870003;;pmc4740385;;10.3389/fmicb.2016.00022;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;25465800;;10.1016/j.ccell.2014.10.018;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;28978021;;pmc5620161;;10.18632/oncotarget.18004;;22437872;;10.1038/nrc3236;;10.1016/j.cell.2012.02.034;;pmc3310896;;22424219,"Nosanchuk JD., the interdependence of antibody C and V regions on specificity and affinity: significant implications for the engineering of therapeutic antibodies., Virulence. Aug. 15, 2013;4(6):439-40. doi: 10.4161/viru.26153.;;Janda et al., Ig Constant Region Effects on Variable Region Structure and Function., Front Microbiol. Feb. 4, 2016;7:22. doi: 10.3389/fmicb.2016.00022. eCollection 2016.;;Gene ID: PVRIG antibody—middle region, Rabbit Polyclonal Antibody Catalog #AI13083, retrieved from the internet: URL:http://www.funakoshi.co.jp/data/datasheet/ABG/AI13083.pdf.;;Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): P135.;;Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Orentas et al., Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.;;He et al., Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., Oncotarget. May 19, 2007;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection Sep. 15, 2017.;;Scott et al., Antibody therapy of cancer., 2012, Nature Reviews, vol. 12: 278-287.;;Weiner et al., Antibody-based immunotherapy of cancer., Cell. Mar 16, 2012;148(6):1081-4. doi: 10.1016/j.ce11.2012.02.034.",ACTIVE
181,KR,A,KR 20230145510 A,117-086-777-755-561,2023-10-17,2023,KR 20237033526 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P;;KR 20227009297 A;;IB 2017001256 W,2016-08-17,-TIGIT -PVRIG ANTI-TIGIT ANTIBODIES ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF,항-PVRIG 및 항-TIGIT 항체가 제공된다.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/117-086-777-755-561,Patent Application,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00;;A61P35/00,,0,0,,,,DISCONTINUED
182,US,B2,US 10124061 B2,093-509-912-677-82X,2018-11-13,2018,US 201715795135 A,2017-10-26,US 201715795135 A;;US 201715680187 A;;US 201762513771 P;;US 201662376335 P;;US 201662417217 P;;US 201762513775 P;;US 201762477974 P;;US 201762513916 P;;US 201762538561 P;;US 201662376334 P,2016-08-17,"Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,COMPUGEN LTD (2017-09-03);;COMPUGEN USA INC (2017-10-16),https://lens.org/093-509-912-677-82X,Granted Patent,yes,53,7,50,52,612,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,A61K39/395;;A61K39/00;;C07K16/28,,13,10,020-883-295-175-85X;;003-204-276-209-117;;003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;022-608-838-432-215;;042-879-791-960-298;;028-947-110-430-895;;082-735-005-968-62X;;047-792-343-788-48X,10.4161/viru.26153;;pmc5359721;;23979029;;26870003;;pmc4740385;;10.3389/fmicb.2016.00022;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;25465800;;10.1016/j.ccell.2014.10.018;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;28978021;;pmc5620161;;10.18632/oncotarget.18004;;22437872;;10.1038/nrc3236;;10.1016/j.cell.2012.02.034;;pmc3310896;;22424219,"Nosanchuk JD., The interdependence of antibody C and V regions on specificity and affinity: significant implications for the engineering of therapeutic antibodies., Virulence. Aug. 15, 2013;4(6):439-40. doi: 10.4161/viru.26153.;;Janda et al., Ig Constant Region Effects on Variable Region Structure and Function., Front Microbiol. Feb. 4, 2016;7:22. doi: 10.3389/fmicb.2016.00022. eCollection 2016.;;Gene ID: PVRIG antibody—middle region, Rabbit Polyclonal Antibody Catalog #Al13083, retrieved from the internet: URL:http://www.funakoshi.co.jp/data/datasheet/ABG/Al1308.pdf.;;Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): P135.;;Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Orentas et al., Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.;;He et al., Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., Oncotarget. May 19, 2017;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection Sep. 15, 2017.;;Scott et al., Antibody therapy of cancer., 2012, Nature Reviews, vol. 12: 278-287.;;Weiner et al., Antibody-based immunotherapy of cancer., Cell. Mar. 16, 2012;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034.",ACTIVE
183,WO,A1,WO 2018/033798 A1,122-889-475-937-044,2018-02-22,2018,IB 2017001256 W,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513775 P;;US 201762513916 P;;US 201762513771 P;;US 201762538561 P,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/122-889-475-937-044,Patent Application,yes,66,64,50,52,611,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,93,79,020-883-295-175-85X;;003-204-276-209-117;;055-941-254-232-339;;010-801-824-793-588;;079-191-303-518-861;;061-453-882-230-419;;000-631-306-299-887;;012-165-170-835-272;;082-472-766-436-845;;012-780-527-944-741;;024-956-179-363-052;;005-018-877-991-494;;006-451-527-297-818;;039-289-782-216-880;;043-632-912-449-253;;109-281-805-500-720;;141-009-316-280-461;;059-063-827-066-032;;032-412-591-971-193;;032-462-237-933-86X;;049-134-753-209-354;;006-574-964-805-278;;045-094-249-115-990;;012-273-285-250-15X;;002-141-834-487-41X;;006-574-964-805-278;;042-204-626-457-327;;030-323-674-660-051;;066-419-294-278-929;;009-483-512-107-343;;044-522-255-085-902;;017-677-372-355-841;;039-004-732-914-566;;013-142-717-038-23X;;015-395-754-996-662;;106-032-800-597-23X;;116-193-705-533-609;;072-548-742-004-170;;019-090-814-439-613;;014-113-432-888-031;;055-627-013-189-514;;097-637-621-469-520;;004-458-031-333-650;;033-955-564-406-161;;005-219-687-670-471;;026-164-216-541-151;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;094-244-865-622-863;;025-440-140-405-971;;050-672-300-487-304;;072-042-364-654-214;;076-912-994-506-04X;;066-486-712-233-96X;;077-640-818-602-884;;131-380-770-470-779;;060-699-153-259-75X;;045-623-729-340-346;;002-171-587-882-558;;013-242-591-207-277;;007-681-485-057-727;;004-701-625-088-792;;088-434-716-536-224;;048-961-183-736-197;;100-399-671-580-29X;;057-692-130-684-50X;;026-314-498-200-929;;003-082-950-776-533;;022-608-838-432-215;;001-581-530-503-356;;041-466-573-640-315;;038-569-018-972-189;;075-341-946-006-056;;087-161-446-916-210;;052-956-966-509-490;;000-846-337-409-979;;114-078-098-241-965;;002-391-233-537-014,10.4161/viru.26153;;pmc5359721;;23979029;;26870003;;pmc4740385;;10.3389/fmicb.2016.00022;;10.1016/j.semcancer.2005.07.009;;16140545;;10.1146/annurev.immunol.23.021704.115611;;15771580;;15771565;;10.1146/annurev.immunol.23.021704.115839;;10.1158/1078-0432.ccr-07-0016;;17606736;;pmc2867907;;20385810;;10.1073/pnas.1003345107;;10.1158/0008-5472.can-11-2637;;22205715;;pmc3288235;;24667641;;pmc4001555;;10.1172/jci73639;;10.1093/intimm/5.8.957;;8398989;;10.1002/dvg.22938;;pmc5084746;;27012318;;10.1073/pnas.63.1.78;;5257969;;pmc534037;;12148987;;10.1021/ja027007w;;12404640;;10.1002/1439-7633(20021104)3:11<1135::aid-cbic1135>3.0.co;2-m;;10.1073/pnas.172226299;;12154230;;pmc123203;;1409642;;10.1073/pnas.89.20.9367;;pmc50132;;10.1016/j.tig.2004.09.013;;15522458;;15138302;;10.1073/pnas.0401517101;;pmc419646;;12920298;;10.1126/science.1084772;;10.1034/j.1600-065x.2002.19009.x;;12493010;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/321522a0;;3713831;;10.1126/science.2451287;;2451287;;10.1021/bp030070k;;15176864;;10.1016/b978-012053641-2/50034-4;;10.1038/321522a0;;3713831;;3127726;;10.1038/332323a0;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;9551944;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;9377574;;pmc51622;;10.1073/pnas.88.10.4181;;1903536;;8302875;;pmc521435;;10.1073/pnas.91.3.969;;10556035;;10.1006/jmbi.1999.3141;;9099717;;10.1074/jbc.272.16.10678;;10.1074/jbc.271.37.22611;;8798431;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;14600205;;10.1093/protein/gzg096;;10.4049/jimmunol.169.2.1119;;12097421;;12218124;;10.4049/jimmunol.169.6.3076;;11849310;;10.1046/j.0019-2805.2001.01341.x;;pmc1782638;;10.1016/s0165-2478(02)00019-6;;12008035;;11096108;;10.1074/jbc.m009483200;;10.1038/nri2761;;20414204;;10.1093/nar/gks1370;;3382986;;10.1093/bioinformatics/4.1.11;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;23386332;;10.1007/978-1-62703-296-4_1;;10.1016/s1074-7613(00)70060-4;;8673704;;10.1016/s0092-8674(00)81683-9;;10647931;;21376230;;10.1016/j.cell.2011.02.013;;24122236;;pmc4255306;;10.1002/path.4287;;23890065;;10.1016/j.immuni.2013.06.014;;10.1073/pnas.1607836113;;pmc5137776;;27837027;;27079802;;pmc5381938;;10.1038/nrc.2016.36;;10.1158/1078-0432.ccr-15-1849;;27084739;;pmc4872712;;10.1038/nrc3239;;pmc4856023;;22437870;;10.1007/3-540-30683-8_443;;25860605;;pmc5905674;;10.1016/j.cell.2015.03.030;;24871131;;pmc4558099;;10.1126/scitranslmed.3008211;;10.1158/1078-0432.ccr-15-1088;;26180060;;10.1038/nature13954;;pmc4246418;;25428505;;10.21417/b7z59d;;22285893;;10.1016/j.coi.2012.01.009;;25743219;;10.1038/nri3799;;10.1084/jem.20150785;;26755705;;pmc4749091;;10.1084/jem.20030788;;pmc2194180;;12913096;;10.1038/ni.1674;;19011627;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;25465800;;10.1016/j.ccell.2014.10.018;;26842126;;10.1007/s00262-016-1799-4;;10.1038/ni.2850;;24658051;;10.4049/jimmunol.172.7.3994;;15034010;;10.1158/0008-5472.can-07-3119;;18339883;;10.1007/s00251-011-0519-7;;21390552;;22461641;;pmc3568523;;10.1126/scitranslmed.3003689;;24432022;;10.3389/fimmu.2013.00508;;pmc3882864;;24343663;;10.1038/icb.2013.95;;pmc2212458;;10.1084/jem.188.2.277;;9670040,"JOSHUA D. NOSANCHUK: ""The interdependence of antibody C and V regions on specificity and affinity : Significant implications for the engineering of therapeutic antibodies"", VIRULENCE, vol. 4, no. 6, 15 August 2013 (2013-08-15), US, pages 439 - 440, XP055436928, ISSN: 2150-5594, DOI: 10.4161/viru.26153;;ALENA JANDA ET AL: ""Ig Constant Region Effects on Variable Region Structure and Function"", FRONTIERS IN MICROBIOLOGY, vol. 7, 4 February 2016 (2016-02-04), XP055436953, DOI: 10.3389/fmicb.2016.00022;;WANG: ""Immune Suppression by Tumor Specific CD4+ Regulatory T cells in Cancer"", SEMIN. CANCER. BIOL., vol. 16, 2006, pages 73 - 79, XP024908039, DOI: doi:10.1016/j.semcancer.2005.07.009;;GREENWALD ET AL.: ""The B7 Family Revisited"", ANN. REV. IMMUNOL., vol. 23, 2005, pages 515 - 548, XP002481408, DOI: doi:10.1146/annurev.immunol.23.021704.115611;;WATTS: ""TNF/TNFR Family Members in Co-stimulation of T Cell Responses"", ANN. REV. IMMUNOL., vol. 23, 2005, pages 23 - 68, XP008051583, DOI: doi:10.1146/annurev.immunol.23.021704.115839;;SADUM ET AL.: ""Immune Signatures of Murine and Human Cancers Reveal Unique Mechanisms of Tumor Escape and New Targets for Cancer Immunotherapy"", CLIN. CANE. RES., vol. 13, no. 13, 2007, pages 4016 - 4025, XP055248327, DOI: doi:10.1158/1078-0432.CCR-07-0016;;AHMADZADEH ET AL., BLOOD, vol. 114, 2009, pages 1537;;MATSUZAKI ET AL., PNAS, vol. 107, no. 17, 2010, pages 7875 - 7880;;FOURCADE ET AL., CANCER RES., vol. 72, no. 4, 2012, pages 887 - 896;;GROS ET AL., J. CLINICAL INVEST, vol. 124, no. 5, 2014, pages 2246;;KOENTGEN ET AL., INT IMMUNOL, vol. 5, 1993, pages 957 - 964;;KOENTGEN ET AL., GENESIS, vol. 54, 2016, pages 326 - 333;;EDELMAN ET AL., PROC NATL ACAD SCI USA, vol. 63, 1969, pages 78 - 85;;J. W. CHIN ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, 2002, pages 9026 - 9027;;J. W. CHIN; P. G. SCHULTZ, CHEMBIOCHEM, vol. 11, 2002, pages 1135 - 1137;;J. W. CHIN ET AL., PICAS UNITED STATES OF AMERICA, vol. 99, 2002, pages 11020 - 11024;;L. WANG; P. G. SCHULTZ, CHEM., 2002, pages 1 - 10;;SIMON ET AL., PNAS USA, vol. 89, no. 20, 1992, pages 9367;;CROPP; SHULTZ, TRENDS GENET, vol. 20, no. 12, 2004, pages 625 - 630;;ANDERSON ET AL., PROC NATL ACAD SCI USA, vol. 101, no. 2, 2004, pages 7566 - 7571;;CHIN ET AL., SCIENCE, vol. 301, no. 5635, 2003, pages 964 - 967;;DAVIS; 2002 ET AL., IMMUNOLOGICAL REVIEWS, vol. 190, pages 123 - 136;;KABAT ET AL.: ""SEQUENCES OF PROTEINS OF IMMUNOLOGICAL INTEREST"", 1991, NATIONAL INSTITUTES OF HEALTH;;CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;LAFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, no. 1, 2003, pages 55 - 77;;JONES, NATURE, vol. 321, 1986, pages 522 - 525;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536;;ROQUE ET AL., BIOTECHNOL. PROG., vol. 20, 2004, pages 639 - 654;;TSURUSHITA; VASQUEZ: ""Humanization of Monoclonal Antibodies, Molecular Biology of B Cells"", 2004, ELSEVIER SCIENCE, article ""Humanization of Monoclonal Antibodies, Molecular Biology of B Cells"", pages: 533 - 545;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;QUEEN ET AL., PROC NATL ACAD SCI, USA, vol. 86, 1989, pages 10029 - 10033;;HE ET AL., J. IMMUNOL., vol. 160, 1998, pages 1029 - 1035;;CARTER ET AL., PROC NATL ACAD SCI USA, vol. 89, 1992, pages 4285 - 4289;;PRESTA ET AL., CANCER RES., vol. 57, no. 20, 1997, pages 4593 - 4599;;GORMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 4181 - 4185;;O'CONNOR ET AL., PROTEIN ENG, vol. 11, 1998, pages 321 - 328;;ROGUSKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 969 - 973;;WU ET AL., J. MOL. BIOL., vol. 294, 1999, pages 151 - 162;;BACA ET AL., J. BIOL. CHEM., vol. 272, no. 16, 1997, pages 10678 - 10684;;ROSOK ET AL., J. BIOL. CHEM., vol. 271, no. 37, 1996, pages 22611 - 22618;;RADER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 8910 - 8915;;KRAUSS ET AL., PROTEIN ENGINEERING, vol. 16, no. 10, 2003, pages 753 - 759;;TAN ET AL., J. IMMUNOL., vol. 169, 2002, pages 1119 - 1125;;DE PASCALIS ET AL., J. IMMUNOL., vol. 169, 2002, pages 3076 - 3084;;AALBERSE, RC; SCHUURMAN J., IMMUNOLOGY, vol. 105, 2002, pages 9 - 19;;JEFFERIS ET AL., IMMUNOL LETT, vol. 82, 2002, pages 57 - 65;;SHIELDS, R. L. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;CHAN CA; CARTER PJ, NATURE REVLMMUNOL, vol. 10, 2010, pages 301 - 316;;YE ET AL., NUCLEIC ACIDS RES., vol. 41, 2013, pages W34 - W40;;E. MEYERS; W. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17;;NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., J MOL. BIOL., vol. 215, 1990, pages 403 - 410;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;OSOL A.: ""Remington's Pharmaceutical Sciences. 16th Ed."", 1980;;AGNEW, CHEM INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186;;GOODKIND ET AL., COMPUTERS AND CHEM. ENG., vol. 29, no. 3, 2005, pages 589;;HAN ET AL., BIOINFORM. BIOL. INSIGHTS, vol. 9, no. 1, 15 November 2015 (2015-11-15), pages 29 - 46;;CAMPO ET AL., NOD. PATHOL., vol. 26, no. 1, January 2013 (2013-01-01), pages S97 - S110;;WANG ET AL.: ""Recent Advances in Capillary Electrophoresis-Based Proteomic Techniques for Biomarker Discovery"", METHODS. MOL. BIOL., vol. 984, 2013, pages 1 - 12;;TAYLOR ET AL., BIOMED RES, vol. 2014, pages 8;;BECERK ET AL., MUTAT. RES, vol. 722, no. 2, 17 June 2011 (2011-06-17), pages 171 - 182;;SHIBUYA ET AL., IMMUNITY, vol. 4, no. 6, 1 June 1996 (1996-06-01), pages 573 - 581;;ZHU, J. EXP. MED., 2016, pages 1 - 10;;AALBERSE ET AL., IMMUNOLOGY, vol. 202, no. 105, pages 9 - 19;;HANAHAN D; WEINBERG RA: ""The hallmarks of cancer"", CELL, vol. 100, no. 1, 2000, pages 57 - 70;;HANAHAN D; WEINBERG RA: ""Hallmarks of cancer: the next generation"", CELL, vol. 144, no. 5, 2011, pages 646 - 674, XP028185429, DOI: doi:10.1016/j.cell.2011.02.013;;GALON J; MLECNIK B; BINDEA G; ANGELL HK; BERGER A; LAGORCE C ET AL.: ""Towards the introduction of the 'Immunoscore' in the classification of malignant tumours"", J PATHOL, vol. 232, no. 2, 2014, pages 199 - 209, XP055246049, DOI: doi:10.1002/path.4287;;ZITVOGEL L; GALLUZZI L; SMYTH MJ; KROEMER G: ""Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance"", IMMUNITY, vol. 39, no. l, 2013, pages 74 - 88;;DANILOVA L; WANG H; SUNSHINE J; KAUNITZ GJ; COTTRELL TR; XU H ET AL.: ""Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors"", PROC NATL ACAD SCI U S A, vol. 113, no. 48, 2016, pages E7769 - E7777;;TOPALIAN SL; TAUBE JM; ANDERS RA; PARDOLL DM: ""Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy"", NAT REV CANCER, vol. 16, no. 5, 2016, pages 275 - 287, XP055375806, DOI: doi:10.1038/nrc.2016.36;;ZAROUR HM: ""Reversing T-cell Dysfunction and Exhaustion in Cancer"", CLIN CANCER RES, vol. 22, no. 8, 2016, pages 1856 - 1864;;PARDOLL DM: ""The blockade of immune checkpoints in cancer immunotherapy"", NAT REV CANCER, vol. 12, no. 4, 2012, pages 252 - 64, XP055415943, DOI: doi:10.1038/nrc3239;;SHARMA P; ALLISON JP: ""Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential"", CELL, vol. 161, no. 2, 2015, pages 205 - 214, XP055427087, DOI: doi:10.1016/j.cell.2015.03.030;;CHA E; KLINGER M; HOU Y; CUMMINGS C; RIBAS A; FAHAM M ET AL.: ""Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients"", SCI TRANSL MED, vol. 6, no. 238, 2014, pages 238ra70, XP055219304, DOI: doi:10.1126/scitranslmed.3008211;;ROBERT L; TSOI J; WANG X; EMERSON R; HORNET B; CHODON T ET AL.: ""CTLA4 blockade broadens the peripheral T-cell receptor repertoire"", CLIN CANCER RES, vol. 20, no. 9, 2014, pages 2424 - 2432, XP055145637, DOI: doi:10.1158/1078-0432.CCR-13-2648;;TUMEH PC; HARVIEW CL; YEARLEY JH; SHINTAKU IP; TAYLOR EJ; ROBERT L ET AL.: ""PD-1 blockade induces responses by inhibiting adaptive immune resistance"", NATURE, vol. 515, no. 7528, 2014, pages 568 - 571, XP055247294, DOI: doi:10.1038/nature13954;;CHAN CJ; ANDREWS DM; SMYTH MJ: ""Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer"", CURR OPIN IMMUNOL, vol. 24, no. 2, 2012, pages 246 - 251, XP055147483, DOI: doi:10.1016/j.coi.2012.01.009;;MARTINET L; SMYTH MJ: ""Balancing natural killer cell activation through paired receptors"", NAT REV IMMUNOL, vol. 15, no. 4, 2015, pages 243 - 254, XP055424277, DOI: doi:10.1038/nri3799;;ZHU Y; PANICCIA A; SCHULICK AC; CHEN W; KOENIG MR; BYERS JT ET AL.: ""Identification of CD112R as a novel checkpoint for human T cells"", J EXP MED, vol. 213, no. 2, 2016, pages 167 - 176, XP055314642, DOI: doi:10.1084/jem.20150785;;BOTTINO C; CASTRICONI R; PENDE D; RIVERA P; NANNI M; CARNEMOLLA B ET AL.: ""Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule"", J EXP MED, vol. 198, no. 4, 2003, pages 557 - 567, XP055011690, DOI: doi:10.1084/jem.20030788;;YU X; HARDEN K; GONZALEZ LC; FRANCESCO M; CHIANG E; IRVING B ET AL.: ""The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells"", NAT IMMUNOL, vol. 10, no. 1, 2009, pages 48 - 57, XP055273979, DOI: doi:10.1038/ni.1674;;STANIETSKY N; SIMIC H; ARAPOVIC J; TOPORIK A; LEVY O; NOVIK A ET AL.: ""The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity"", PROC NATL ACAD SCI USA, vol. 106, no. 42, 2009, pages 17858 - 17863, XP055215810, DOI: doi:10.1073/pnas.0903474106;;JOHNSTON RJ; COMPS-AGRAR L; HACKNEY J; YU X; HUSENI M; YANG Y ET AL.: ""The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function"", CANCER CELL, vol. 26, no. 6, 2014, pages 923 - 937, XP029111576, DOI: doi:10.1016/j.ccell.2014.10.018;;ZHANG B; ZHAO W; LI H; CHEN Y; TIAN H; LI L ET AL.: ""Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155"", CANCER IMMUNOL IMMUNOTHER, vol. 65, no. 3, 2016, pages 305 - 314, XP035871383, DOI: doi:10.1007/s00262-016-1799-4;;CHAN CJ; MARTINET L; GILFILLAN S; SOUZA-FONSECA-GUIMARAES F; CHOW MT; TOWN L ET AL.: ""The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions"", NAT IMMUNOL, vol. 15, no. 5, 2014, pages 431 - 438, XP055344476, DOI: doi:10.1038/ni.2850;;FUCHS A; CELLA M; GIURISATO E; SHAW AS; COLONNA M: ""Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155"", J IMMUNOL, vol. 172, no. 7, 2004, pages 3994 - 3998, XP055344481, DOI: doi:10.4049/jimmunol.172.7.3994;;MACHLENKIN A; UZANA R; FRANKENBURG S; EISENBERG G; EISENBACH L; PITCOVSKI J ET AL.: ""Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs"", CANCER RES, vol. 68, no. 6, 2008, pages 2006 - 2013;;OHTANI H; NAKAJIMA T; AKARI H; ISHIDA T; KIMURA A: ""Molecular evolution of immunoglobulin superfamily genes in primates"", IMMUNOGENETICS, vol. 63, no. 7, 2011, pages 417 - 428, XP019914282, DOI: doi:10.1007/s00251-011-0519-7;;TAUBE JM; ANDERS RA; YOUNG GD; XU H; SHARMA R; MCMILLER TL ET AL.: ""Colocalization of inflammatory response with B7-hl expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape"", SCI TRANSL MED, vol. 4, no. 127, 2012, pages 127ra37, XP055370851, DOI: doi:10.1126/scitranslmed.3003689;;CERBONI C; FIONDA C; SORIANI A; ZINGONI A; DORIA M; CIPPITELLI M ET AL.: ""The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells"", FRONT IMMUNOL, vol. 4, 2014, pages 508;;DE ANDRADE LF; SMYTH MJ; MARTINET L: ""DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins"", IMMUNOL CELL BIOL, vol. 92, no. 3, 2014, pages 237 - 244;;OVERWIJK WW; TSUNG A; IRVINE KR; PARKHURST MR; GOLETZ TJ; TSUNG K ET AL.: ""gplOO/pmel 17 is a murine tumor rejection antigen: induction of ''self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand"", J EXP MED, vol. 188, no. 2, 1998, pages 277 - 286, XP002938364, DOI: doi:10.1084/jem.188.2.277",PENDING
184,AU,A1,AU 2017/313405 A1,167-100-830-751-415,2019-02-28,2019,AU 2017/313405 A,2017-08-17,US 201762513916 P;;US 201662376335 P;;US 201662376334 P;;US 201762513771 P;;US 201762538561 P;;US 201762477974 P;;US 201762513775 P;;US 201662417217 P;;IB 2017001256 W,2016-08-17,"Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/167-100-830-751-415,Patent Application,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,PENDING
185,CL,A1,CL 2019000424 A1,045-514-153-558-357,2019-07-05,2019,CL 2019000424 A,2019-02-15,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P,2016-08-17,"Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.",Se proporcionan anticuerpos anti-PVRIG y anti-TIGIT.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/045-514-153-558-357,Patent Application,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28,,0,0,,,,PENDING
186,KR,A,KR 20220041246 A,065-225-718-423-738,2022-03-31,2022,KR 20227009297 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P;;KR 20197006497 A;;IB 2017001256 W,2016-08-17,-TIGIT -PVRIG ANTI-TIGIT ANTIBODIES ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF,항-PVRIG 및 항-TIGIT 항체가 제공된다.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/065-225-718-423-738,Patent Application,no,7,0,50,52,1224,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61P35/00,,0,0,,,,ACTIVE
187,MX,A,MX 2019001878 A,043-320-648-790-600,2019-07-01,2019,MX 2019001878 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF.",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,ERAN OPHIR;;LIAT DASSA;;MARK WHITE;;SANDEEP KUMAR;;CHRISTOPHER CHAN;;SPENCER LIANG;;LANCE STAPLETON;;YOSI GOZLAN;;ZOHAR TIRAN;;LEONARD PRESTA;;RICHARD THEOLIS;;ILAN VAKNIN;;ANDREW W DRAKE;;SHIRLEY SAMEAH-GREENWALD;;GAD S COJOCARU;;MAYA KOTTURI;;HSIN-YUAN CHENG;;KYLE HANSEN;;DAVID NISIM GILADI;;EINAV SAFYON;;RADHIKA DESAI;;PATRICK WALL,,https://lens.org/043-320-648-790-600,Patent Application,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,PENDING
188,HR,T1,HR P20200189 T1,170-271-144-987-019,2020-05-01,2020,HR P20200189 T,2020-02-05,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P;;EP 17797429 A;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/170-271-144-987-019,Granted Patent,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,ACTIVE
189,DK,T3,DK 3347379 T3,033-649-797-493-176,2020-02-17,2020,DK 17797429 T,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT-ANTISTOFFER, ANTI-PVRIG-ANTISTOFFER OG KOMBINATIONER DERAF",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/033-649-797-493-176,Granted Patent,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,ACTIVE
190,EP,B1,EP 3347379 B1,026-565-982-430-909,2019-11-06,2019,EP 17797429 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/026-565-982-430-909,Granted Patent,yes,7,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,2,0,,,"JOSHUA D. NOSANCHUK: ""The interdependence of antibody C and V regions on specificity and affinity : Significant implications for the engineering of therapeutic antibodies"", VIRULENCE, vol. 4, no. 6, 15 August 2013 (2013-08-15) , pages 439-440, XP055436928, US ISSN: 2150-5594, DOI: 10.4161/viru.26153;;ALENA JANDA ET AL: ""Ig Constant Region Effects on Variable Region Structure and Function"", FRONTIERS IN MICROBIOLOGY, vol. 7, 4 February 2016 (2016-02-04), XP055436953, DOI: 10.3389/fmicb.2016.00022",ACTIVE
191,EP,A1,EP 3347379 A1,041-681-662-980-17X,2018-07-18,2018,EP 17797429 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/041-681-662-980-17X,Patent Application,yes,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,ACTIVE
192,MX,A,MX 2021006237 A,019-997-387-779-028,2021-08-11,2021,MX 2021006237 A,2019-02-15,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF.",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,OPHIR ERAN;;DASSA LIAT;;KUMAR SANDEEP;;GOZLAN YOSI;;TIRAN ZOHAR;;VAKNIN ILAN;;DRAKE ANDREW W;;SAMEAH-GREENWALD SHIRLEY;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;DESAI RADHIKA;;WALL PATRICK;;LIANG SPENCER;;CHAN CHRISTOPHER;;WHITE MARK;;STAPLETON LANCE;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/019-997-387-779-028,Patent Application,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00;;A61K39/395,,0,0,,,,PENDING
193,US,A1,US 2018/0169238 A1,046-541-834-863-066,2018-06-21,2018,US 201715795135 A,2017-10-26,US 201715795135 A;;US 201715680187 A;;US 201762513771 P;;US 201662376335 P;;US 201662417217 P;;US 201762513775 P;;US 201762477974 P;;US 201762513916 P;;US 201762538561 P;;US 201662376334 P,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",Anti-PVRIG and anti-TIGIT antibodies are provided.,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,COMPUGEN LTD (2017-09-03);;COMPUGEN USA INC (2017-10-16),https://lens.org/046-541-834-863-066,Patent Application,yes,0,9,50,52,611,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,A61K39/395,,0,0,,,,ACTIVE
194,BR,A2,BR 112019003129 A2,041-962-038-800-391,2019-07-09,2019,BR 112019003129 A,2017-08-17,IB 2017001256 W;;US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P,2016-08-17,"composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer.","composição compreendendo um domínio de ligação a antígeno que se liga a tigit humano, composição de ácido nucleico e de vetor de expressão, célula hospedeira, e, métodos para preparação de um anticorpo anti-tigit e para tratar cancer são fornecidos anticorpos anti-pvrig e anti-tigit.",COMPUGEN LTD,ANDREW W DRAKE;;CHRISTOPHER CHAN;;DAVID NISIM GILADI;;EINAV SAFYON;;ERAN OPHIR;;GAD S COJOCARU;;HSIN-YUAN CHENG;;ILAN VAKNIN;;KYLE HANSEN;;LANCE STAPLETON;;LEONARD PRESTA;;LIAT DASSA;;MARK WHITE;;MAYA KOTTURI;;PATRICK WALL;;RADHIKA DESAI;;RICHARD THEOLIS;;SANDEEP KUMAR;;SHIRLEY SAMEAH-GREENWALD;;SPENCER LIANG;;YOSI GOZLAN;;ZOHAR TIRAN,,https://lens.org/041-962-038-800-391,Patent Application,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,PENDING
195,KR,A,KR 20190039421 A,065-548-639-121-439,2019-04-11,2019,KR 20197006497 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"항-TIGIT 항체, 항-PVRIG 항체 및 이들의 조합",항-PVRIG 및 항-TIGIT 항체가 제공된다.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/065-548-639-121-439,Patent Application,no,7,0,50,52,1224,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00;;A61K39/395;;A61P35/00,,0,0,,,,ACTIVE
196,CO,A2,CO 2019001980 A2,135-839-638-619-70X,2019-03-08,2019,CO 2019001980 A,2019-02-28,IB 2017001256 W;;US 201762513771 P;;US 201662376334 P;;US 201662376335 P;;US 201762513916 P;;US 201662417217 P;;US 201762513775 P;;US 201762477974 P;;US 201762538561 P,2016-08-17,"Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos",Se proporcionan anticuerpos anti-PVRIG y anti-TIGIT,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/135-839-638-619-70X,Patent Application,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,PENDING
197,US,A1,US 2024/0075137 A1,138-257-400-837-167,2024-03-07,2024,US 18322545,2023-05-23,,,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",Anti-PVRIG and anti-TIGIT antibodies are provided.,Compugen Ltd.,Mark White;;Sandeep Kumar;;Christopher Chan;;Spencer Liang;;Lance Stapleton;;Andrew W. Drake;;Yosi Gozlan;;Ilan Vaknin;;Shirley Sameah-Greenwald;;Liat Dassa;;Zohar Tiran;;Gad S. Cojocaru;;Maya Kotturi;;Hsin-Yuan Cheng;;Kyle Hansen;;David Nisim Giladi;;Einav Safyon;;Eran Ophir;;Leonard Presta;;Richard Theolis;;Radhika Desai;;Patrick Wall,,https://lens.org/138-257-400-837-167,Patent Application,yes,0,0,1,1,0,A61K39/39558;;A61K39/39541;;A61P35/00;;C07K16/2803;;C07K16/2809;;C07K16/2818;;C07K16/2827;;A61K2039/505,A61K39/395;;A61P35/00;;C07K16/28,,0,0,,,,UNKNOWN
198,EP,B9,EP 3347379 B9,136-520-184-060-455,2020-03-25,2020,EP 17797429 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/136-520-184-060-455,Amended Patent,yes,7,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,2,0,,,"JOSHUA D. NOSANCHUK: ""The interdependence of antibody C and V regions on specificity and affinity : Significant implications for the engineering of therapeutic antibodies"", VIRULENCE, vol. 4, no. 6, 15 August 2013 (2013-08-15) , pages 439-440, XP055436928, US ISSN: 2150-5594, DOI: 10.4161/viru.26153;;ALENA JANDA ET AL: ""Ig Constant Region Effects on Variable Region Structure and Function"", FRONTIERS IN MICROBIOLOGY, vol. 7, 4 February 2016 (2016-02-04), XP055436953, DOI: 10.3389/fmicb.2016.00022",ACTIVE
199,MX,A,MX 2021006235 A,046-114-925-295-598,2021-08-11,2021,MX 2021006235 A,2019-02-15,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF.",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,OPHIR ERAN;;DASSA LIAT;;KUMAR SANDEEP;;GOZLAN YOSI;;TIRAN ZOHAR;;VAKNIN ILAN;;DRAKE ANDREW W;;SAMEAH-GREENWALD SHIRLEY;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;DESAI RADHIKA;;WALL PATRICK;;LIANG SPENCER;;CHAN CHRISTOPHER;;WHITE MARK;;STAPLETON LANCE;;PRESTA LEONARD;;THEOLIS RICHARD,,https://lens.org/046-114-925-295-598,Patent Application,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00;;A61K39/395,,0,0,,,,PENDING
200,CY,T1,CY 1122653 T1,085-495-381-895-523,2021-05-05,2021,CY 201100108 T,2020-02-05,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΤΙGΙΤ, ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΡVRIG ΚΑΙ ΣΥΝΔΥΑΣΜΟΙ ΕΞ ΑΥΤΩΝ",Αντισώματα αντι-ΡVRIG και αντι-ΤΙGΙΤ παρέχονται.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/085-495-381-895-523,Granted Patent,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,ACTIVE
201,CL,A1,CL 2021002836 A1,091-862-107-109-832,2022-07-29,2022,CL 2021002836 A,2021-10-28,US 201662376334 P;;US 201962376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P,2016-08-17,"Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos (divisional de la solicitud n° 201900424)",Se proporcionan anticuerpos anti-PVRIG y anti-TIGIT.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK;;COJOCARU GAD S,,https://lens.org/091-862-107-109-832,Patent Application,no,0,0,1,52,0,,A61K39/00;;C07K16/28,,0,0,,,,PENDING
202,UA,C2,UA 126802 C2,103-169-583-526-467,2023-02-08,2023,UA A201902564 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/103-169-583-526-467,Limited Patent,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,,,0,0,,,,ACTIVE
203,CN,A,CN 110088132 A,187-891-290-918-163,2019-08-02,2019,CN 201780050131 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513775 P;;US 201762513916 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/187-891-290-918-163,Patent Application,no,4,6,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,1,0,,,"NOA STANIETSKY等: ""The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity"", 《PNAS》",ACTIVE
204,PL,T3,PL 3347379 T3,015-560-857-709-044,2020-05-18,2020,PL 17797429 T,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;EP 17797429 A;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/015-560-857-709-044,Patent Application,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,PENDING
205,SI,T1,SI 3347379 T1,021-793-221-187-484,2020-04-30,2020,SI 201730157 T,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;IB 2017001256 W;;EP 17797429 A,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/021-793-221-187-484,Granted Patent,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/00;;A61K39/00,,0,0,,,,ACTIVE
206,EP,A1,EP 3617232 A1,178-641-151-006-49X,2020-03-04,2020,EP 19199752 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;EP 17797429 A;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF","Anti-PVRIG and anti-TIGIT antibodies are provided.
",COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/178-641-151-006-49X,Patent Application,yes,71,0,50,52,611,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00;;A61K39/395,,87,75,055-941-254-232-339;;010-801-824-793-588;;079-191-303-518-861;;061-453-882-230-419;;000-631-306-299-887;;012-165-170-835-272;;082-472-766-436-845;;012-780-527-944-741;;024-956-179-363-052;;005-018-877-991-494;;006-451-527-297-818;;039-289-782-216-880;;043-632-912-449-253;;109-281-805-500-720;;141-009-316-280-461;;059-063-827-066-032;;032-412-591-971-193;;032-462-237-933-86X;;017-677-372-355-841;;049-134-753-209-354;;006-574-964-805-278;;045-094-249-115-990;;012-273-285-250-15X;;038-569-018-972-189;;042-204-626-457-327;;030-323-674-660-051;;066-419-294-278-929;;009-483-512-107-343;;044-522-255-085-902;;039-004-732-914-566;;013-142-717-038-23X;;015-395-754-996-662;;106-032-800-597-23X;;116-193-705-533-609;;072-548-742-004-170;;014-113-432-888-031;;055-627-013-189-514;;097-637-621-469-520;;004-458-031-333-650;;033-955-564-406-161;;005-219-687-670-471;;026-164-216-541-151;;032-728-154-591-070;;056-201-471-905-934;;028-862-168-091-90X;;008-493-575-849-013;;094-244-865-622-863;;025-440-140-405-971;;050-672-300-487-304;;072-042-364-654-214;;076-912-994-506-04X;;066-486-712-233-96X;;077-640-818-602-884;;131-380-770-470-779;;060-699-153-259-75X;;045-623-729-340-346;;002-171-587-882-558;;013-242-591-207-277;;007-681-485-057-727;;004-701-625-088-792;;088-434-716-536-224;;048-961-183-736-197;;100-399-671-580-29X;;057-692-130-684-50X;;026-314-498-200-929;;003-082-950-776-533;;022-608-838-432-215;;001-581-530-503-356;;041-466-573-640-315;;075-341-946-006-056;;087-161-446-916-210;;052-956-966-509-490;;000-846-337-409-979;;114-078-098-241-965;;002-391-233-537-014,10.1016/j.semcancer.2005.07.009;;16140545;;10.1146/annurev.immunol.23.021704.115611;;15771580;;15771565;;10.1146/annurev.immunol.23.021704.115839;;10.1158/1078-0432.ccr-07-0016;;17606736;;pmc2867907;;20385810;;10.1073/pnas.1003345107;;10.1158/0008-5472.can-11-2637;;22205715;;pmc3288235;;24667641;;pmc4001555;;10.1172/jci73639;;10.1093/intimm/5.8.957;;8398989;;10.1002/dvg.22938;;pmc5084746;;27012318;;10.1073/pnas.63.1.78;;5257969;;pmc534037;;12148987;;10.1021/ja027007w;;12404640;;10.1002/1439-7633(20021104)3:11<1135::aid-cbic1135>3.0.co;2-m;;10.1073/pnas.172226299;;12154230;;pmc123203;;1409642;;10.1073/pnas.89.20.9367;;pmc50132;;10.1016/j.tig.2004.09.013;;15522458;;15138302;;10.1073/pnas.0401517101;;pmc419646;;12920298;;10.1126/science.1084772;;10.1034/j.1600-065x.2002.19009.x;;12493010;;pmc51622;;10.1073/pnas.88.10.4181;;1903536;;10.1016/0022-2836(87)90412-8;;3681981;;10.1038/321522a0;;3713831;;10.1126/science.2451287;;2451287;;10.1021/bp030070k;;15176864;;10.4049/jimmunol.172.7.3994;;15034010;;3127726;;10.1038/332323a0;;pmc298637;;2513570;;10.1073/pnas.86.24.10029;;9551944;;10.1073/pnas.89.10.4285;;1350088;;pmc49066;;9377574;;8302875;;pmc521435;;10.1073/pnas.91.3.969;;10556035;;10.1006/jmbi.1999.3141;;9099717;;10.1074/jbc.272.16.10678;;10.1074/jbc.271.37.22611;;8798431;;9671778;;pmc21176;;10.1073/pnas.95.15.8910;;14600205;;10.1093/protein/gzg096;;12218124;;10.4049/jimmunol.169.6.3076;;11849310;;10.1046/j.0019-2805.2001.01341.x;;pmc1782638;;10.1016/s0165-2478(02)00019-6;;12008035;;11096108;;10.1074/jbc.m009483200;;10.1038/nri2761;;20414204;;10.1093/nar/gks1370;;3382986;;10.1093/bioinformatics/4.1.11;;10.1016/0022-2836(70)90057-4;;5420325;;2231712;;10.1006/jmbi.1990.9999;;10.1016/s0022-2836(05)80360-2;;10.1093/nar/25.17.3389;;9254694;;pmc146917;;26609224;;10.4137/bbi.s28991;;pmc4648566;;23386332;;10.1007/978-1-62703-296-4_1;;10.1016/s1074-7613(00)70060-4;;8673704;;10.1016/s0092-8674(00)81683-9;;10647931;;21376230;;10.1016/j.cell.2011.02.013;;24122236;;pmc4255306;;10.1002/path.4287;;23890065;;10.1016/j.immuni.2013.06.014;;10.1073/pnas.1607836113;;pmc5137776;;27837027;;27079802;;pmc5381938;;10.1038/nrc.2016.36;;10.1158/1078-0432.ccr-15-1849;;27084739;;pmc4872712;;10.1038/nrc3239;;pmc4856023;;22437870;;10.1007/3-540-30683-8_443;;25860605;;pmc5905674;;10.1016/j.cell.2015.03.030;;24871131;;pmc4558099;;10.1126/scitranslmed.3008211;;10.1158/1078-0432.ccr-15-1088;;26180060;;10.1038/nature13954;;pmc4246418;;25428505;;10.21417/b7z59d;;22285893;;10.1016/j.coi.2012.01.009;;25743219;;10.1038/nri3799;;10.1084/jem.20150785;;26755705;;pmc4749091;;10.1084/jem.20030788;;pmc2194180;;12913096;;10.1038/ni.1674;;19011627;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;25465800;;10.1016/j.ccell.2014.10.018;;26842126;;10.1007/s00262-016-1799-4;;10.1038/ni.2850;;24658051;;10.1158/0008-5472.can-07-3119;;18339883;;10.1007/s00251-011-0519-7;;21390552;;22461641;;pmc3568523;;10.1126/scitranslmed.3003689;;24432022;;10.3389/fimmu.2013.00508;;pmc3882864;;24343663;;10.1038/icb.2013.95;;pmc2212458;;10.1084/jem.188.2.277;;9670040,"WANG: ""Immune Suppression by Tumor Specific CD4+ Regulatory T cells in Cancer"", SEMIN. CANCER. BIOL., vol. 16, 2006, pages 73 - 79, XP024908039, doi:10.1016/j.semcancer.2005.07.009;;GREENWALD ET AL.: ""The B7 Family Revisited"", ANN. REV. IMMUNOL., vol. 23, 2005, pages 515 - 48, XP002481408, doi:10.1146/annurev.immunol.23.021704.115611;;WATTS: ""TNF/TNFR Family Members in Co-stimulation of T Cell Responses"", ANN. REV. IMMUNOL., vol. 23, 2005, pages 23 - 68;;SADUM ET AL.: ""Immune Signatures of Murine and Human Cancers Reveal Unique Mechanisms of Tumor Escape and New Targets for Cancer Immunotherapy"", CLIN. CANE. RES., vol. 13, no. 13, 2007, pages 4016 - 4025, XP055248327, doi:10.1158/1078-0432.CCR-07-0016;;AHMADZADEH ET AL., BLOOD, vol. 114, 2009, pages 1537;;MATSUZAKI ET AL., PNAS, vol. 107, no. 17, 2010, pages 7875 - 7880;;FOURCADE ET AL., CANCER RES., vol. 72, no. 4, 2012, pages 887 - 896;;GROS ET AL., J. CLINICAL INVEST., vol. 124, no. 5, 2014, pages 2246;;KOENTGEN ET AL., INT IMMUNOL, vol. 5, 1993, pages 957 - 964;;KOENTGEN ET AL., GENESIS, vol. 54, 2016, pages 326 - 333;;EDELMAN ET AL., PROC NATL ACAD SCI USA, vol. 63, 1969, pages 78 - 85;;J. W. CHIN ET AL., JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, 2002, pages 9026 - 9027;;J. W. CHINP. G. SCHULTZ, CHEMBIOCHEM, vol. 11, 2002, pages 1135 - 1137;;J. W. CHIN ET AL., PICAS UNITED STATES OF AMERICA, vol. 99, 2002, pages 11020 - 11024;;L. WANGP. G. SCHULTZ, CHEM., 2002, pages 1 - 10;;SIMON ET AL., PNAS USA, vol. 89, no. 20, 1992, pages 9367;;CROPPSHULTZ, TRENDS GENET, vol. 20, no. 12, 2004, pages 625 - 30;;ANDERSON ET AL., PROC NATL ACAD SCI USA, vol. 101, no. 2, 2004, pages 7566 - 71;;CHIN ET AL., SCIENCE, vol. 301, no. 5635, 2003, pages 964 - 7;;DAVIS ET AL., IMMUNOLOGICAL REVIEWS, vol. 190, 2002, pages 123 - 136;;GORMAN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 4181 - 4185;;CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917;;LAFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, no. 1, 2003, pages 55 - 77;;JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525;;VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534 - 1536;;ROQUE ET AL., BIOTECHNOL. PROG., vol. 20, 2004, pages 639 - 654;;FUCHS ACELLA MGIURISATO ESHAW ASCOLONNA M: ""Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155"", J IMMUNOL, vol. 172, no. 7, 2004, pages 3994 - 545, XP055344481, doi:10.4049/jimmunol.172.7.3994;;RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329;;QUEEN ET AL., PROC NATL ACAD SCI, vol. 86, 1989, pages 10029 - 33;;HE ET AL., J. IMMUNOL., vol. 160, 1998, pages 1029 - 1035;;CARTER ET AL., PROC NATL ACAD SCI USA, vol. 89, 1992, pages 4285 - 9;;PRESTA ET AL., CANCER RES., vol. 57, no. 20, 1997, pages 4593 - 9;;O'CONNOR ET AL., PROTEIN ENG, vol. 11, 1998, pages 321 - 8;;ROGUSKA ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 969 - 973;;WU ET AL., J. MOL. BIOL., vol. 294, 1999, pages 151 - 162;;BACA ET AL., J. BIOL. CHEM., vol. 272, no. 16, 1997, pages 10678 - 10684;;ROSOK ET AL., J. BIOL. CHEM., vol. 271, no. 37, 1996, pages 22611 - 22618;;RADER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, 1998, pages 8910 - 8915;;KRAUSS ET AL., PROTEIN ENGINEERING, vol. 16, no. 10, 2003, pages 753 - 759;;DE PASCALIS ET AL., J. IMMUNOL., vol. 169, 2002, pages 3076 - 3084;;AALBERSE, RCSCHUURMAN J., IMMUNOLOGY, vol. 105, 2002, pages 9 - 19;;JEFFERIS ET AL., IMMUNOL LETT, vol. 82, 2002, pages 57 - 65;;SHIELDS, R. L ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 6591 - 6604;;CARTER PJ, NATURE REV IMMUNOL, vol. 10, 2010, pages 301 - 316;;YE ET AL., NUCLEIC ACIDS RES., vol. 41, 2013, pages W34 - W40;;E. MEYERSW. MILLER, COMPUT. APPL. BIOSCI., vol. 4, 1988, pages 11 - 17;;NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 444 - 453;;ALTSCHUL ET AL., J MOL. BIOL., vol. 215, 1990, pages 403 - 10;;ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, no. 17, 1997, pages 3389 - 3402;;""Remington's Pharmaceutical Sciences"", 1980;;AGNEW, CHEM INTL. ED. ENGL., vol. 33, 1994, pages 183 - 186;;GOODKIND ET AL., COMPUTERS AND CHEM. ENG., vol. 29, no. 3, 2005, pages 589;;HAN ET AL., BIOINFORM. BIOL. INSIGHTS, vol. 9, no. 1, pages 29 - 46;;CAMPO ET AL., NOD. PATHOL., vol. 26, no. 1, January 2013 (2013-01-01), pages S97 - S110;;WANG ET AL.: ""Recent Advances in Capillary Electrophoresis-Based Proteomic Techniques for Biomarker Discovery"", METHODS. MOL. BIOL., vol. 984, 2013, pages 1 - 12;;TAYLOR ET AL., BIOMED RES., vol. 2014, pages 8;;BECERK ET AL., MUTAT. RES, vol. 722, no. 2, 17 June 2011 (2011-06-17), pages 171 - 182;;SHIBUYA ET AL., IMMUNITY, vol. 4, no. 6, 1 June 1996 (1996-06-01), pages 573 - 581;;ZHU, J. EXP. MED., 2016, pages 1 - 10;;AALBERSE ET AL., IMMUNOLOGY, vol. 202, no. 105, pages 9 - 19;;HANAHAN DWEINBERG RA: ""The hallmarks of cancer"", CELL, vol. 100, no. 1, 2000, pages 57 - 70, XP055447752;;HANAHAN DWEINBERG RA: ""Hallmarks of cancer: the next generation"", CELL, vol. 144, no. 5, 2011, pages 646 - 74, XP028185429, doi:10.1016/j.cell.2011.02.013;;GALON JMLECNIK BBINDEA GANGELL HKBERGER ALAGORCE C ET AL.: ""Towards the introduction of the 'Immunoscore' in the classification of malignant tumours"", J PATHOL, vol. 232, no. 2, 2014, pages 199 - 209, XP055246049, doi:10.1002/path.4287;;ZITVOGEL LGALLUZZI LSMYTH MJKROEMER G: ""Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance"", IMMUNITY, vol. 39, no. l, 2013, pages 74 - 88;;DANILOVA LWANG HSUNSHINE JKAUNITZ GJCOTTRELL TRXU H ET AL.: ""Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors"", PROC NATL ACAD SCI U S A, vol. 113, no. 48, 2016, pages E7769 - E77;;TOPALIAN SLTAUBE JMANDERS RAPARDOLL DM: ""Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy"", NAT REV CANCER, vol. 16, no. 5, 2016, pages 275 - 87, XP002771342, doi:10.1038/nrc.2016.36;;ZAROUR HM: ""Reversing T-cell Dysfunction and Exhaustion in Cancer"", CLIN CANCER RES, vol. 22, no. 8, 2016, pages 1856 - 64;;PARDOLL DM: ""The blockade of immune checkpoints in cancer immunotherapy"", NAT REV CANCER, vol. 12, no. 4, 2012, pages 252 - 64, XP055415943, doi:10.1038/nrc3239;;SHARMA PALLISON JP: ""Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential"", CELL, vol. 161, no. 2, 2015, pages 205 - 14, XP055427087, doi:10.1016/j.cell.2015.03.030;;CHA EKLINGER MHOU YCUMMINGS CRIBAS AFAHAM M ET AL.: ""Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients"", SCI TRANSL MED, vol. 6, no. 238, 2014, pages 238ra70, XP055433328, doi:10.1126/scitranslmed.3008211;;ROBERT LTSOI JWANG XEMERSON RHORNET BCHODON T ET AL.: ""CTLA4 blockade broadens the peripheral T-cell receptor repertoire"", CLIN CANCER RES, vol. 20, no. 9, 2014, pages 2424 - 32, XP055145637, doi:10.1158/1078-0432.CCR-13-2648;;TUMEH PCHARVIEW CLYEARLEY JHSHINTAKU IPTAYLOR EJROBERT L ET AL.: ""PD-1 blockade induces responses by inhibiting adaptive immune resistance"", NATURE, vol. 515, no. 7528, 2014, pages 568 - 71, XP055247294, doi:10.1038/nature13954;;CHAN CJANDREWS DMSMYTH MJ: ""Receptors that interact with nectin and nectin-like proteins in the immunosurveillance and immunotherapy of cancer"", CURR OPIN IMMUNOL, vol. 24, no. 2, 2012, pages 246 - 51, XP055147483, doi:10.1016/j.coi.2012.01.009;;MARTINET LSMYTH MJ: ""Balancing natural killer cell activation through paired receptors"", NAT REV IMMUNOL, vol. 15, no. 4, 2015, pages 243 - 54, XP055424277, doi:10.1038/nri3799;;ZHU YPANICCIA ASCHULICK ACCHEN WKOENIG MRBYERS JT ET AL.: ""Identification of CD112R as a novel checkpoint for human T cells"", J EXP MED, vol. 213, no. 2, 2016, pages 167 - 76, XP055314642, doi:10.1084/jem.20150785;;BOTTINO CCASTRICONI RPENDE DRIVERA PNANNI MCARNEMOLLA B ET AL.: ""Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule"", J EXP MED, vol. 198, no. 4, 2003, pages 557 - 67, XP055011690, doi:10.1084/jem.20030788;;YU XHARDEN KGONZALEZ LCFRANCESCO MCHIANG EIRVING B ET AL.: ""The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells"", NAT IMMUNOL, vol. 10, no. 1, 2009, pages 48 - 57;;STANIETSKY NSIMIC HARAPOVIC JTOPORIK ALEVY ONOVIK A ET AL.: ""The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity"", PROC NATL ACAD SCI USA, vol. 106, no. 42, 2009, pages 17858 - 63, XP055215810, doi:10.1073/pnas.0903474106;;JOHNSTON RJCOMPS-AGRAR LHACKNEY JYU XHUSENI MYANG Y ET AL.: ""The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function"", CANCER CELL, vol. 26, no. 6, 2014, pages 923 - 37, XP029111576, doi:10.1016/j.ccell.2014.10.018;;ZHANG BZHAO WLI HCHEN YTIAN HLI L ET AL.: ""Immunoreceptor TIGIT inhibits the cytotoxicity of human cytokine-induced killer cells by interacting with CD155"", CANCER IMMUNOL IMMUNOTHER, vol. 65, no. 3, 2016, pages 305 - 14, XP035871383, doi:10.1007/s00262-016-1799-4;;CHAN CJMARTINET LGILFILLAN SSOUZA-FONSECA-GUIMARAES FCHOW MTTOWN L ET AL.: ""The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions"", NAT IMMUNOL, vol. 15, no. 5, 2014, pages 431 - 8, XP055344476, doi:10.1038/ni.2850;;MACHLENKIN AUZANA RFRANKENBURG SEISENBERG GEISENBACH LPITCOVSKI J ET AL.: ""Capture of tumor cell membranes by trogocytosis facilitates detection and isolation of tumor-specific functional CTLs"", CANCER RES, vol. 68, no. 6, 2008, pages 2006 - 13;;OHTANI HNAKAJIMA TAKARI HISHIDA TKIMURA A: ""Molecular evolution of immunoglobulin superfamily genes in primates"", IMMUNOGENETICS, vol. 63, no. 7, 2011, pages 417 - 28, XP019914282, doi:10.1007/s00251-011-0519-7;;TAUBE JMANDERS RAYOUNG GDXU HSHARMA RMCMILLER TL ET AL.: ""Colocalization of inflammatory response with B7-hl expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape"", SCI TRANSL MED, vol. 4, no. 127, 2012, pages 127ra37, XP055370851, doi:10.1126/scitranslmed.3003689;;CERBONI CFIONDA CSORIANI AZINGONI ADORIA MCIPPITELLI M ET AL.: ""The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells"", FRONT IMMUNOL, vol. 4, 2014, pages 508;;DE ANDRADE LFSMYTH MJMARTINET L: ""DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins"", IMMUNOL CELL BIOL, vol. 92, no. 3, 2014, pages 237 - 44;;OVERWIJK WWTSUNG AIRVINE KRPARKHURST MRGOLETZ TJTSUNG K ET AL.: ""gplOO/pmel 17 is a murine tumor rejection antigen: induction of ''self'-reactive, tumoricidal T cells using high-affinity, altered peptide ligand"", J EXP MED, vol. 188, no. 2, 1998, pages 277 - 86, XP002938364, doi:10.1084/jem.188.2.277",PENDING
207,DK,T5,DK 3347379 T5,031-576-500-012-187,2020-06-15,2020,DK 17797429 T,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT-ANTISTOFFER, ANTI-PVRIG-ANTISTOFFER OG KOMBINATIONER DERAF",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/031-576-500-012-187,Amended Patent,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,ACTIVE
208,ES,T9,ES 2774320 T9,111-886-709-475-848,2020-07-21,2020,ES 17797429 T,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"Anticuerpos anti-TIGIT, anticuerpos anti-PVRIG y combinaciones de los mismos",,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/111-886-709-475-848,Unknown,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,ACTIVE
209,MY,A,MY 194032 A,124-190-073-020-771,2022-11-09,2022,MY PI2019000633 A,2017-08-17,IB 2017001256 W;;US 201762513771 P;;US 201662376334 P;;US 201662376335 P;;US 201762513916 P;;US 201662417217 P;;US 201762513775 P;;US 201762477974 P;;US 201762538561 P,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",Anti-PVRIG and anti-TIGIT antibodies are provided. (FIG.1),COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/124-190-073-020-771,Granted Patent,no,0,0,50,52,0,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,ACTIVE
210,US,A1,US 2021/0000952 A1,083-640-503-698-153,2021-01-07,2021,US 202016904511 A,2020-06-17,US 202016904511 A;;US 201715680187 A;;US 201662417217 P;;US 201762513775 P;;US 201762477974 P;;US 201762513916 P;;US 201762538561 P;;US 201662376334 P;;US 201762513771 P;;US 201662376335 P,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,COMPUGEN LTD (2017-09-03);;COMPUGEN USA INC (2017-10-16),https://lens.org/083-640-503-698-153,Patent Application,yes,1,2,50,52,612,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,A61K39/395;;A61P35/00;;C07K16/28,,0,0,,,,ACTIVE
211,US,A1,US 2018/0280506 A1,127-281-651-999-508,2018-10-04,2018,US 201815937784 A,2018-03-27,US 201815937784 A;;US 201715795135 A;;US 201715680187 A;;US 201662376335 P;;US 201662417217 P;;US 201762513775 P;;US 201762477974 P;;US 201762513916 P;;US 201762538561 P;;US 201662376334 P;;US 201762513771 P,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,COMPUGEN LTD (2017-09-03);;COMPUGEN USA INC (2017-10-16),https://lens.org/127-281-651-999-508,Patent Application,yes,0,1,50,52,612,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,A61K39/395;;A61K39/00;;C07K16/28,,0,0,,,,ACTIVE
212,US,A1,US 2018/0305456 A1,131-999-408-581-256,2018-10-25,2018,US 201715680187 A,2017-08-17,US 201715680187 A;;US 201662376334 P;;US 201762513771 P;;US 201662376335 P;;US 201662417217 P;;US 201762513775 P;;US 201762477974 P;;US 201762513916 P;;US 201762538561 P,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",Anti-PVRIG and anti-TIGIT antibodies are provided.,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,COMPUGEN LTD (2017-09-03);;COMPUGEN USA INC (2017-10-16),https://lens.org/131-999-408-581-256,Patent Application,yes,0,2,50,52,611,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61P35/00,,0,0,,,,ACTIVE
213,CA,A1,CA 3032331 A1,176-801-279-699-683,2018-02-22,2018,CA 3032331 A,2017-08-17,US 201662376334 P;;US 201662376335 P;;US 201662417217 P;;US 201762477974 P;;US 201762513771 P;;US 201762513916 P;;US 201762513775 P;;US 201762538561 P;;IB 2017001256 W,2016-08-17,"ANTI-TIGIT ANTIBODIES, ANTI-PVRIG ANTIBODIES AND COMBINATIONS THEREOF",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,,https://lens.org/176-801-279-699-683,Patent Application,no,0,0,50,52,611,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/28;;A61K39/00,,0,0,,,,PENDING
214,US,B2,US 10751415 B2,030-388-164-789-75X,2020-08-25,2020,US 201715680187 A,2017-08-17,US 201715680187 A;;US 201662376334 P;;US 201762513771 P;;US 201662376335 P;;US 201662417217 P;;US 201762513775 P;;US 201762477974 P;;US 201762513916 P;;US 201762538561 P,2016-08-17,"Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof",Anti-PVRIG and anti-TIGIT antibodies are provided.,COMPUGEN LTD,WHITE MARK;;KUMAR SANDEEP;;CHAN CHRISTOPHER;;LIANG SPENCER;;STAPLETON LANCE;;DRAKE ANDREW W;;GOZLAN YOSI;;VAKNIN ILAN;;SAMEAH-GREENWALD SHIRLEY;;DASSA LIAT;;TIRAN ZOHAR;;COJOCARU GAD S;;KOTTURI MAYA;;CHENG HSIN-YUAN;;HANSEN KYLE;;GILADI DAVID NISIM;;SAFYON EINAV;;OPHIR ERAN;;PRESTA LEONARD;;THEOLIS RICHARD;;DESAI RADHIKA;;WALL PATRICK,COMPUGEN LTD (2017-09-03);;COMPUGEN USA INC (2017-10-16),https://lens.org/030-388-164-789-75X,Granted Patent,yes,53,2,50,52,612,C07K16/2803;;C07K16/2809;;C07K16/2818;;A61P35/00;;C07K2317/565;;C07K2317/76;;C07K2317/522;;C07K2317/53;;C07K2317/55;;C07K2317/622;;C07K2317/21;;C07K2317/732;;C07K2317/34;;C07K2317/524;;C07K2317/526;;C07K2317/56;;C07K2317/33;;C07K2317/94;;C07K2317/24;;C07K2317/92;;C07K2319/33;;A61K2039/507;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;A61P35/00;;Y02A50/30;;A61K39/39558;;A61P35/00;;C07K2319/33;;C07K2317/24;;C07K2317/565;;C07K2317/622;;A61K2039/572;;C07K2317/53;;C07K2317/33;;C07K2317/56;;C07K2317/524;;C07K16/2827;;C07K2319/035;;C07K16/2809;;C07K16/2803;;C07K2317/55;;A61K39/39541;;C07K2317/522;;C07K16/2818;;C07K2317/732;;A61K2039/505;;A61K2039/507;;C07K2317/34;;C07K2317/526;;C07K2317/94;;C07K2317/21;;C07K2317/92;;C07K2317/76;;A61P35/00;;C07K16/2803;;C07K16/2809;;A61K2039/505;;C07K2317/33;;C07K2317/24;;C07K2317/21;;C07K2317/92;;C07K2317/76;;C07K16/2896;;C07K16/2803;;C07K16/2818;;C07K16/2827;;A61K2039/505;;C07K2317/21;;C07K2317/24;;C07K2317/33;;C07K2317/34;;C07K2317/76;;C07K2317/92;;Y02A50/30;;A61K39/39541;;A61K39/39558;;A61K2039/507;;C07K2317/524;;C07K2317/526;;C07K2317/53;;C07K2317/56;;C07K2317/732;;C07K2319/035;;C07K2319/33;;A61P35/00;;A61K2039/572;;C07K16/2809;;C07K2317/522;;C07K2317/55;;C07K2317/565;;C07K2317/622;;C07K2317/94,C07K16/00;;A61K39/00;;A61K39/395;;A61P35/00;;C07K16/28,,15,12,020-883-295-175-85X;;003-204-276-209-117;;003-082-950-776-533;;026-314-498-200-929;;100-399-671-580-29X;;022-608-838-432-215;;042-879-791-960-298;;028-947-110-430-895;;082-735-005-968-62X;;047-792-343-788-48X;;051-707-000-800-833;;016-291-551-264-744,10.4161/viru.26153;;pmc5359721;;23979029;;26870003;;pmc4740385;;10.3389/fmicb.2016.00022;;19815499;;pmc2764881;;10.1073/pnas.0903474106;;10.1038/ni.1674;;19011627;;10.1084/jem.20150785;;26755705;;pmc4749091;;25465800;;10.1016/j.ccell.2014.10.018;;24959420;;pmc4050364;;10.3389/fonc.2014.00134;;28978021;;pmc5620161;;10.18632/oncotarget.18004;;22437872;;10.1038/nrc3236;;10.1016/j.cell.2012.02.034;;pmc3310896;;22424219;;12079396;;10.1016/s0022-2836(02)00264-4;;1512548;;10.1084/jem.176.3.855;;pmc2119366,"Nosanchuk JD., The interdependence of antibody C and V regions on specificity and affinity: significant implications for the engineering of therapeutic antibodies., Virulence. Aug. 15, 2013;4(6):439-40. doi: 10.4161/viru.26153.;;Janda et al., Ig Constant Region Effects on Variable Region Structure and Function., Front Microbiol. Feb. 4, 2016;7:22. doi: 10.3389/fmicb.2016.00022. eCollection 2016.;;Gene ID: PVRIG antibody—middle region, Rabbit Polyclonal Antibody Catalog #Al13083, retrieved from the internet: URL:http://www.funakoshi.co.jp/data/datasheet/ABG/Al13083.pdf.;;Stanietsky et al., The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity., Proc Natl Acad Sci U S A. Oct. 20, 2009;106(42):17858-63.;;Yu et al., The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat Immunol. Jan. 2009;10(1):48-57.;;Zhu et al., Identification of CD112R as a novel checkpoint for human T cells., J Exp Med. Feb. 8, 2016;213(2):167-76.;;Rotman et al., Identification of novel immune checkpoints as targets for cancer immunotherapy., J Immunother Cancer. 2013; 1(Suppl 1): p. 135.;;Johnston et al., The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function., Cancer Cell. Dec. 8, 2014;26(6):923-37.;;Orentas et al., Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison., Front Oncol. Jun. 10, 2014;4:134.;;Quinones et al., 2205 High-throughput cellular assays using a well-less plate format. Genentech, South San Francisco, CA, Curiox Biosystems, Singapore, New Technologies and Frontiers, Dec. 6, 2011.;;He et al., Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies., Oncotarget. May 19, 2017;8(40):67129-67139. doi: 10.18632/oncotarget.18004. eCollection Sep. 15, 2017.;;Scott et al., Antibody therapy of cancer., 2012, Nature Reviews, vol. 12: 278-287.;;Weiner et al., Antibody-based immunotherapy of cancer., Cell. Mar. 16, 2012;148(6):1081-4. doi: 10.1016/j.ce11.2012.02.034.;;Vajdos et al., 2002, Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis, J. Mol. Biol. vol. 320: 415-428.;;Chen et al., 1992, Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen., J. Exp. Med. vol. 176: 855-866.",ACTIVE
